WO2005123719A1 - Compounds and compositions as protein kinase inhibitors - Google Patents

Compounds and compositions as protein kinase inhibitors Download PDF

Info

Publication number
WO2005123719A1
WO2005123719A1 PCT/US2005/020371 US2005020371W WO2005123719A1 WO 2005123719 A1 WO2005123719 A1 WO 2005123719A1 US 2005020371 W US2005020371 W US 2005020371W WO 2005123719 A1 WO2005123719 A1 WO 2005123719A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
imidazol
ylamino
pyrimidin
phenyl
Prior art date
Application number
PCT/US2005/020371
Other languages
French (fr)
Inventor
Pingda Ren
Xia Wang
Guobao Zhang
Qiang Ding
Shuli You
Qiong Zhang
Greg Chopiuk
Pamela A. Albaugh
Taebo Sim
Nathanael Schiander Gray
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MXPA06014247A priority Critical patent/MXPA06014247A/en
Application filed by Irm Llc filed Critical Irm Llc
Priority to US11/628,881 priority patent/US7745437B2/en
Priority to EP05759571A priority patent/EP1758892B1/en
Priority to ES05759571T priority patent/ES2396135T3/en
Priority to JP2007527742A priority patent/JP4688876B2/en
Priority to CN2005800175344A priority patent/CN1960988B/en
Priority to BRPI0511978-2A priority patent/BRPI0511978A/en
Priority to CA2567662A priority patent/CA2567662C/en
Priority to AU2005254982A priority patent/AU2005254982B2/en
Publication of WO2005123719A1 publication Critical patent/WO2005123719A1/en
Priority to IL179613A priority patent/IL179613A0/en
Priority to TNP2006000406A priority patent/TNSN06406A1/en
Priority to NO20070160A priority patent/NO20070160L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Definitions

  • the invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, PDGF-R, trkB, c-SRC, BMX, FGFR3, b-RAF, SGK, Tie2, Lck, JNK2 2, MKK4, c-RAF, MKK6, SAPK2 ⁇ and SAPK2 ⁇ kinases.
  • the protein kinases represent a large family of proteins, which play a central role in the regulation of a wide variety of cellular processes and maintaining control over cellular function.
  • a partial, non-limiting, list of these kinases include: receptor tyrosine kinases such as platelet-derived growth factor receptor kinase (PDGF-R), the nerve growth factor receptor, trkB, and the fibroblast growth factor receptor, FGFR3, B-RAF; non- receptor tyrosine kinases such Abl and the fusion kinase BCR-Abl, Lck, Bmx and c-src; and serine/threonine kinases such as c-RAF, sglc, MAP kinases (e.g., MKK4, MKK6, etc.) and SAPK2 ⁇ and SAPK2 ⁇ .
  • Aberrant kinase activity has been observed in many disease states including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activ
  • novel compounds of this invention inhibit the activity of one or more protein kinases and are, therefore, expected to be useful in the treatment of kinase-associated diseases.
  • the present invention provides compounds of Formula I:
  • Ri is selected from -XNR 5 R6, -XOR 5 , -XC(O)R 5 , -XR 5 and -XS(O) 0 .
  • R 5 wherein X is a bond or C ⁇ -4 alkylene optionally substituted by 1 to 2 C ⁇ aH yl radicals;
  • R 5 is selected from hydrogen, C ⁇ -6 alkyl, C 6 - ⁇ oaryl-Co- alkyl, C 5- ⁇ oheteroaryl-Co- 4 alkyl, C 3- ⁇ ocycloalkyl-C 0-4 alkyl and C 3- ⁇ oheterocycloalkyl-Co alkyl;
  • R 6 is selected from hydrogen and C ⁇ -6 alkyl; or R 5 and R 6 together with the nitrogen to which R 5 and ⁇ are both attached form heteroaryl or heterocycloalkyl; wherein any aryl, heteroaryl, cycloalkyl and heterocycloalkyl of R 5 or the combination of R 5 and R 6 can be optionally substituted with 1 to 3 radicals independently selected from halo, nitro, cyano, hydroxy, Cj- ⁇ alkyl, Ci- ⁇ alkoxy,
  • R 3 is selected from -NR 10 R ⁇ i, -NR ⁇ 0 C(O)R ⁇ 1 , -NR ⁇ 0 S(O) 0-2 R ⁇ 1 and -
  • Rw is selected from hydrogen and Cj- ⁇ alkyl
  • R ⁇ is selected from C ⁇ .ioaryl, Cs-ioheteroaryl, C 3- ⁇ ocycloalkyl and C 3- ⁇ 0 heterocycloalkyl
  • any aryl, heteroaryl, cycloalkyl or heterocycloalkyl of R ⁇ is optionally substituted by 1 to 3 radicals selected from halo, nitro, cyano, hydroxy, C ⁇ -6 alkyl, Ci- ⁇ alkoxy, halo-substituted-alkyl, halo- substituted-alkoxy, -NR 12 C(O)R, 3 , -NR 12 C(O)NR ⁇ 2 R 13 , -C(O)NR ⁇ 2 R i3 , -NR ⁇ 2 S(O) 0-2 R] 3 and -S(O)o- 2 NR] 2 R ⁇ 3 ; wherein Rj 2 is
  • any aryl, heteroaryl, cycloalkyl or heterocycloalkyl of Rj 3 is optionally substituted with 1 to 3 radicals independently selected from halo, Ci- ⁇ alkyl, halo-substituted-C ⁇ -6 alkyl, C ⁇ ealkoxy, halo- substituted-C ⁇ .6alkoxy, -XNR 7 R 8 , C 6- ⁇ oaryl-Co -4 alkyl, C5- ⁇ oheteroaryl-Co -4 alkyl, C 3- ⁇ ocycloalkyl-Co- 4 alkyl, C 3 - ⁇ oheterocycloalkyl-Co- alkoxy and C 3- ⁇ 0 heterocycloalkyl-Co- alkyl; wherein X, R 7 and R 8 are as described above and wherein any aryl, heteroaryl, cycloalkyl or heterocycloalkyl substituent of R ⁇ 3 is further optionally substituted by 1 to 3 radicals independently selected from halo
  • the present invention provides a pharmaceutical composition which contains a compound of Formula I or a N-oxide derivative, individual isomers and mixture of isomers thereof; or a pharmaceutically acceptable salt thereof, in admixture with one or more suitable excipients.
  • the present invention provides a method of treating a disease in an animal in which inhibition of kinase activity, particularly Abl, BCR-Abl, PDGF-R, trkB, c-SRC, BMX, FGFR3, B-RAF, SGK, Tie2, Lck, JNK2 ⁇ 2, MKK4, c-RAF, MK 6, SAPK2 ⁇ and/or SAPK2 ⁇ activity, can prevent, inhibit or ameliorate the pathology and/or symptomology of the diseases, which method comprises administering to the animal a therapeutically effective amount of a compound of Formula I or a N-oxide derivative, individual isomers and mixture of isomers thereof, or a pharmaceutically acceptable salt thereof.
  • kinase activity particularly Abl, BCR-Abl, PDGF-R, trkB, c-SRC, BMX, FGFR3, B-RAF, SGK, Tie2, Lck, JNK2 ⁇ 2, MKK4, c-RAF, MK 6, SAPK2 ⁇
  • the present invention provides the use of a compound of
  • the present invention provides a process for preparing compounds of Formula I and the N-oxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixture of isomers thereof, and the pharmaceutically acceptable salts thereof.
  • Alkyl as a group and as a structural element of other groups, for example halo-substituted-alkyl and alkoxy, can be either straight-chained or branched.
  • C ⁇ - -alkoxy includes, methoxy, ethoxy, and the like.
  • Halo-substituted alkyl includes trifluoromethyl, pentafluoroethyl, and the like.
  • Aryl means a monocyclic or fused bicyclic aromatic ring assembly containing six to ten ring carbon atoms.
  • aryl may be phenyl or naphthyl, preferably phenyl.
  • Arylene means a divalent radical derived from an aryl group.
  • Heteroaryl is as defined for aryl above where one or more of the ring members is a heteroatom.
  • heteroaryl includes pyridyl, indolyl, indazolyl, quinoxalinyl, quinolinyl, benzofuranyl, benzopyranyl, benzothiopyranyl, benzo[l,3]dioxole, imidazolyl, benzo-imidazolyl, pyrimidinyl, furanyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl, pyrazolyl, thienyl, etc.
  • Cycloalkyl means a saturated or partially unsaturated, monocyclic, fused bicyclic or bridged polycyclic ring assembly containing the number of ring atoms indicated.
  • C 3- ⁇ ocycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc.
  • C 3-8 heterocycloalkyl as used in this application to describe compounds of the invention includes morpholino, pyrrolidinyl, pyrrolidinyl-2-one, piperazinyl, piperidinyl, piperidinylone, l,4-dioxa-8-aza-spiro[4.5]dec-8-yl, etc.
  • "Halogen" (or halo) preferably represents chloro or fluoro, but may also be bromo or iodo.
  • mutant forms of BCR-Abl means single or multiple amino acid changes from the wild-type sequence. Over 22 mutations have been reported to date with the most common being G250E, E255V, T315I, F317L and M351T.
  • Treatment refers to a method of alleviating or abating a disease and/or its attendant symptoms.
  • the fusion protein BCR-Abl is a result of a reciprocal translocation that fuses the Abl proto-oncogene with the Bcr gene. BCR-Abl is then capable of transforming B-cells through the increase of mitogenic activity. This increase results in a reduction of sensitivity to apoptosis, as well as altering the adhesion and homing of CML progenitor cells.
  • the present invention provides compounds, compositions and methods for the treatment of kinase related disease, particularly Abl, BCR-Abl, PDGF-R, trkB, c-SRC, BMX, FGFR3, B-RAF, b-RAF, SGK, Tie2, Lck, JNK2 ⁇ 2, MKK4, c-RAF, MKK6, SAPK2 ⁇ and SAPK2 ⁇ kinase related diseases.
  • kinase related disease particularly Abl, BCR-Abl, PDGF-R, trkB, c-SRC, BMX, FGFR3, B-RAF, b-RAF, SGK, Tie2, Lck, JNK2 ⁇ 2, MKK4, c-RAF, MKK6, SAPK2 ⁇ and SAPK2 ⁇ kinase related diseases.
  • leukemia and other proliferation disorders related to BCR-Abl can be treated through the inhibition of wild type and mutant forms of Bcr-Abl.
  • R 5 is selected from hydrogen, C ⁇ . 6 alkyl, C6- ⁇ oaryl-Co- 4 alkyl, C 3-1 oheteroaryl-Co- 4 alkyl, C 3- ⁇ ocycloalkyl-C 0 - alkyl and C 3 . ⁇ oheterocycloalkyl-C 0- alkyl; and Re is selected from hydrogen and C ⁇ -6 alkyl; or R 5 and R 6 together with the nitrogen to which R 5 and R 6 are both attached form heteroaryl or heterocycloalkyl; wherein any aryl, heteroaryl, cycloalkyl and heterocycloalkyl of R 5 or the combination of Rs and R ⁇ can be optionally substituted with 1 to 3 radicals independently selected from halo, nitro, cyano, hydroxy, C 1-6 alkyl, C 1-6 alkoxy, halo-sub
  • R 5 is selected from hydrogen, morpholino-ethyl, cyclopropyl, methyl, 3-(2-oxo-pyrrolidin-l-yl)-propyl, benzo[l,3]dioxol-5-yl, 3-(4-methyl- piperazin-l-yl)-propyl, hydroxymethyl-phenyl, (l-hydroxyethyl)-phenyl, morpholino, pyridinyl, methyl-carbonyl, methyl-sulfonyl, methyl-pyridinyl, amino-cyclohexyl, piperidinyl, methyl-piperazinyl-ethyl, dimethyl-pyrazolyl, methyl-pyrazolyl, dimethyl- pyridinyl, methyl-pyridinyl, ethyl-piperazinyl-pyridinyl, amino-carbonyl-pyridinyl, cyano- pyr
  • R ⁇ 6 is selected from -NHC(O)R ⁇ 3 , -
  • R 13 is selected from phenyl, pyridazinyl, pyridinyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, quinoxalinyl, thienyl and thiazolyl; wherein R ⁇ 3 is optionally substituted with 1 to 3 radicals independently selected from methyl, t-butyl, halo, trifluoromethyl, diethyl-amino, dimethyl-amino, benzyl, piperidinyl-amino, pyrrolidinyl-methoxy, ethyl-piperazinyl-methyl, morpholino, methyl- piperazinyl, methyl-piperazinyl-methyl, ethyl-piperazinyl, methyl-imidazo
  • Preferred compounds of the invention are selected from N-[4-methyl-3-(l-)
  • Compounds of the invention modulate the activity of kinases and, as such, are useful for treating diseases or disorders in which kinases, contribute to the pathology and/or symptomology of the disease.
  • kinases that are inhibited by the compounds and compositions described herein and against which the methods described herein are useful include, but are not limited to, Abl, BCR-Abl (wild-type and mutant forms), PDGF-R, trkB, c-SRC, BMX, FGFR3, b-RAF, SGK, Tie2, Lck, JNK2 ⁇ 2, MKK4, c- RAF, MKK6, SAPK2 ⁇ and SAPK2 ⁇ .
  • Abelson tyrosine kinase i.e. Abl, c-Abl
  • Abl Abl
  • c-Abl abelson tyrosine kinase
  • Abelson tyrosine kinase includes sub-types derivatives such as the chimeric fusion (oncoprotein) BCR-Abl with deregulated tyrosine kinase activity or the v- Abl.
  • BCR-Abl is critical in the pathogenesis of 95% of chronic myelogenous leukemia (CML) and 10% of acute lymphocytic leukemia.
  • STI-571 (Gleevec) is an inhibitor of the oncogenic BCR-Abl tyrosine kinase and is used for the treatment of chronic myeloid leukemia (CML).
  • CML chronic myeloid leukemia
  • some patients in the blast crisis stage of CML are resistant to STI-571 due to mutations in the BCR-Abl kinase. Over 22 mutations have been reported to date with the most common being G250E, E255V, T315I, F317L and M351T.
  • Compounds of the present invention inhibit abl kinase, especially v-abl kinase.
  • the compounds of the present invention also inhibit wild-type BCR-Abl kinase and mutations of BCR-Abl kinase and are thus suitable for the treatment of Bcr-abl-positive cancer and tumor diseases, such as leukemias (especially chronic myeloid leukemia and acute lymphoblastic leukemia, where especially apoptotic mechanisms of action are found), and also shows effects on the subgroup of leukemic stem cells as well as potential for the purification of these cells in vitro after removal of said cells (for example, bone marrow removal) and reimplantation of the cells once they have been cleared of cancer cells (for example, reimplantation of purified bone marrow cells).
  • Bcr-abl-positive cancer and tumor diseases such as leukemias (especially chronic myeloid leukemia and acute lymphoblastic leukemia, where especially apoptotic mechanisms of action are found)
  • the Ras-Raf-MEK-ERK signaling pathway mediates cellular response to growth signals. Ras is mutated to an oncogenic form in ⁇ 15% of human cancer.
  • the Raf family belongs to the serine/threonine protein kinase and it includes three members, A-Raf, B-Raf and c-Raf (or Raf-1).
  • the focus on Raf being a drug target has centered on the relationship of Raf as a downstream effector of Ras.
  • B- Raf may have a prominent role in the formation of certain tumors with no requirement for an activated Ras allele (Nature 417, 949 - 954 (01 Jul 2002).
  • B-Raf mutations have been detected in a large percentage of malignant melanomas.
  • Existing medical treatments for melanoma are limited in their effectiveness, especially for late stage melanomas.
  • the compounds of the present invention also inhibit cellular processes involving b-Raf kinase, providing a new therapeutic opportunity for treatment of human cancers, especially for melanoma.
  • the compounds of the present invention also inhibit cellular processes involving c-Raf kinase. c-Raf is activated by the ras oncogene, which is mutated in a wide number of human cancers.
  • PDGF Platinum-derived Growth Factor
  • PDGFR PDGF receptor
  • Compounds of the present invention can be used not only as a tumor- inhibiting substance, for example in small cell lung cancer, but also as an agent to treat non- malignant proliferative disorders, such as atherosclerosis, thrombosis, psoriasis, scleroderma and fibrosis, as well as for the protection of stem cells, for example to combat the hemotoxic effect of chemotherapeutic agents, such as 5-fluoruracil, and in asthma.
  • Compounds of the invention can especially be used for the treatment of diseases, which respond to an inhibition of the PDGF receptor kinase.
  • Compounds of the present invention show useful effects in the treatment of disorders arising as a result of transplantation, for example, allogenic transplantation, especially tissue rejection, such as especially obliterative bronchiolitis (OB), i.e. a chronic rejection of allogenic lung transplants. In contrast to patients without OB, those with OB often show an elevated PDGF concentration in bronchoalveolar lavage fluids.
  • OB obliterative bronchiolitis
  • Compounds of the present invention are also effective in diseases associated with vascular smooth-muscle cell migration and proliferation (where PDGF and PDGF-R often also play a role), such as restenosis and atherosclerosis.
  • the trk family of neurotrophin receptors promotes the survival, growth and differentiation of the neuronal and non-neuronal tissues.
  • the TrkB protein is expressed in neuroendocrine-type cells in the small intestine and colon, in the alpha cells of the pancreas, in the monocytes and macrophages of the lymph nodes and of the spleen, and in the granular layers of the epidermis (Shibayama and Koizumi, 1996). Expression of the TrkB protein has been associated with an unfavorable progression of Wilms tumors and of neuroblastomas.
  • TkrB is, moreover, expressed in cancerous prostate cells but not in normal cells.
  • the signaling pathway downstream of the trk receptors involves the cascade of MAPK activation through the She, activated Ras, ERK-1 and ERK-2 genes, and the PLC-gammal transduction pathway (Sugimoto et al., 2001).
  • the kinase, c-Src transmits oncogenic signals of many receptors. For example, over-expression of EGFR or HER2/neu in tumors leads to the constitutive activation of c-src, which is characteristic for the malignant cell but absent from the normal cell.
  • mice deficient in the expression of c-src exhibit an osteopetrotic phenotype, indicating a key participation of c-src in osteoclast function and a possible involvement in related disorders.
  • Fibroblast growth factor receptor 3 was shown to exert a negative regulatory effect on bone growth and an inhibition of chondrocyte proliferation. Thanatophoric dysplasia is caused by different mutations in fibroblast growth factor receptor 3, and one mutation, TDII FGFR3, has a constitutive tyrosine kinase activity which activates the transcription factor Statl, leading to expression of a cell-cycle inhibitor, growth arrest and abnormal bone development (Su et al., Nature, 1997, 386, 288-292).
  • FGFR3 is also often expressed in multiple myeloma-type cancers.
  • Inhibitors of FGFR3 activity are useful in the treatment of T-cell mediated inflammatory or autoimmune diseases including but not limited to rheumatoid arthritis (RA), collagen II arthritis, multiple sclerosis (MS), systemic lupus erythematosus (SLE), psoriasis, juvenile onset diabetes, Sjogren's disease, thyroid disease, sarcoidosis, autoimmune uveitis, inflammatory bowel disease (Crohn's and ulcerative colitis), celiac disease and myasthenia gravis.
  • RA rheumatoid arthritis
  • MS multiple sclerosis
  • SLE systemic lupus erythematosus
  • psoriasis juvenile onset diabetes
  • Sjogren's disease thyroid disease
  • sarcoidosis autoimmune uveitis
  • inflammatory bowel disease Crohn's and ulcerative colitis
  • Tie2 inhibitors can be used in situations where neovascularization takes place inappropriately (i.e. in diabetic retinopathy, chronic inflammation, psoriasis, Kaposi's sarcoma, chronic neovascularization due to macular degeneration, rheumatoid arthritis, infantile haemangioma and cancers).
  • Lck plays a role in T-cell signaling. Mice that lack the Lck gene have a poor ability to develop thymocytes. The function of Lck as a positive activator of T-cell signaling suggests that Lck inhibitors may be useful for treating autoimmune disease such as rheumatoid arthritis.
  • JNKs have been implicated in having a role in mediating cellular response to Cancer, thrombin-induced platelet aggregation, immunodeficiency disorders, autoimmune diseases, cell death, allergies, osteoporosis and heart disease.
  • the therapeutic targets related to activation of the JNK pathway include chronic myelogenous leukemia (CML), rheumatoid arthritis, asthma, osteoarthritis, ischemia, cancer and neurodegenerative diseases.
  • CML chronic myelogenous leukemia
  • rheumatoid arthritis rheumatoid arthritis
  • asthma chronic myelogenous leukemia
  • osteoarthritis rheumatoid arthritis
  • ischemia ischemia
  • compounds of the invention may also be useful to treat various hepatic disorders.
  • JNK Kaposi's sarcoma
  • VEGF vascular endothelial growth factor
  • IL-6 IL-6
  • TNF vascular endothelial growth factor
  • Certain abnormal proliferative conditions are believed to be associated with raf expression and are, therefore, believed to be responsive to inhibition of raf expression. Abnormally high levels of expression of the raf protein are also implicated in transformation and abnormal cell proliferation. These abnormal proliferative conditions are also believed to be responsive to inhibition of raf expression. For example, expression of the c-raf protein is believed to play a role in abnormal cell proliferation since it has been reported that 60% of all lung carcinoma cell lines express unusually high levels of c-raf mRNA and protein.
  • abnormal proliferative conditions are hyper- proliferative disorders such as cancers, tumors, hyperplasia, pulmonary fibrosis, angiogenesis, psoriasis, atherosclerosis and smooth muscle cell proliferation in the blood vessels, such as stenosis or restenosis following angioplasty.
  • the cellular signaling pathway of which raf is a part has also been implicated in inflammatory disorders characterized by T- cell proliferation (T-cell activation and growth), such as tissue graft rejection, endotoxin shock, and glomerular nephritis, for example.
  • SAPKs stress activated protein kinases
  • c-jun is involved in the transcription of genes that encode proteins involved in the repair of DNA that is damaged due to genotoxic insults. Therefore, agents that inhibit SAPK activity in a cell prevent DNA repair and sensitize the cell to agents that induce DNA damage or inhibit DNA synthesis and induce apoptosis of a cell or that inhibit cell proliferation.
  • MAPKs Mitogen-activated protein kinases
  • MKKs mitogen- activated protein kinase kinases
  • ribosomal S6 protein kinases consists of at least 8 members (RSK1, RSK2, RSK3, RSK4, MSK1, MSK2, p70S6K and p70S6 Kb). Ribosomal protein S6 protein kinases play important pleotropic functions, among them is a key role in the regulation of mRNA translation during protein biosynthesis (Eur. J. Biochem 2000 November; 267(21): 6321-30, Exp Cell Res. Nov.
  • SAPK's also called "jun N-terminal kinases” or “JNK's”
  • JNK's are a family of protein kinases that represent the penultimate step in signal transduction pathways that result in activation of the c-jun transcription factor and expression of genes regulated by c- jun.
  • c-jun is involved in the transcription of genes that encode proteins involved in the repair of DNA that is damaged due to genotoxic insults.
  • SAPK activity in a cell prevent DNA repair and sensitize the cell to those cancer therapeutic modalities that act by inducing DNA damage.
  • BTK plays a role in autoimmune and/or inflammatory disease such as systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple vasculitides, idiopathic thrombocytopenic purpura (ITP), myasthenia gravis, and asthma. Because of BTK's role in SLE, systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple vasculitides, idiopathic thrombocytopenic purpura (ITP), myasthenia gravis, and asthma. Because of BTK's role in SLE, rheumatoid arthritis, multiple vasculitides, idiopathic thrombocytopenic purpura (ITP), myasthenia gravis, and asthma. Because of BTK's role in SLE, rheumatoid arthritis, multiple vasculitides, idiopathic thrombocytopenic purpura (
  • inhibitors of BTK are useful as inhibitors of B-cell mediated pathogenic activity, such as autoantibody production, and are useful for the treatment of B-cell lymphoma and leukemia.
  • CHK2 is a member of the checkpoint kinase family of serine/threonine protein kinases and is involved in a mechanism used for surveillance of DNA damage, such as damage caused by environmental mutagens and endogenous reactive oxygen species. As a result, it is implicated as a tumor suppressor and target for cancer therapy.
  • CSK influences the metastatic potential of cancer cells, particularly colon cancer.
  • Fes is a non-receptor protein tyrosine kinase that has been implicated in a variety of cytokine signal transduction pathways, as well as differentiation of myeloid cells.
  • Fes is also a key component of the granulocyte differentiation machinery.
  • Flt3 receptor tyrosine kinase activity is implicated in leukemias and myelodysplastic syndrome.
  • the leukemia cells express a constitutively active form of auto-phosphorylated (p) FLT3 tyrosine kinase on the cell surface.
  • the activity of p-FLT3 confers growth and survival advantage on the leukemic cells.
  • Patients with acute leukemia, whose leukemia cells express p-FLT3 kinase activity have a poor overall clinical outcome. Inhibition of p-FLT3 kinase activity induces apoptosis
  • Inhibitors of IKK ⁇ and IKK ⁇ (1 & 2) are therapeutics for diseases which include rheumatoid arthritis, transplant rejection, inflammatory bowel disease, osteoarthritis, asthma, chronic obstructive pulmonary disease, atherosclerosis, psoriasis, multiple sclerosis, stroke, systemic lupus erythematosus, Alzheimer's disease, brain ischemia, traumatic brain injury, Parkinson's disease, amyotrophic lateral sclerosis, subarachnoid hemorrhage or other diseases or disorders associated with excessive production of inflammatory mediators in the brain and central nervous system.
  • diseases include rheumatoid arthritis, transplant rejection, inflammatory bowel disease, osteoarthritis, asthma, chronic obstructive pulmonary disease, atherosclerosis, psoriasis, multiple sclerosis, stroke, systemic lupus erythematosus, Alzheimer's disease, brain ischemia, traumatic brain injury, Parkinson's disease, amyotrophic
  • Met is associated with most types of the major human cancers and expression is often correlated with poor prognosis and metastasis.
  • Inhibitors of Met are therapeutics for diseases which include cancers such as lung cancer, NSCLC (non small cell lung cancer), bone cancer, pancreatic cancer, skin cancer, cancer of the head and neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, colon cancer, breast cancer, gynecologic tumors (e.
  • uterine sarcomas carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina or carcinoma of the vulva
  • Hodgkin's Disease cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system (e. g., cancer of the thyroid, parathyroid or adrenal glands), sarcomas of soft tissues, cancer of the urethra, cancer of the penis, prostate cancer, chronic or acute leukemia, solid tumors of childhood, lymphocytic lymphomas, cancer of the bladder, cancer of the kidney or ureter (e.
  • neoplasms of the central nervous system e. g., primary CNS lymphoma, spinal axis tumors, brain stem glioma or pituitary adenomas
  • cancers of the blood such as acute myeloid leukemia, chronic myeloid leukemia, etc, Barrett's esophagus (pre-malignant syndrome) neoplastic cutaneous disease, psoriasis, mycoses fungoides and benign prostatic hypertrophy
  • diabetes related diseases such as diabetic retinopathy, retinal ischemia and retinal neovascularization, hepatic cirrhosis
  • cardiovascular disease such as atherosclerosis
  • immunological disease such as autoimmune disease and renal disease.
  • the disease is cancer such as acute myeloid leukemia and colorectal cancer.
  • the Nima-related kinase 2 (Nek2) is a cell cycle-regulated protein kinase with maximal activity at the onset of mitosis that localizes to the centrosome. Functional studies have implicated Nek2 in regulation of centrosome separation and spindle formation. Nek2 protein is elevated 2- to 5-fold in cell lines derived from a range of human tumors including those of cervical, ovarian, prostate, and particularly breast.
  • p70S6K-mediated diseases or conditions include, but are not limited to, proliferative disorders, such as cancer and tuberous sclerosis.
  • the present invention further provides a method for preventing or treating any of the diseases or disorders described above in a subject in need of such treatment, which method comprises administering to said subject a therapeutically effective amount See, "Administration and Pharmaceutical Compositions ", infra) of a compound of Formula I or a pharmaceutically acceptable salt thereof.
  • administering to said subject a therapeutically effective amount See, "Administration and Pharmaceutical Compositions ", infra) of a compound of Formula I or a pharmaceutically acceptable salt thereof.
  • the required dosage will vary depending on the mode of administration, the particular condition to be treated and the effect desired.
  • compounds of the invention will be administered in therapeutically effective amounts via any of the usual and acceptable modes known in the art, either singly or in combination with one or more therapeutic agents.
  • a therapeutically effective amount may vary widely depending on the severity of the disease, the age and relative health of the subject, the potency of the compound used and other factors. In general, satisfactory results are indicated to be obtained systemically at daily dosages of from about 0.03 to 2.5mg/kg per body weight.
  • An indicated daily dosage in the larger mammal, e.g. humans, is in the range from about 0.5mg to about lOOmg, conveniently administered, e.g. in divided doses up to four times a day or in retard form.
  • Suitable unit dosage forms for oral administration comprise from ca. 1 to 50mg active ingredient.
  • Compounds of the invention can be administered as pharmaceutical compositions by any conventional route, in particular enterally, e.g., orally, e.g., in the form of tablets or capsules, or parenterally, e.g., in the form of injectable solutions or suspensions, topically, e.g., in the form of lotions, gels, ointments or creams, or in a nasal or suppository form.
  • Pharmaceutical compositions comprising a compound of the present invention in free form or in a pharmaceutically acceptable salt form in association with at least one pharmaceutically acceptable carrier or diluent can be manufactured in a conventional manner by mixing, granulating or coating methods.
  • oral compositions can be tablets or gelatin capsules comprising the active ingredient together with a) diluents, e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycine; b) lubricants, e.g., silica, talcum, stearic acid, its magnesium or calcium salt and/or polyethyleneglycol; for tablets also c) binders, e.g., magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylceliulose and or polyvinylpyrrolidone; if desired d) disintegrants, e.g., starches, agar, alginic acid or its sodium salt, or effervescent mixtures; and/or e) absorbents, colorants, flavors and sweeteners.
  • diluents e.g., lactose, dextrose,
  • Injectable compositions can be aqueous isotonic solutions or suspensions, and suppositories can be prepared from fatty emulsions or suspensions.
  • the compositions may be sterilized and/or contain adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers. In addition, they may also contain other therapeutically valuable substances.
  • Suitable formulations for transdermal applications include an effective amount of a compound of the present invention with ' a carrier.
  • a carrier can include absorbable pharmacologically acceptable solvents to assist passage through the skin of the host.
  • transdermal devices are in the form of a bandage comprising a backing member, a reservoir containing the compound optionally with carriers, optionally a rate controlling barrier to deliver the compound to the skin of the host at a controlled and predetermined rate over a prolonged period of time, and means to secure the device to the skin.
  • Matrix transdermal formulations may also be used.
  • Suitable formulations for topical application, e.g., to the skin and eyes, are preferably aqueous solutions, ointments, creams or gels well-known in the art. Such may contain solubilizers, stabilizers, tonicity enhancing agents, buffers and preservatives.
  • Compounds of the invention can be administered in therapeutically effective amounts in combination with one or more therapeutic agents (pharmaceutical combinations).
  • therapeutic agents for example, synergistic effects can occur with other immunomodulatory or anti-inflammatory substances, for example when used in combination with cyclosporin, rapamycin, or ascomycin, or immunosuppressant analogues thereof, for example cyclosporin A (CsA), cyclosporin G, FK-506, rapamycin, or comparable compounds, corticosteroids, cyclophosphamide, azathioprine, methotrexate, brequinar, leflunomide, mizoribine, mycophenolic acid, mycophenolate mofetil, 15-deoxyspergualin, immunosuppressant antibodies, especially monoclonal antibodies for leukocyte receptors, for example MHC, CD2, CD3, CD4, CD7, CD25, CD28, B7, CD45, CD58 or their ligands, or other immunomodulatory compounds, such as CT
  • the invention also provides for a pharmaceutical combinations, e.g. a kit, comprising a) a first agent which is a compound of the invention as disclosed herein, in free form or in pharmaceutically acceptable salt form, and b) at least one co-agent.
  • a pharmaceutical combination e.g. a kit, comprising a) a first agent which is a compound of the invention as disclosed herein, in free form or in pharmaceutically acceptable salt form, and b) at least one co-agent.
  • the kit can comprise instructions for its administration.
  • co-administration or “combined administration” or the like as utilized herein are meant to encompass administration of the selected therapeutic agents to a single patient, and are intended to include treatment regimens in which the agents are not necessarily administered by the same route of administration or at the same time.
  • pharmaceutical combination as used herein means a product that results from the mixing or combining of more than one active ingredient and includes both fixed and non-fixed combinations of the active ingredients.
  • fixed combination means that the active ingredients, e.g. a compound of Formula I and a co- agent, are both administered to a patient simultaneously in the form of a single entity or dosage.
  • non-fixed combination means that the active ingredients, e.g.
  • a compound of Formula I and a co-agent are both administered to a patient as separate entities either simultaneously, concurrently or sequentially with no specific time limits, wherein such administration provides therapeutically effective levels of the 2 compounds in the body of the patient.
  • cocktail therapy e.g. the administration of 3 or more active ingredients.
  • the present invention also includes processes for the preparation of compounds of the invention.
  • reactive functional groups for example hydroxy, amino, imino, thio or carboxy groups, where these are desired in the final product, to avoid their unwanted participation in the reactions.
  • Conventional protecting groups can be used in accordance with standard practice, for example, see T.W. Greene and P. G. M. Wuts in "Protective Groups in Organic Chemistry", John Wiley and Sons, 1991.
  • Compounds of Formula I can be prepared by proceeding as in the following Reaction Scheme I:
  • a compound of Formula I can be prepared by reacting a compound of formula 2 with a compound of formula 3 in the presence of a suitable base (e.g., DIPEA, or the like) and a suitable solvent (e.g., butanol, THF, DMF, or the like). The reaction proceeds in a temperature range of about 80 to about 120°C and can take up to about 20 hours to complete.
  • a suitable base e.g., DIPEA, or the like
  • a suitable solvent e.g., butanol, THF, DMF, or the like.
  • a compound of the invention can be prepared as a pharmaceutically acceptable acid addition salt by reacting the free base form of the compound with a pharmaceutically acceptable inorganic or organic acid.
  • a pharmaceutically acceptable base addition salt of a compound of the invention can be prepared by reacting the free acid form of the compound with a pharmaceutically acceptable inorganic or organic base.
  • the salt forms of the compounds of the invention can be prepared using salts of the starting materials or intermediates.
  • the free acid or free base forms of the compounds of the invention can be prepared from the corresponding base addition salt or acid addition salt from, respectively.
  • a compound of the invention in an acid addition salt form can be converted to the corresponding free base by treating with a suitable base (e.g., ammonium hydroxide solution, sodium hydroxide, and the like).
  • a suitable base e.g., ammonium hydroxide solution, sodium hydroxide, and the like.
  • a compound of the invention in a base addition salt form can be converted to the corresponding free acid by treating with a suitable acid
  • Compounds of the invention in unoxidized form can be prepared from N- oxides of compounds of the invention by treating with a reducing agent (e.g., sulfur, sulfur dioxide, triphenyl phosphine, lithium borohydride, sodium borohydride, phosphorus trichloride, tribromide, or the like) in a suitable inert organic solvent (e.g. acetonitrile, ethanol, aqueous dioxane, or the like) at 0 to 80°C.
  • a reducing agent e.g., sulfur, sulfur dioxide, triphenyl phosphine, lithium borohydride, sodium borohydride, phosphorus trichloride, tribromide, or the like
  • a suitable inert organic solvent e.g. acetonitrile, ethanol, aqueous dioxane, or the like
  • Prodrug derivatives of the compounds of the invention can be prepared by methods known to those of ordinary skill in the art (e.g., for further details see Saulnier et al., (1994), Bioorganic and Medicinal Chemistry Letters, Vol. 4, p. 1985).
  • appropriate prodrugs can be prepared by reacting a non-derivatized compound of the invention with a suitable carbamylating agent (e.g., 1,1-acyloxyalkylcarbanochloridate, para- nitrophenyl carbonate, or the like).
  • Hydrates of compounds of the present invention can be conveniently prepared, or formed during the process of the invention, as solvates (e.g., hydrates). Hydrates of compounds of the present invention can be conveniently prepared by recrystallization from an aqueous/organic solvent mixture, using organic solvents such as dioxin, tetrahydrofuran or methanol.
  • Compounds of the invention can be prepared as their individual stereoisomers by reacting a racemic mixture of the compound with an optically active resolving agent to form a pair of diastereoisomeric compounds, separating the diastereomers and recovering the optically pure enantiomers. While resolution of enantiomers can be carried out using covalent diastereomeric derivatives of the compounds of the invention, dissociable complexes are preferred (e.g., crystalline diastereomeric salts). Diastereomers have distinct physical properties (e.g., melting points, boiling points, solubilities, reactivity, etc.) and can be readily separated by taking advantage of these dissimilarities.
  • the diastereomers can be separated by chromatography, or preferably, by separation/resolution techniques based upon differences in solubility.
  • the optically pure enantiomer is then recovered, along with the resolving agent, by any practical means that would not result in racemization.
  • a more detailed description of the techniques applicable to the resolution of stereoisomers of compounds from their racemic mixture can be found in Jean Jacques, Andre Collet, Samuel H. Wilen, "Enantiomers, Racemates and Resolutions", John Wiley And Sons, Inc., 1981.
  • the compounds of Formula I can be made by a process, which involves: (a) those of reaction schemes I and II, for example coupling compounds of formula 8 with R 6 YOH according to reaction scheme I; and (b) optionally converting a compound of the invention into a pharmaceutically acceptable salt; (c) optionally converting a salt form of a compound of the invention to a non-salt form; (d) optionally converting an unoxidized form of a compound of the invention into a pharmaceutically acceptable N-oxide; (e) optionally converting an N-oxide form of a compound of the invention to its unoxidized form; (f) optionally resolving an individual isomer of a compound of the invention from a mixture of isomers; (g) optionally converting a non-derivatized compound of the invention into a pharmaceutically acceptable prodrug derivative; and (h) optionally converting a prodrug derivative of a compound of the invention to its non-derivatized form.
  • the nitro compound was dissolved in ethanol (250 mL). After hydrogenation on palladium (10 wt% on activated carbon, wet, Degussa type, 5 g) using Parr Shaker, 20 -30 psi H , 16 h, the reaction mixture was filtered through a pad of celite and washed with ethanol. The combined filtrate and washings were concentrated to afford the title compound N-(3-Amino-4-methyl-phenyl)-benzamide (22.43 g, 95 % over two steps), which was used for next reaction without any further purification.
  • the reaction mixture was then partitioned between dichloromethane and saturated sodium carbonate solution.
  • the organic layer was separated and the aqueous layer was extracted with dichloromethane.
  • the combined organic extracts were washed with water, brine, dried over Na 2 SO 4 , filtered and concentrated to afford the desired product (4.58 g, 98%).
  • the desired compound was used in the next step without further purification.
  • Compounds of the present invention are assayed to measure their capacity to selectively inhibit cell proliferation of 32D cells expressing BCR-Abl (32D-p210) compared with parental 32D cells. Compounds selectively inhibiting the proliferation of these BCR-Abl transformed cells are tested for anti-proliferative activity on Ba/F3 cells expressing either wild type or the mutant forms of Bcr-abl.
  • compounds are assayed to measure their capacity to inhibit FGFR3, b-RAF, Abl, BMX, BTK, CHK2, c- RAF, CSK, c-SRC, Fes, Flt3, IKK ⁇ , IKK ⁇ , JNK2 ⁇ 2, Lck, Met, MKK4, MKK6, MST2, NEK2, p70S6K, PDGFR ⁇ , PKA, PKB ⁇ , PKD2, Rskl, SAPK2 ⁇ , SAPK2 ⁇ , SAPK3, SGK, Tie2 and TrkB kinases.
  • the murine cell line used is the 32D hemopoietic progenitor cell line transformed with BCR-Abl cDNA (32D-p210). These cells are maintained in RPMI/10% fetal calf serum (RPMI FCS) supplemented with penicillin 50 ⁇ g/mL, streptomycin 50 ⁇ g/mL and L-glutamine 200 mM. Untransformed 32D cells are similarly maintained with the addition of 15% of WEHI conditioned medium as a source of IL3. [0097] 50 ⁇ l of a 32D or 32D-p210 cells suspension are plated in Greiner 384 well microplates (black) at a density of 5000 cells per well.
  • Greiner 384 well microplates black
  • test compound 1 mM in DMSO stock solution
  • STI571 is included as a positive control
  • the cells are incubated for 72 hours at 37 'C, 5% CO 2 .
  • 10 ⁇ l of a 60% Alamar Blue solution (Tek diagnostics) is added to each well and the cells are incubated for an additional 24 hours.
  • the fluorescence intensity (Excitation at 530 run, Emission at 580 nm) is quantified using the AcquestTM system (Molecular Devices).
  • 32D-p210 cells are plated into 96 well TC plates at a density of 15,000 cells per well. 50 ⁇ L of two fold serial dilutions of the test compound (C max is 40 ⁇ M) are added to each well (STI571 is included as a positive control). After incubating the cells for 48 hours at 37 °C, 5% CO 2 , 15 ⁇ L of MTT (Promega) is added to each well and the cells are incubated for an additional 5 hours. The optical density at 570nm is quantified spectrophotometrically and IC$o values, the concentration of compound required for 50% inhibition, determined from a dose response curve. Effect on cell cycle distribution
  • BCR-Abl autophosphorylation is quantified with capture Elisa using a c-abl specific capture antibody and an antiphosphotyrosine antibody.
  • 32D-p210 cells are plated in 96 well TC plates at 2xl0 5 cells per well in 50 ⁇ L of medium. 50 ⁇ L of two fold serial dilutions of test compounds (C max is 10 ⁇ M) are added to each well (STI571 is included as a positive control). The cells are incubated for 90 minutes at 37 °C, 5% CO 2 .
  • the cells are then treated for 1 hour on ice with 150 ⁇ L of lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 5 mM EDTA, 1 mM EGTA and l% NP-40) containing protease and phosphatase inhibitors.
  • 50 ⁇ L of cell lysate is added to 96 well optiplates previously coated with anti-abl specific antibody and blocked. The plates are incubated for 4 hours at 4 °C After washing with TBS-Tween 20 buffer, 50 ⁇ L of alkaline-phosphatase conjugated anti-phosphotyrosine antibody is added and the plate is further incubated overnight at 4 °C.
  • Test compounds of the invention that inhibit the proliferation of the BCR-Abl expressing cells, inhibit the cellular BCR-Abl autophosphorylation in a dose-dependent manner.
  • Ba/F3 cells expressing either wild type or the mutant forms of BCR-Abl (G250E, E255V, T315I, F317L, M351T) that confers resistance or diminished sensitivity to STI571.
  • the antiproliferative effect of these compounds on the mutant-BCR-Abl expressing cells and on the non transformed cells were tested at 10, 3.3, 1.1 and 0.37 ⁇ M as described above (in media lacking IL3).
  • the IC50 values of the compounds lacking toxicity on the untransformed cells were determined from the dose response curves obtained as describe above.
  • Kinase activity assay with purified FGFR3 (Upstate) is carried out in a final volume of 10 ⁇ L containing 0.25 ⁇ g/mL of enzyme in kinase buffer (30 mM Tris-HCl ⁇ H7.5, 15 mM MgCI 2 , 4.5 mM MnCl 2 , 15 ⁇ M Na 3 VO and 50 ⁇ g/mL BSA), and substrates (5 ⁇ g/mL biotin-poly-EY(Glu, Tyr) (CIS-US, Inc.) and 3 ⁇ M ATP).
  • the first solution of 5 ⁇ l contains the FGFR3 enzyme in kinase buffer was first dispensed into 384- format ProxiPlate® (Perkin-Elmer) followed by adding 50 nL of compounds dissolved in DMSO, then 5 ⁇ l of second solution contains the substrate (poly- EY) and ATP in kinase buffer was added to each wells.
  • the reactions are incubated at room temperature for one hour, stopped by adding 10 ⁇ L of HTRF detection mixture, which contains 30 mM Tris-HCl pH7.5, 0.5 M KF, 50 mM ETDA, 0.2 mg/mL BSA, 15 ⁇ g/mL streptavidin-XL665 (CIS-US, Inc.) and 150 ng/mL cryptate conjugated anti-phosphotyrosine antibody (CIS-US, Inc.). After one hour of room temperature incubation to allow for streptavidin-biotin interaction, time resolved florescent signals are read on Analyst GT (Molecular Devices Corp.).
  • IC 50 values are calculated by linear regression analysis of the percentage inhibition of each compound at 12 concentrations (1:3 dilution from 50 ⁇ M to 0.28 nM). In this assay, compounds of the invention have an IC 5 o in the range of 10 nM to 2 ⁇ M.
  • Compounds of the invention are tested for their ability to inhibit transformed Ba F3-TEL-FGFR3 cells proliferation, which is depended on FGFR3 cellular kinase activity.
  • Ba F3-TEL-FGFR3 are cultured up to 800,000 cells/mL in suspension, with RPMI 1640 supplemented with 10% fetal bovine serum as the culture medium. Cells are dispensed into 384-well format plate at 5000 cell/well in 50 ⁇ L culture medium.
  • Compounds of the invention are dissolved and diluted in dimethylsufoxide (DMSO). Twelve points 1 :3 serial dilutions are made into DMSO to create concentrations gradient ranging typically from 10 mM to 0.05 ⁇ M.
  • DMSO dimethylsufoxide
  • AlamarBlue® (TREK Diagnostic Systems), which can be used to monitor the reducing environment created by proliferating cells, are added to cells at final concentration of 10%. After additional four hours of incubation in a 37 °C cell culture incubator, fluorescence signals from reduced AlamarBlue® (Excitation at 530 nm, Emission at 580 nm) are quantified on Analyst GT (Molecular Devices Corp.). IC 50 values are calculated by linear regression analysis of the percentage inhibition of each compound at 12 concentrations.
  • Compounds of the invention are tested for their ability to inhibit the activity of b-Raf.
  • the assay is carried out in 384-well MaxiSorp plates (NUNC) with black walls and clear bottom.
  • the substrate, I ⁇ B ⁇ is diluted in DPBS (1 :750) and 15 ⁇ l is added to each well.
  • the plates are incubated at 4°C overnight and washed 3 times with TBST (25 mM Tris, pH 8.0, 150 mM NaCl and 0.05% Tween-20) using the EMBLA plate washer. Plates are blocked by Superblock (15 ⁇ l/well) for 3 hours at room temperature, washed 3 times with TBST and pat-dried.
  • Assay buffer containing 20 ⁇ M ATP (lO ⁇ l) is added to each well followed by lOOnl or 500nl of compound.
  • B-Raf is diluted in the assay buffer (l ⁇ l into 25 ⁇ l) and lO ⁇ l of diluted b-Raf is added to each well (0.4 ⁇ g/well).
  • the plates are incubated at room temperature for 2.5 hours.
  • the kinase reaction is stopped by washing the plates 6 times with TBST.
  • Phosph-I ⁇ B ⁇ (Ser32/36) antibody is diluted in Superblock (1:10,000) and 15 ⁇ l is added to each well. The plates are incubated at 4°C overnight and washed 6 times with TBST.
  • AP-conjugated goat-anti-mouse IgG is diluted in Superblock (1:1,500) and 15 ⁇ l is added to each well. Plates are incubated at room temperature for 1 hour and washed 6 times with TBST. 15 ⁇ l of fluorescent Attophos AP substrate (Promega) is added to each well and plates are incubated at room temperature for 15 minutes. Plates are read on Acquest or Analyst GT using a Fluorescence Intensity Program (Excitation 455 nm, Emission 580 nm).
  • A375 cell line (ATCC) is derived from a human melanoma patient and it has a V599E mutation on the B-Raf gene. The levels of phosphorylated MEK are elevated due to the mutation of B-Raf.
  • Sub-confluent to confluent A375 cells are incubated with compounds for 2 hours at 37 °C in serum free medium. Cells are then washed once with cold PBS and lysed with the lysis buffer containing 1% Triton X100. After centrifugation, the supernatants are subjected to SDS-PAGE, and then transferred to nitrocellulose membranes.
  • the membranes are then subjected to western blotting with anti-phospho-MEK antibody (ser217/221) (Cell Signaling).
  • the amount of phosphorylated MEK is monitored by the density of phospho-MEK bands on the nitrocellulose membranes.
  • kinase buffer (2.5 ⁇ L, lOx - containing MnCl 2 when required), active kinase (0.001-0.01 Units; 2.5 ⁇ L), specific or Poly(Glu4-Tyr) peptide (5-500 ⁇ M or .Olmg/ml) in kinase buffer and kinase buffer (50 ⁇ M; 5 ⁇ L) are mixed in an eppendorf on ice, A Mg/ATP mix (lO ⁇ L; 67.5 (or 33.75) mM MgCl 2 , 450 (or 225) ⁇ M ATP and 1 ⁇ Ci/ ⁇ l [ ⁇ - 32 P]-ATP (3000Ci/mmol)) is added and the reaction is incubated at about 30°C for about 10 minutes.
  • Mg/ATP mix (lO ⁇ L; 67.5 (or 33.75) mM MgCl 2 , 450 (or 225) ⁇ M ATP and 1 ⁇ Ci/ ⁇ l [ ⁇ - 32 P
  • the reaction mixture is spotted (20 ⁇ L) onto a 2cm x 2cm P81 (phosphocellulose, for positively charged peptide substrates) or Whatman No. 1 (for Poly (Glu4-Tyr) peptide substrate) paper square.
  • the assay squares are washed 4 times, for 5 minutes each, with 0.75% phosphoric acid and washed once with acetone for 5 minutes.
  • the assay squares are transferred to a scintillation vial, 5 ml scintillation cocktail are added and 3 P incorporation (cpm) to the peptide substrate is quantified with a Beckman scintillation counter. Percentage inhibition is calculated for each reaction.
  • compounds of Formula I in free form or in pharmaceutically acceptable salt form, exhibit valuable pharmacological properties, for example, as indicated by the in vitro tests described in this application.
  • compounds of Formula I preferably show an IC 50 in the range of 1 x 10 "10 to 1 x 10 "5 M, preferably less than 50nM for wild type BCR-Abl and G250E, E255V, T315I, F317L and M351T BCR-Abl mutants.
  • Compounds of Formula I preferably, at a concentration of lOmM, preferably show a percentage inhibition of greater than 50%>, preferably greater than about 70%, against Abl, Bcr-abl, c-RAF, c-SRC, JNK2 ⁇ 2, lck, MKK6, PDGFR ⁇ , SAPK2 ⁇ , SAPK2 ⁇ , Tie2 and TrkB kinases.
  • a concentration of lOmM preferably show a percentage inhibition of greater than 50%>, preferably greater than about 70%, against Abl, Bcr-abl, c-RAF, c-SRC, JNK2 ⁇ 2, lck, MKK6, PDGFR ⁇ , SAPK2 ⁇ , SAPK2 ⁇ , Tie2 and TrkB kinases.
  • Compound 27 has an IC 50 of ⁇ 0.5 nM, 20 nM, 36 nM, 59 nM ⁇ 0.5 nM and ⁇ 0.5 nM for wild type, G250E, E255V, T315I, F317L and M351T Bcr-abl, respectively; b).
  • Compound 25 has an IC50 of 130nM and 34nM for the FGFR3 enzyme and cellular assays, respectively, and 149nM and 2nM for FLT3 and PDGFR ⁇ , respectively; c).
  • Compound 26 has an IC50 of 65nM and 37nM for the FGFR3 enzyme and cellular assays, respectively, and 89nM and 2nM for FLT3 and PDGFR ⁇ , respectively, d).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, PDGF-R, trkB, c-SRC, BMX, FGFR3, b-RAF, SGK, Tie2, Lck, JNK2 2, MKK4, c-RAF, MKK6, SAPK2 and SAPK2 kinases.

Description

COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of priority to U.S. Provisional
Patent Application Number 60/578,491, filed 10 June 2004. The full disclosure of this application is incorporated herein by reference in its entirety and for all purposes.
BACKGROUND OF THE INVENTION
Field of the Invention
[0002] The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, PDGF-R, trkB, c-SRC, BMX, FGFR3, b-RAF, SGK, Tie2, Lck, JNK2 2, MKK4, c-RAF, MKK6, SAPK2α and SAPK2β kinases.
Background
[0003] The protein kinases represent a large family of proteins, which play a central role in the regulation of a wide variety of cellular processes and maintaining control over cellular function. A partial, non-limiting, list of these kinases include: receptor tyrosine kinases such as platelet-derived growth factor receptor kinase (PDGF-R), the nerve growth factor receptor, trkB, and the fibroblast growth factor receptor, FGFR3, B-RAF; non- receptor tyrosine kinases such Abl and the fusion kinase BCR-Abl, Lck, Bmx and c-src; and serine/threonine kinases such as c-RAF, sglc, MAP kinases (e.g., MKK4, MKK6, etc.) and SAPK2α and SAPK2β. Aberrant kinase activity has been observed in many disease states including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems.
[0004] The novel compounds of this invention inhibit the activity of one or more protein kinases and are, therefore, expected to be useful in the treatment of kinase-associated diseases.
SUMMARY OF THE INVENTION
[0005] In one aspect, the present invention provides compounds of Formula I:
Figure imgf000003_0001
I in which: m and n are independently selected from 0, 1 and 2; Ri is selected from -XNR5R6, -XOR5, -XC(O)R5, -XR5 and -XS(O)0.2R5; wherein X is a bond or Cι-4alkylene optionally substituted by 1 to 2 C^aH yl radicals; R5 is selected from hydrogen, Cι-6alkyl, C6-ιoaryl-Co- alkyl, C5-ιoheteroaryl-Co-4alkyl, C3- ιocycloalkyl-C0-4alkyl and C3-ιoheterocycloalkyl-Co alkyl; and R6 is selected from hydrogen and Cι-6alkyl; or R5 and R6 together with the nitrogen to which R5 and ^ are both attached form heteroaryl or heterocycloalkyl; wherein any aryl, heteroaryl, cycloalkyl and heterocycloalkyl of R5 or the combination of R5 and R6 can be optionally substituted with 1 to 3 radicals independently selected from halo, nitro, cyano, hydroxy, Cj-βalkyl, Ci-βalkoxy, halo-substituted-alkyl, halo- substituted-alkoxy, -XNR7RS, -XOR7, -XNR7S(O)2R8, -XNR7S(O)Rs, -XNR7SR8, - XC(O)NR7R8, -XC(O)NR7XNR7R8, -XNR7C(O)NR7R8, -XNR7XNR7R8, -XNR7XOR7, - XNR7C(=NR7)NR7R8, -XS(O)2R9, -XNR7C(O)R8, -XNR7C(O)R9, -XR9) -XC(O)OR8, - XS(O)2NR7R8, -XS(O)NR7R8 and -XSNR7R8; wherein X is a bond or Cμ4alkylene; R7 and R8 are independently selected from the group consisting of hydrogen and Cι- alkyl; and R9 is selected from C3-ιoheterocycloalkyl and Cs-ioheteroaryl; wherein said heterocycloalkyl or heteroaryl of R9 is optionally substituted with a radical selected from the group consisting of C alkyl, -XNR7XNR7R7, XNR7XOR7 and -XOR7; R2 and R4 are independently selected from halo, hydroxy, Cι-4alkyl, C\.
4alkoxy,
Figure imgf000004_0001
and halo-substituted-Cι-4alkoxy; R3 is selected from -NR10Rι i, -NRι0C(O)Rι 1, -NRι0S(O)0-2Rι 1 and -
NRjoC(O)NRιoRπ; wherein Rw is selected from hydrogen and Cj-όalkyl; Rπ is selected from Cβ.ioaryl, Cs-ioheteroaryl, C3-ιocycloalkyl and C3-ι0heterocycloalkyl; wherein any aryl, heteroaryl, cycloalkyl or heterocycloalkyl of Rπ is optionally substituted by 1 to 3 radicals selected from halo, nitro, cyano, hydroxy, Cι-6alkyl, Ci-βalkoxy, halo-substituted-alkyl, halo- substituted-alkoxy, -NR12C(O)R,3, -NR12C(O)NRι2R13, -C(O)NRι2Ri3, -NRι2S(O)0-2R]3 and -S(O)o-2NR]2Rι3; wherein Rj2 is selected from hydrogen and Ci-βalkyl; Ri3 is selected from C6-1oaryl, C5-ι0heteroaryl, C3-ι0cycloalkyl and C3.10heterocycloalkyl; wherein any aryl, heteroaryl, cycloalkyl or heterocycloalkyl of Rj3 is optionally substituted with 1 to 3 radicals independently selected from halo, Ci-βalkyl, halo-substituted-Cι-6alkyl, Cμealkoxy, halo- substituted-Cι.6alkoxy, -XNR7R8, C6-ιoaryl-Co-4alkyl, C5-ιoheteroaryl-Co-4alkyl, C3- ιocycloalkyl-Co-4alkyl, C3-ιoheterocycloalkyl-Co- alkoxy and C3-ι0heterocycloalkyl-Co- alkyl; wherein X, R7 and R8 are as described above and wherein any aryl, heteroaryl, cycloalkyl or heterocycloalkyl substituent of Rι3 is further optionally substituted by 1 to 3 radicals independently selected from halo, CMalkyl, halo-substituted-Cι-6alkyl, hydroxy-substituted- Cι.6alkyl, Cι-6alkoxy, C3-ι0heterocycloalkyl and halo-substituted-Cι-6alkoxy; and the N-oxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixture of isomers thereof; and the pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds.
[0006] In a second aspect, the present invention provides a pharmaceutical composition which contains a compound of Formula I or a N-oxide derivative, individual isomers and mixture of isomers thereof; or a pharmaceutically acceptable salt thereof, in admixture with one or more suitable excipients.
[0007] In a third aspect, the present invention provides a method of treating a disease in an animal in which inhibition of kinase activity, particularly Abl, BCR-Abl, PDGF-R, trkB, c-SRC, BMX, FGFR3, B-RAF, SGK, Tie2, Lck, JNK2α2, MKK4, c-RAF, MK 6, SAPK2α and/or SAPK2β activity, can prevent, inhibit or ameliorate the pathology and/or symptomology of the diseases, which method comprises administering to the animal a therapeutically effective amount of a compound of Formula I or a N-oxide derivative, individual isomers and mixture of isomers thereof, or a pharmaceutically acceptable salt thereof.
[0008] In a fourth aspect, the present invention provides the use of a compound of
Formula I in the manufacture of a medicament for treating a disease in an animal in which kinase activity, particularly Abl, BCR-Abl, PDGF-R, trkB, c-SRC, BMX, FGFR3, B-RAF, SGK, Tie2, Lck, JNK2α2, MKK4, c-RAF, MKK6, SAPK2α and/or SAPK2β activity, contributes to the pathology and/or symptomology of the disease. [0009] In a fifth aspect, the present invention provides a process for preparing compounds of Formula I and the N-oxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixture of isomers thereof, and the pharmaceutically acceptable salts thereof.
DETAILED DESCRIPTION OF THE INVENTION
Definitions
[0010] "Alkyl" as a group and as a structural element of other groups, for example halo-substituted-alkyl and alkoxy, can be either straight-chained or branched. Cι- -alkoxy includes, methoxy, ethoxy, and the like. Halo-substituted alkyl includes trifluoromethyl, pentafluoroethyl, and the like.
[0011] "Aryl" means a monocyclic or fused bicyclic aromatic ring assembly containing six to ten ring carbon atoms. For example, aryl may be phenyl or naphthyl, preferably phenyl. "Arylene" means a divalent radical derived from an aryl group. [0012] "Heteroaryl" is as defined for aryl above where one or more of the ring members is a heteroatom. For example heteroaryl includes pyridyl, indolyl, indazolyl, quinoxalinyl, quinolinyl, benzofuranyl, benzopyranyl, benzothiopyranyl, benzo[l,3]dioxole, imidazolyl, benzo-imidazolyl, pyrimidinyl, furanyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl, pyrazolyl, thienyl, etc. [0013] "Cycloalkyl" means a saturated or partially unsaturated, monocyclic, fused bicyclic or bridged polycyclic ring assembly containing the number of ring atoms indicated. For example, C3-ιocycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc. [0014] "Heterocycloalkyl" means cycloalkyl, as defined in this application, provided that one or more of the ring carbons indicated, are replaced by a moiety selected from -O-, -N= -NR-, -C(O)-, -S-, -S(O) - or -S(O)2-, wherein R is hydrogen, Cι-4alkyl or a nitrogen protecting group. For example, C3-8heterocycloalkyl as used in this application to describe compounds of the invention includes morpholino, pyrrolidinyl, pyrrolidinyl-2-one, piperazinyl, piperidinyl, piperidinylone, l,4-dioxa-8-aza-spiro[4.5]dec-8-yl, etc. [0015] "Halogen" (or halo) preferably represents chloro or fluoro, but may also be bromo or iodo.
[0016] "Mutant forms of BCR-Abl" means single or multiple amino acid changes from the wild-type sequence. Over 22 mutations have been reported to date with the most common being G250E, E255V, T315I, F317L and M351T.
[0017] "Treat", "treating" and "treatment" refer to a method of alleviating or abating a disease and/or its attendant symptoms.
Description of the Preferred Embodiments
[0018] The fusion protein BCR-Abl is a result of a reciprocal translocation that fuses the Abl proto-oncogene with the Bcr gene. BCR-Abl is then capable of transforming B-cells through the increase of mitogenic activity. This increase results in a reduction of sensitivity to apoptosis, as well as altering the adhesion and homing of CML progenitor cells. The present invention provides compounds, compositions and methods for the treatment of kinase related disease, particularly Abl, BCR-Abl, PDGF-R, trkB, c-SRC, BMX, FGFR3, B-RAF, b-RAF, SGK, Tie2, Lck, JNK2α2, MKK4, c-RAF, MKK6, SAPK2α and SAPK2β kinase related diseases. For example, leukemia and other proliferation disorders related to BCR-Abl can be treated through the inhibition of wild type and mutant forms of Bcr-Abl. [0019] In one embodiment, with reference to compounds of Formula I, are compounds of Formula la:
Figure imgf000007_0001
la in which: p is selected from 0 and 1; n is selected from 0, 1, 2 and 3; q is selected from 0 and 1; R5 is selected from hydrogen, Cι.6alkyl, C6-ιoaryl-Co-4alkyl, C3-1oheteroaryl-Co- 4alkyl, C3-ιocycloalkyl-C0- alkyl and C3.ιoheterocycloalkyl-C0- alkyl; and Re is selected from hydrogen and Cι-6alkyl; or R5 and R6 together with the nitrogen to which R5 and R6 are both attached form heteroaryl or heterocycloalkyl; wherein any aryl, heteroaryl, cycloalkyl and heterocycloalkyl of R5 or the combination of Rs and Rβ can be optionally substituted with 1 to 3 radicals independently selected from halo, nitro, cyano, hydroxy, C1-6alkyl, C1-6alkoxy, halo-substituted-alkyl, halo- substituted-alkoxy, -XNR7R8, -XOR7, -XNR7S(O)2R8, -XNR7S(O)R8, -XNR7SR8, - XC(O)NR7R8, -XC(O)NR7XNR7R8, -XNR7C(O)NR7R8, -XNR7XNR7R8, -XNR7XOR7, - XNR7C(=NR7)NR7R8, -XS(O)2R9, -XNR7C(O)R8, -XNR7C(O)R9, -XR9, -XC(O)OR8, - XS(O)2NR7R8, -XS(O)NR7R8 and -XSNR7R8; wherein X is a bond or Cι-4alkylene; R7 and R8 are( independently selected from the group consisting of hydrogen and Cι-4alkyl; and R9 is selected from C3-ιoheterocycloalkyl and C5-ιoheteroaryl; wherein said heterocycloalkyl or heteroaryl of R9 is optionally substituted with a radical selected from the group consisting of Cι-4alkyl, -XNR7XNR7R7, XNR7XOR7 and -XOR7; wherein X and R7 are as described above; Rio is selected from hydrogen and C^aHcyl; R15 is selected from halo, nitro, cyano, hydroxy, C]-6alkyl,
Figure imgf000008_0001
halo- substituted-alkyl and halo-substituted-alkoxy; and Ri6 is selected from -NR12C(O)Rι3, -NRι2C(O)NR12R13, -C(O)NR12R13, - NRι S(O)o-2Rι3 and -S(O)o-2NRι2Rι3; wherein Rι is selected from hydrogen and Ci-βalkyl; Ri3 is selected from Cβ-ioaryL C5-10heteroaryl, C3-ιocycloalkyl and C3-ιoheterocycloalkyl; wherein any aryl, heteroaryl, cycloalkyl or heterocycloalkyl of R}3 is optionally substituted with 1 to 3 radicals independently selected from halo, C1-6alkyl, halo-substituted-Cι.6alkyI, Cι.6alkoxy, halo-substituted-Cι-6alkoxy, -XNR7R8, C6-ιoaryl-Co-4alkyl, C5-1oheteroaryl-Co- 4alkyl, C3-ιocycloalkyl-Co-4alkyl, C -ιoheterocycloalkyl-Co-4alkoxy and C3-ιoheterocycloalkyl- Co^alkyl; wherein X, R7 and R8 are as described above and wherein any aryl, heteroaryl, cycloalkyl or heterocycloalkyl substituent of Rπ is further optionally substituted by 1 to 3 radicals independently selected from halo, Ci-βalkyl, halo-substituted-Cι-6alkyl, hydroxy- substituted-Ci-ealkyl, Cι-6alkoxy, C3-ι0heterocycloalkyl and halo-substituted-Cι-6alkoxy. [0020] In another embodiment, R5 is selected from hydrogen, morpholino-ethyl, cyclopropyl, methyl, 3-(2-oxo-pyrrolidin-l-yl)-propyl, benzo[l,3]dioxol-5-yl, 3-(4-methyl- piperazin-l-yl)-propyl, hydroxymethyl-phenyl, (l-hydroxyethyl)-phenyl, morpholino, pyridinyl, methyl-carbonyl, methyl-sulfonyl, methyl-pyridinyl, amino-cyclohexyl, piperidinyl, methyl-piperazinyl-ethyl, dimethyl-pyrazolyl, methyl-pyrazolyl, dimethyl- pyridinyl, methyl-pyridinyl, ethyl-piperazinyl-pyridinyl, amino-carbonyl-pyridinyl, cyano- pyridinyl, dimethyl-amino-ethyl, methoxy-ethyl, methyl-pyrrolidinyl-ethyl, ethyl-pyrazolyl, dimethyl-amino-propyl, isopropyl, furanyl-methyl, methyl-piperazinyl-propyl, benzo[l,3]dioxol-5-ylmethyl, 2-methyl-6-morpholin-4-yl-pyridin-3-yl, methyl-pyrimidinyl, methoxy-pyridinyl, fluoro-phenyl, dimethyl-amino-ethyl-aminocarbonyl, pyridinyl-methyl, thiazoiyl-methyl, methyl-pyrazinyl-methyl, imidazolyl-propyl, amino-carbonyl-phenyl, ; or R5 and Re together with the nitrogen atom to which they are both attached form a group selected from morpholino, piperidinyl and piperazinyl optionally substituted with a group selected from ethyl, pyridinyl and morpholino.
[0021] In a further embodiment, Rι6 is selected from -NHC(O)Rι3, -
NHC(O)NHRi3, -C(O)NHR13, -NHS(O)2Rn and ~S(O)2NHRι3; wherein R13 is selected from phenyl, pyridazinyl, pyridinyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, quinoxalinyl, thienyl and thiazolyl; wherein Rι3 is optionally substituted with 1 to 3 radicals independently selected from methyl, t-butyl, halo, trifluoromethyl, diethyl-amino, dimethyl-amino, benzyl, piperidinyl-amino, pyrrolidinyl-methoxy, ethyl-piperazinyl-methyl, morpholino, methyl- piperazinyl, methyl-piperazinyl-methyl, ethyl-piperazinyl, methyl-imidazolyl, morpholino- methyl, pyrrolidinyl-piperidinyl, piperazinyl-methyl, hydroxy-piperidinyl, 1-methyl- piperidin-4-yloxy, piperidinyl-oxy, methyl-pyrazinyl, pyrazinyl and hydroxyethyl- piperazinyl.
[0022] Preferred compounds of the invention are selected from N-[4-methyl-3-(l-
{6-[4-(2-morpholin-4-yl-ethyl)-phenylamino]-pyrimidin-4-yl}-lH-imidazol-2-ylamino)- pheny 1] -3 -trifluoromethyl-benzamide, N- { 3 - [ 1 -(6-cy cloproρylamino-pyrimidin-4-yl)- 1 H- imidazol-2-ylamino]-4-methyl-phenyl}-3-(4-ethyl-piperazin-l-yl)-5-trifluoromethyl- benzamide, N-(4-methyl-3-{l-[6-(2-morpholin-4-yl-ethylamino)-pyrimidin-4-yl]-lH- imidazol-2-ylamino}-phenyl)-3 -trifluoromethyl-benzamide, N-{3-[l-(6-cyclopropylamino- pyrimidin-4-yl)- 1 H-imidazol-2-ylamino]-4-methyl-phenyl} -3 -trifluoromethyl-benzamide, N-{4-methyl-3-[ 1 -(6-methylamino-pyrimidin-4-yl)- 1 H-imidazol-2-ylamino] -phenyl} -3 - trifluoromethyl-benzamide, N-[4-methyl-3-(l-{6-[3-(2 -oxo-pyrrolidin-l-yl)-propylamino]- pyrimidin-4-yl}-lH-imidazol-2-ylamino)-phenyl]-3 -trifluoromethyl-benzamide, N-(3-{l-[6- (benzo[l,3]dioxol-5-ylamino)-pyrimidin-4-yl]-lH-imidazol-2-ylamino}-4-methyl-phenyl)- 3 -trifluoromethyl-benzamide, N-[4-methyl-3-(l-{6-[3-(4-methyl-piperazin-l-yl)- propylamino]-pyrimidin-4-yl}-lH-imidazol-2-ylamino)-phenyl]-3-trifluoromethyl- benzamide, {6-[2-(2-chloro-phenylamino)-imidazol-l-yl]-pyrimidin-4-yI}-cyclopropyl- amine, (3 - { 6- [2-(2-chloro-phenylamino)-imidazol- 1 -yl] -pyrimidin-4-y lamino } -pheny 1)- methanol, 1 -(3 - { 6-[2-(2-chloro-phenylamino)-imidazol- 1 -yl]-pyrimidin-4-ylamino} - phenyl)-ethanol, {6-[2-(2-chloro-phenylamino)-imidazol-l-yl]-pyrimidin-4-yl}-[4-(2- morpholin-4-yl-ethyl)-phenyl]-amine, {6-[2-(2-chloro-phenylamino)-imidazol- 1 -yl]- pyrimidin-4-yl}-(4-morpholin-4-yl-phenyl)-amine, N-(3-{6-[2-(2-chloro-phenylamino)- imidazol-l-yl]-pyrimidin-4-y lamino} -phenyl)-acetamide, l-(3-{6-[2-(2-chloro- phenylamino)-imidazoi~ 1 -yl]-pyrimidin-4-ylamino} -propyl)-pyrrolidin-2-one, benzo[l,3]dioxol-5-yl-{6-[2-(2-chloro-phenylamino)-imidazol-l-yl]-pyrimidin-4-yl}-amine, {6-[2-(2-chloro-phenylamino)-imidazol-l-yl]-pyrimidin-4-yl}-pyridin-3-yl-amine, N-(4- methyl-3-{l-[6-(ρyridin-3-ylamino)-pyrimidin-4-yl]-lH-imidazol-2-ylamino}-phenyl)-3- trifluoromethyl-benzamide, {6-[2-(2-chloro-phenylamino)-imidazol-l-yl]-pyrimidin-4-yl}- (6-methyl-pyridin-3-yl)-amine, N-(4-methyl-3-{l-[6-(6-methyl-pyridin-3-ylamino)- pyrimidin-4-yl]-lH-imidazoI-2-ylamino}-phenyl)-3-trifluoromethyl-benzamide, N-{3-[l-(6- cyclopropylamino-pyrimidin-4-yl)-lH-imidazol-2-ylamino]-4-methyl-phenyl}-3-morpholin- 4-yl-5-trifluoromethyl-benzamide, N-{3-[l-(6-cyclopropylamino-pyrimidin-4-yl)-lH- imidazol-2-ylamino]-4-methyl-phenyl}-3-(4-methyl-piperazin-l-yl)-5-trifluoromethyl- benzamide, N-{3-[l-(6-cycIopropylamino-pyrimidin-4-yl)-lH-imidazol-2-ylamino]-4- methyl-phenyl}-3-(4-ethyl-piperazin-l-yl)-5-trifluoromethyl-benzamide, N-{3-[l-(6- cyclopropylamino-pyrimidin-4-yl)-lH-imidazol-2-ylamino]-4-methyl-phenyl}-4-morpholin- 4-yl-3-trifluoromethyl-benzamide, N- { 3-[l -(6-cyclopropylamino-pyrimidin-4-yl)- 1H- imidazol-2-ylamino]-4-methyl-phenyl}-4-(4-ethyl-piperazin-l-ylmethyl)-3-trifluoromethyl- benzamide, N- {3-[l -(6-cyclopropyIamino-pyτimidin-4-yl)- lH-imidazol-2-ylarnino]-4- methyl-phenyl}-4-(4-methyl-piperazin-l-ylmethyl)-3 -trifluoromethyl-benzamide, N-{3-[l- (6-cyclopropylamino-pyrimidin-4-yl)-lH-imidazol-2-ylamino]-4-methyl-phenyl}-3-(4- methyl-imidazol- 1 -yl)-5-trifluoromethyl-benzamide, 3 -(4-methyl-imidazol- 1 -yl)-N- {4- methyl-3-[l-(6-methyIamino-pyrimidin-4-yl)-lH-imidazol-2-ylamino]-phenyl}-5- trifluoromethyl-benzamide, N-{4-methyl-3-[l-(6-methylamino-pyrimidin-4-yl)-lH- imidazol-2-ylamino]-phenyl}-4-morpholin-4-yl-3-trifluoromethyl-benzamide, 3-(4-ethyl- piperazin-l-yl)-N-{4-methyl-3-[l-(6-methylamino-pyrimidin-4-yl)-lH-imidazol-2-ylamino]- phenyl}-5-trifluoromethyl-benzamide, N-{4-methyl-3-[l-(6-methylamino-pyrimidin-4-yl)- lH-imidazol-2-ylamino]-phenyl}-3-(4-methyl-piperazin-l-yl)-5-trifluoromethyl-benzamide, N- { 3 -[ 1 -(6-methylamino-pyrimidin-4-yl)- lH-imidazol-2-ylamino]-phenyl} -4-(4-methyl- piperazin- 1 -ylmethyl)-3-trifluoromethyl-benzamide, 3 -(4-ethyl-piperazin- 1 -ylmethyl)-N- {4- methyl-3-[l-(6-methylamino-pyrimidin-4-yl)-lH-imidazol-2-ylamino]-phenyl}-5- trifluoromethyl-benzamide, N-{3-[l-(6-cycIopropylamino-pyrimidin-4-yl)-lH-imidazol-2- ylamino] -4-methyl-phenyl} -4-morpholin-4-ylmethyl-3 -trifluoromethyl-benzamide, N- {4- methyl-3-[l-(6-methylamino-pyrimidin-4-yl)-lH-imidazol-2-ylamino]-phenyl}-4- morphol in-4-ylmethy 1-3 -trifluoromethyl-benzamide, N- { 3 -[ 1 -(6-amino-pyrimidin-4-y 1)- 1 H- imidazol-2-ylamino]-4-methyl-phenyl} -4-(4-ethyl-piperazin- 1 -y lmethyl)-3 -trifluoromethylbenzamide, N-{3-[l-(6-amino-pyrimidin-4-yl)-lH-imidazol-2-ylamino]-4-methyl-phenyl}- 4-(4-methyl-piperazin-l-ylmethyl)-3 -trifluoromethyl-benzamide, N-{3-[l-(6-amino- pyrimidin-4-yl)-lH-imidazol-2-ylamino]-phenyl}-3~(4-methyl-imidazol-l-yl)-5- trifluoromethyl-benzamide, N- {3 -[ 1 -(6-amino-pyrimidin-4-yl)- 1 H-imidazol-2-ylamino]-4- methyl-phenyl} -4-morpholin-4-yl-3 -trifluoromethyl-benzamide, N- { 3 -[ 1 -(6-amino- pyrimidin-4-yl)-lH-imidazol-2-ylamino]-4-methyl-phenyl}-3-(4-ethyl-piperazin-l-yl)-5- trifluoromethyl-benzamide, N-{3-[l-(6-amino-pyrimidin-4-yl)-lH-imidazol-2-ylamino]-4- methyl-phenyl}-3-(4-methyl-piperazin-l-yl)-5-trifluoromethyl-benzamide, N-{3-[l-(6- amino-pyrimidin-4-yl)- 1 H-imidazol-2-y lamino] -4-methyl-phenyl } -3 -morpholin-4-y lmethyl- 5 -trifluoromethyl-benzamide, 3-[l-(6-cycloρropylamino-pyrimidin-4-yl)-lH-imidazol-2- ylamino]-5-methoxy-N-[4-(2-methyl-imidazol-l-yl)-3-trifluoromethyl-phenyl]-benzamide, N-{3-[l-(6-acetylamino-pyrimidin-4-yl)-lH-imidazol-2-ylamino]-4-methyl-phenyl}-3- trifluoromethyl-benzamide, N-{3-[l-(6-methanesulfonylamino-pyrimidin-4-yl)-lH- imidazol-2-ylamino]-4-methyl-phenyl}-3-trifluoronιethyl-benzamide, N-{3-[l-(2- cyclopropylamino-pyrimidin-4-yl)-lH-imidazol-2-ylamino]-4-methyl-phenyl}-3- trifluoromethyl-benzamide, 3-[l-(2-cyclopropylamino-pyrimidin-4-yl)-lH-imidazol-2- ylamino]-4-methyl-N-[4-(2-methyl-imidazol-l-yl)-3-trifluoromethyl-phenyl]-benzamide, N- {3-[l-(6-cyclopropyIamino-pyrimidin-4-yl)-lH-imidazol-2-ylamino]-4-methyl-phenyl}-3- piperazin- 1 -y lmethyl-5 -trifluoromethyl-benzamide, N- { 3 - [ 1 -(6-amino-pyrimidin-4-y 1)- 1 H- imidazol-2-y lamino] -4-methyl-phenyl} -3 -piperazin- 1 -y lmethyl-5 -trifluoromethylbenzamide, N-{3-[l-(6-cyclopropylamino-pyrimidin-4-yl)-lH-imidazol-2-ylamino]-5- methoxy-phenyl}-4-(4-methyl-piperazin-l-ylmethyl)-3-trifluoromethyl-benzamide, N-{3-[l- (6-cyclopropylamino-pyrimidin-4-yl)-lH-imidazol-2-ylamino]-5-methoxy-phenyI}-3-(4- ethyl-piperazin-l-ylmethyl)-5 -trifluoromethyl-benzamide, N-{3-[l-(6-cyclopropylamino- pyrimidin-4-yl)-lH-imidazol-2-ylamino]-4-methyl-phenyl}-3-(piperidin-4-yloxy)-5- trifluoromethyl-benzamide, N- { 3-[ 1 -(6-amino-pyrimidin-4-yl)- 1 H-imidazol-2-ylamino]-4- methyl-phenyl}-3-(piperidin-4-yloxy)-5-trifluoromethyl-benzamide, N-{3-[l-(6- cyclopropylamino-pyrimidin-4-yl)-lH-imidazol-2-ylamino]-5-methoxy-phenyl}-3-(4- pyrrolidin- 1 -yl-piperidin-1 -yl)-5 -trifluoromethyl-benzamide, 1 - {3 -[1 -(6-cyclopropylamino- pyrimidin-4-yl)- 1 H-imidazol-2-ylamino]-4-methyl-phenyl} -3 -[4-(2-methyl-imidazol- 1 -yl)- 3 -trifluoromethy 1-pheny 1] -urea, 1 - { 3 -[ 1 -(6-cyclopropy lamino-pyrimidin-4-yl)- 1 H-imidazol- 2-ylamino]-4-methyl-phenyl}-3-[4-(4-ethyl-piperazin-l-ylmethyl)-3-trifluoromethyl- phenyl]-urea, pyridazine-4-carboxylic acid {3-[l-(6-cyclopropylamino-pyrimidin-4-yl)-lH- imidazol-2-ylamino]-4-methyl-ρhenyl}-amide, 2-chloro-N-{3-[l-(6-cyclopropylamino- pyrimidin-4-yl)-lH-imidazol-2-ylamino]-4-methyl-phenyl}-isonicotinamide, furan-2- carboxylic acid {3-[l -(6-cyclopropylamino-pyrimidin-4-yl)- lH-imidazol-2 -ylamino] -4- methyl-phenyl} -amide, l-methyI-lH-pyrrole-2-carboxylic acid {3-[l-(6-cyclopropylamino- pyrimidin-4-y 1)- 1 H-imidazol-2-y lamino] -4-methyl-phenyl} -amide, 1 H-imidazole-2- carboxylic acid {3-[l-(6-cyclopropylamino-pyrimidin-4-yl)-lH-imidazol-2-ylamino]-4- methyl-phenyl} -amide, N-{3-[l-(6-cyclopropylamino-pyrimidin-4-yl)-lH-imidazol-2~ y lamino] -4-methyl-phenyl } -4-trifluor omethyl-benzamide, N- { 3 - [ 1 -(6-cycloρropylamino- pyrimidin-4-yl)-lH-imidazol-2-ylamino]-4-methyl-phenyl}-6-methyl-nicotinamide, 1-tert- butyl-5-methyl-lH-pyrazole-3-carboxylic acid {3-[l-(6-cyclopropylamino-pyrimidin-4-yl)- 1 H-imidazol-2-ylamino] -4-methyl-phenyl} -amide, N-[4-(4-ethyl-ρiperazin- 1 -ylmethyl)-3 - trifluoromethyl-phenyl]-4-methyl-3-{l-[6-(2-morpholin-4-yl-ethylamino)-pyrimidin-4-yl]- lH-imidazol-2 -ylamino} -benzamide, 3-(4-methyl-imidazol-l-yl)-N-(4-methyl-3-{l-[6-(2- morpholin-4-yl-ethylamino)-pyrimidin-4-yl]-lH-imidazol-2-ylamino}-phenyl)-5- trifluoro ethyl-benzamide, 4-methyl-N-[4-(2-methyl-imidazol-l-yl)-3-trifluoromethyl- phenyl]-3-{l-[6-(2-morpholin-4-yl-ethylamino)-pyrimidin-4-yl]-lH-imidazol-2-ylamino}- benzamide, N-(4-methyl-3 - { 1 -[6-(2-morpholin-4-yl-ethylamino)-pyrimidin-4-yl]- 1 H- imidazol-2-ylamino}-phenyl)-3-(l-methyl-piperidin-4-yloxy)-5-trifluoromethyl-benzamide, pyrazine-2 -carboxylic acid { 3 -[ 1 -(6-cyclopropylamino-pyrimidin-4-yl)- 1 H-imidazol-2- ylamino]-4-methyl-phenyl}-amide, 5 -methyl-pyrazine-2 -carboxylic acid {3-[l-(6- cyclopropylamino-pyrimidin-4-yl)-lH-imidazol-2-ylamino]-4-methyl-phenyl}-amide, quinoxaline-6-carboxylic acid {3-[l-(6-cyclopropylamino-pyrimidin-4-yl)-lH-imidazol-2- ylamino]-4-methyl-phenyl}-amide, 5-tert-butyl-2-methyl-4-morpholin-4-ylmethyl-furan-3- carboxylic acid {3-[l-(6-cyclopropylamino-pyrimidin-4-yl)-lH-imidazol-2-ylamino]-4- methyl-phenyl} -amide, 5-tert-butyl-2-methyl-2H-pyrazole-3-carboxylic acid {3-[l-(6- cyclopropylamino-pyrimidin-4-yl)-lH-imidazol-2-ylamino]-4-methyl-phenyl}-amide, 2- benzyl-5-tert-butyl-2H-pyrazole-3-carboxylic acid {3-[l-(6-cyclopropylamino-pyrimidin-4- yl)-lH-imidazol-2-ylamino]-4-methyl-phenyl}-amide, N-{3-[l-(6-cyclopropylamino- pyrimidin-4-yl)-lH-imidazol-2-ylamino]-4-methyl-phenyl}-3-(piperidin-4-ylamino)-5- trifiuoromethyl-benzamide, N-{3-[l-(6-cyclopropylamino-pyrimidin-4-yl)-lH-imidazol-2- y lamino] -4-methyl-phenyl } -3 -(pyrrolidin-2-ylmethoxy)-5 -trifluoromethyl-benzamide, 5 -tert- butyl-2-methyl-ftiran-3 -carboxylic acid {3-[l-(6-cyclopropylamino-pyrimidin-4-yl)-lH- imidazol-2-ylamino]-4-methyl-phenyl}-amide, 5-tert-but l-3-methyl-furan-2-carboxylic acid { 3 -[ 1 -(6-cyclopropylamino-pyrimidin-4-yl)- 1 H-imidazol-2-y lamino] -4-methyl-phenyl} - amide, 5-tert-butyl-2-diethylamino-furan-3-carboxylic acid {3-[l-(6-cyclopropylamino- pyrimidin-4-yl)-lH-imidazol-2-ylamino]-4-methyl-phenyl}-amide, 5-tert-butyl-4- diethylamino-2-methyl-furan-3 -carboxylic acid {3-[l-(6-cyclopropylamino-pyrimidin-4-yl)- lH-imidazol-2 -ylamino] -4-methyl-phenyl} -amide, 5 -tert-butyl -thiophene-2-carboxylic acid {3-[l-(6-cycloρropylamino-pyτimidin-4-yl)-lH-imidazol-2-ylamino]-4-methyl-phenyl}- amide, 5-tert-butyl-3-methyl-furan-2-carboxylic acid (4-methyl-3-{l-[6-(2-morpholin-4-yl- ethylamino)-pyrimidin-4-yl]- lH-imidazol-2-ylamino} -phenyl)-amide, 5-tert-butyl- thiophene-2-carboxylic acid (4-methyl-3-{ l-[6-(2-morpholin-4-yl-ethylamino)-pyrimidin-4- yl]-lH-imidazol-2-ylamino}-phenyl)-amide, 5 -tert-butyl-2-methyl-furan-3 -carboxylic acid (4-methyl-3-{l-[6-(2-morpholin-4-yl-ethylamino)-pyrimidin-4-yl]-lH-imidazol-2-ylamino}- phenyl)-amide, N-(3 - { 1 -[6-(4-amino-cyclohexylamino)-pyrimidin-4-yl]- 1 H-imidazol-2- ylamino}-4-methyl-phenyl)-3-trifluoromethyl-benzamide, N-(4-methyl-3-{l-[6-(piperidin-4- ylamino)-pyrimidin-4-yl] - 1 H-imidazol-2-y lamino } -phenyl)-3 -trifluoromethyl-benzamide, N-[4-methyI-3-( 1 - {6-[2-(4-methyl-piperazin- 1 -yl)-ethylamino]-pyrimidin-4-yl} - 1 H- imidazol-2-ylamino)-phenyl]-3-trifluoromethyl-benzamide, N-(3-{l-[6-(2,5-dimethyl-2H- pyrazol-3-ylamino)-pyrimidin-4-yl]-lH-imidazol-2-ylamino}-4-methyl-phenyl)-3- trifluoro ethyl-benzamide, N-(4-methyl-3-{l-[6-(4-methyl-piperazin-l-ylamino)-pyrimidin- 4-yl]-lH-imidazol-2-ylamino}-phenyl)-3-trifluoromethyl-benzamide, N-(4-methyl-3-{l-[6- (2-methyl-2H-pyrazol-3-ylamino)-pyrimidin-4-yl]-lH-imidazol-2-ylamino}-phenyl)-3- trifluoromethyl-benzamide, N-(3-{l-[6-(2,6-dimethyl-pyridin-3-ylamino)-pyrimidin-4-yl]- 1 H-imidazol-2-ylamino} -4-methyl-phenyl)-3 -trifluoromethyl-benzamide, N-(4-methyl-3 - { 1 - [6-(2-methyl-pyridin-3-ylamino)-pyrimidin-4-yl]-lH-imidazol-2-ylamino}-ρhenyl)-3- trifluoromethyl-benzamide, N-{3-[l-(6-cyclopropylamino-pyrimidin-4-yl)-lH-imidazol-2- ylamino] -4-methyl-phenyl} -3 -(4-methyl-piperazin- 1 -yl)-5 -trifluoromethyl-benzamide, N- {3-[l-(6-cyclopropylamino-pyrimidin-4-yl)-lH-imidazol-2-ylamino]-4-methyl-phenyl}-3- [4-(2-hydroxy-ethyl)-piperazin- l-yl]-5-trifluoromethyl-benzamide, N-{3-[l -(6- cyclopropylamino-pyrimidin-4-yl)-lH-imidazol-2-ylamino]-4-methyl-phenyl}-3-piperazin- 1-y 1-5 -trifluoromethyl-benzamide, N-{4-chloro-3-[l-(6-cyclopropylamino-pyrimidin-4-yl)- 1 H-imidazol-2-ylamino]-phenyl} -benzamide, N- { 3 -[ 1 -(6-cyclopropylamino-pyrimidin-4- yl)-lH-imidazol-2-ylamino]-4-fluoro-phenyl}-benzamide, N-{3-[l-(6-cyclopropylamino- pyrimidin-4-yl)- 1 H-imidazol-2-ylamino]-2-methyl-phenyl} -benzamide, N- {5 -[ 1 -(6- cycloproρylamino-pyrimidin-4-yl)-lH-imidazol-2-ylamino]-2-fluoro-ρhenyl}-benzamide, N-{5-[l-(6-cyclopropylamino-pyrimidin-4-yl)-lH-imidazol-2-ylamino]-2-methyl-phenyl}- benzamide, N-{4-chloro-3-[l-(6-cyclopropylamino-pyrimidin-4-yl)-lH-imidazol-2- ylamino]-phenyl}-4-morpholin-4-ylmethy]-3-trifluoromethyl-benzamide:, N-{3-[l-(6- cyclopropyIamino-pyrimidin-4-yl)-lH-imidazol-2-ylamino]-4-fluoro-phenyl}-4-morpholin- 4-ylmethyl-3-trifluoromethyl-benzamide, N-{3-[l-(6-cycloρropylamino-pyrimidin-4-yl)-lH- imidazol-2-ylamino]-2-methyl-phenyl}-4-morpholin-4-ylmethyl-3-trifluoromethyl- benzamide, N-{4-chloro-3-[l-(6-cyclopropylamino-pyrimidin-4-yl)-lH-imidazol-2- ylamino]-phenyl}-3-(4-methyl-imidazol-l-yl)-5-trifluoromethyl-benzamide, N-{3-[l-(6- cyclopropylamino-pyrimidin-4-yl)-lH-imidazol-2-yIanιino]-4-fluoro-phenyl}-3-(4-methyl- imidazol- 1 -yl)-5 -trifluoromethyl-benzamide, N- {3 -[ 1 -(6-cyclopropylamino-pyrimidin-4-yl)- 1 H-imidazol-2-ylamino]-2-methyl-phenyl} -3 -(4-methyl-imidazol- 1 -yl)-5 -trifluoromethylbenzamide, N- { 5 - [ 1 -(6-cyclopropylamino-pyrimidin-4-yl)- 1 H-imidazol-2 -ylamino] -2- fluoro-phenyl} -3-(4-methy 1-imidazol- 1 ~yl)-5-trifluoromethyl-benzamide, N- { 5-[ 1 -(6- cyclopropylamino-pyrimidin-4-yl)-lH-imidazol-2-ylamino]-2-methyl-phenyl}-3-(4-methyl- imidazol-l-yl)-5 -trifluoromethyl-benzamide, N-{3-[l-(6-cyclopropylamino-pyrimidin-4-yl)- lH-imidazol-2-ylamino]-4-methoxy-phenyl}-benzamide, N-{3-[l-(6-cyclopropylamino- pyrimidin-4-yl)-lH-imidazol-2-ylamino]-4-methyl-phenyl}-3-trifluoromethyl- benzenesulfonamide, 3-[l-(6-cyclopropylamino-pyrimidin-4-yl)-lH-imidazol-2-ylamino]-4- methyl-N-(3-trifluoromethyl-phenyl)-benzenesulfonamide, N-{3-[l-(6-cyclopropylamino- pyrimidin-4-yl)- 1 H-imidazol-2-ylamino] -4-fluoro-phenyl} -3 -dimethylamino-5 - trifluoromethyl-benzamide, N-{5-[l-(6-cyclopropylamino-pyrimidin-4-yl)-lH-imidazol-2- ylamino]-2-methyl-phenyl}-3-dimethylamino-5-trifluoromethyl-benzamide, N-{4-chloro-3- [ 1 -(6-cyclopropy lamino-pyrimidin-4-yl)- 1 H-imidazol-2-y lamino] -phenyl} -3 - dimethylamino-5-trifluoromethyl-benzamide, 3 -(4-methyl-imidazol- 1 -yl)-N-(4-methyl-3 - { 1 - [6-(pyridin-2-ylamino)-pyrimidin-4-yl]-lH-imidazol-2-ylamino}-phenyl)-5-trifluoromethyl- benzamide, 4-(4-ethyl-piperazin- 1 -ylmethyl)-N-(4-methyI-3 - { 1 -[6-(pyridin-2-yIamino)- pyrimidin-4-yl]-lH-imidazol-2-ylamino}-phenyl)-3-trifluoromethyl-benzamide, 3-(4-ethyl- piperazin-l-yl)-N-(4-methyl-3-{l-[6-(pyridin-2-ylamino)-pyrimidin-4-yl]-lH-imidazol-2- ylamino}-phenyl)-5-trifluoromethyl-benzamide, 4-chloro-N-(4-methyl-3-{l-[6-(pyridin-2- ylamino)-pyrimidin-4-yl]- 1 H-imidazol-2-ylamino} -phenyl)-3 -trifluoromethyl-benzamide, N-[3-(l-{6-[5-(4-ethyl-piperazin-l-yl)-pyridin-2-ylamino]-pyrimidin-4-yl}-lH-imidazol-2- ylamino)-4-methyl-phenyl]-3-trifluoromethyl-benzamide, N-(4-methyl-3-{l-[6-(4-methyl- pyridin-2-ylamino)-pyrimidin-4-yl]-lH-imidazol-2-ylamino}-phenyl)-3-trifluoromethyl- benzamide, N-(3-{l-[6-(4,6-dimethyl-pyridin-2-ylamino)-pyrimidin-4-yl]-lH-imidazol-2- ylamino}-4-methyl-phenyl)-3 -trifluoromethyl-benzamide, 6-(6-{2-[2-methyl-5-(3- trifluoromethyl-benzoylamino)-phenylamino]-imidazol-l-yl}-pyrimidin-4-ylamino)- nicotinamide, N-(4-methyl-3 - { 1 - [6-(5 -methyl-pyridin-2-ylamino)-pyrimidin-4-yl] - 1 H- imidazol-2-ylamino}-ρhenyl)-3-trifluoromethyl-benzamide, N-(3-{l-[6-(5-cyano-pyridin-2- yIamino)-pyrimidin-4-yl]- 1 H-imidazol-2-yIamino } -4-methyl-phenyl)-3 -trifluoromethylbenzamide, 4-chloro-N-{3-[l-(6-cyclopropylamino-pyrimidin-4-yI)-lH-imidazoI-2- ylamino]-4-methyl-phenyl}-3-trifluoromethyl-benzamide, 4~chloro-N-(4-methyl-3-{l-[6-(2- morpholin-4-yl-ethylamino)-pyrimidin-4-yl]-lH-imidazol-2-ylamino}-phenyl)-3- trifluoromethyl-benzamide, 5-tert-butyl-2-methyl-2H-pyrazole-3-carboxylic acid (4-methyl- 3-{l-[6-(2-morpholin-4-yl-ethylamino)-pyrimidin-4-yl]-lH-imidazol-2-ylamino}-phenyl)- amide, N-(3 - { 1 - [6-(2-dimethylamino-ethy lamino)-ρyrimidin-4-yl] - 1 H-imidazol-2-y lamino } - 4-methyl-phenyl)-3-trifluoromethyl-benzamide, N-(4-methyl-3- { 1 -[6-(3-morpholin-4-yl- propylamino)-pyrimidin-4-yl]-lH-imidazol-2-ylamino}-ρhenyl)-3-trifluoromethyl- benzamide, N-(3-{l-[6-(2-methoxy-ethylamino)-pyrimidin-4-yl]-lH-imidazol-2-ylamino}- 4-methyl-phenyl)-3-trifluoromethyl-benzamide, N-[4-methyl-3-(l-{6-[2-(l-methyl- pyrrolidin-2-yl)-ethylamino]-pyrimidin-4-yl}-lH-imidazol-2-ylamino)-ρhenyl]-3- trifluoromethyl-benzamide, N-(4-methyl-3-{l-[6-(pyridin-2-ylamino)-pyrimidin-4-yl]-lH- imidazol-2-ylamino}-phenyl)-3-trifluoromethyl-benzamide, N-[4-methyl-3-(l-pyrimidin-4- yl-lH-imidazol-2-ylamino)-phenyl]-3-trifluoromethyl-benzamide, N-[4-methyl-3-(l- pyrimidin-2-yl-lH-imidazol-2-ylamino)-phenyl]-3 -trifluoromethyl-benzamide, N-{4- methyl-3-[l-(4-methylamino-pyrimidin-2-yl)-lH-imidazol-2-ylamino]-phenyl}-3- trifluoromethyl-benzamide, N-{4-methyl-3-[l-(2-methylamino-pyrimidin-4-yl)-lH- imidazol-2-y lamino] -phenyl} -3 -trifluoromethyl-benzamide, N-(4-methy 1-3 - { 1 - [4-(2- morpholin-4-yl-ethylamino)-pyrimidin-2-yl]-lH-imidazol-2-ylamino}-phenyl)-3- trifluoromethyl-benzamide, N-(4-methyl-3-{l-[2-(2-morpholin-4-yl-ethylamino)-pyrimidin- 4-yIJ- 1 H-imidazol-2-y lamino} -phenyI)-3 -trifluoromethyl-benzamide, N-(3- { 1 -[6-(2-ethyl- 2H-pyrazol-3-ylamino)-pyrimidin-4-yl]-lH-imidazol-2-ylamino}-4-methyl-phenyl)-3- trifluoromethyl-benzamide, N-(3-{l-[6-(3-dimethylamino-ρropylamino)-pyrimidin-4-yl]- lH-imidazol-2-ylamino}-4-methyl-phenyl)-3 -trifluoromethyl-benzamide, N-{3-[l-(6- isopropylamino-pyrimidin-4-yl)-lH-imidazol-2-ylamino]-4-methyl-phenyl}-3- trifluoromethyl-benzamide, N-[3-(l-{6-[(furan-3-ylmethyl)-amino]-pyrimidin-4-yl}-lH- imidazoI-2-ylamino)-4-methyl-phenyl]-3-trifluoromethyl-benzamide, N-[4-methyl-3-(l-{6- [3 -(4-methyl-piρerazin- 1 -yl)-propylamino]-pyrimidin-4-yl} - 1 H-imidazol-2-ylamino)- phenyl]-3-trifluoromethyl-benzamide, N-[3-(l-{6-[(benzo[l,3]dioxol-5-ylmethyl)-amino]- pyrimidin-4-yl}-lH-imidazol-2-ylamino)-4-methyl-phenyl]-3-trifluoromethyl-benzamide, N-(4-methyl-3-{l-[6-(2-methyl-6-morpholin-4-yl-pyridin-3-ylamino)-pyrimidin-4-yl]-lH- imidazol-2-ylamino}-phenyl)-3-trifluoromethyl-benzamide, N-(4-methyl-3-{l-[6-(4-methyl- pyrimidin-2-ylamino)-pyrimidin-4-yl]- 1 H-imidazol-2-y lamino } -phenyl)-3 -trifluoromethylbenzamide, N-(3 - { 1 -[6-(6-methoxy-pyridin-3 -ylamino)-pyrimidin-4-yl]- 1 H-imidazol-2- ylamino} -4-methyl-phenyl)-3-trifluoromethyl-benzamide, N-{4-methyl-3-[l -(6-morpholin- 4-yl-ρyrimidin-4-yl)- 1 H-imidazol-2~ylamino]-phenyl} -3-trifluoromethyl-benzamide, N-(3- { 1 -[6-(4-ethyl-piperazin- 1 -yl)-pyrimidin-4-yl]- lH-imidazol-2-ylamino} -4-methyl-phenyl)- 3 -trifluoromethyl-benzamide, N-(3-{l-[6-(3-fluoro-phenylamino)-pyrimidin-4-yl]-lH- imidazol-2-ylamino}-4-methyl-phenyl)-3-trifluoromethyl-benzamide, N-(3-{l-[6-(3- dimethylamino-ethyl-formamide-phenylamino)-pyrimidin-4-yl]-lH-imidazol-2-ylamino}-4- methyl-ρhenyl)-3-trifluoromethyl-benzamide, N-[4-methyl-3-(l-{6-[(pyridin-3-ylmethyl)- amino]-pyrimidin-4-yl}-lH-imidazol-2-ylamino)-phenyl]-3-trifluoromethyl-benzamide, N- [4-methyl-3-(l-{6-[(pyridin-4-ylmethyl)-amino]-pyrimidin-4-yl}-lH-imidazol-2-ylamino)- phenyl]-3-trifluoromethyl-benzamide, N-(4-methyl-3-{l-[6-(4-morpholin-4-yl-piperidin-l- yl)-pyrimidin-4-yl]-lH-imidazol-2-ylamino}-phenyl)-3-trifluoromethyl-benzamide, N-[4- methyl-3-(l-{6-[(thiazol-2-ylmethyl)-amino]-pyrimidin-4-yl}-lH-imidazol-2-ylamino)- phenyl]-3-trifluoromethyl-benzamide, N-[4-methyl-3-(l-{6-[(pyridin-2-ylmethyl)-amino]- pyrimidin-4-yl}-lH-imidazol-2-ylamino)-phenyl]-3-trifluoromethyl-benzamide, N-[4- methyl-3-(l-{6-[(6-methyl-pyrazin-2-ylmethyl)-amino]-pyrimidin-4-yl}-lH-imidazol-2- ylamino)-phenyl]-3-trifluoromethyl-benzamide, N-(4-methyl-3-{l-[6-(4-pyridin-2-yl- piperazin- 1 -yl)-pyrimidin-4-yl]- 1 H-imidazol-2-ylamino} -phenyl)-3 -trifluoromethyl- benzamide, N-(3-{ l-[6-(3-imidazol-l-yl-propylamino)-pyrimidin-4-yl]-lH-imidazol-2- ylamino}-4-methyl-phenyl)-3-trifluoromethyl-benzamide, N-(4-methyl~3-{l-[6-(pyrazin-2- ylamino)-pyrimidin-4-y 1] - 1 H-imidazol-2-y lamino } -phenyl)-3 -trifluoromethyl-benzamide, N-(3 - { 1 -[6-(3 -formamide-phenylamino)-pyrimidin-4-yl]- 1 H-imidazol-2 -ylamino} -4-methyl- phenyl)-3-trifluoromethyl-benzamide, 4-methyl-3-{l~[6-(2-morpholin-4-yl-ethylamino)- pyrimidin-4-yl]-lH-imidazol-2-ylamino}-N-(3-trifluoromethyl-phenyl)-benzamide, 4- methyl-3 - { 1 -[6-(4-methy 1-piperazin- 1 -ylamino)-pyrimidin-4-yl]- 1 H-imidazol-2-ylamino } - N-(3-trifluoromethyl-phenyl)-benzamide, N-(4-chloro-3-trifluoromethyl-phenyl)-4-methyI- 3-{l-[6-(2-morpholin-4-yl-ethylamino)-pyrimidin-4-yl]-lH-imidazol-2-ylamino}- benzamide, N-(4-chloro-3 -trifluoromethyl-phenyl)-4-methyl-3- { 1 -[6-(4-methyl-ρiρerazin- 1 - ylamino)-pyrimidin-4-yl]- 1 H-imidazol-2-ylamino} -benzamide, 1 -tert-butyl-5-(4-røethyl- piperazin-l-ylmethyl)-lH-pyrazole-3-carboxylic acid {3-[l-(6-cyclopropylamino-pyrimidin- 4-yl)- lH-imidazol-2-y lamino] -4-methyl-phenyl} -amide, 1 -tert-butyl-5 -morpholin-4- ylmethyl- 1 H-pyrazole-3 -carboxylic acid { 3 -[ 1 -(6-cyclopropylamino-ρyrimidin-4-yl)- 1 H- imidazol-2-ylamino]-4-methyl-phenyl} -amide, N-(4-tert-butyl-thiazol-2-yl)-4-methyl-3 - { 1 - [6-(2-morpholin-4-yl-ethylamino)-pyrimidin-4-yl]-lH-imidazol-2-ylamino}-benzamide, N- (4-tert-butyl-thiazol-2-yl)-4-methyl-3-{l-[6-(4-methyl-piperazin-l-ylamino)-pyrimidin-4- yl] - 1 H-imidazol-2 -ylamino} -benzamide, N-(5 -tert-butyl-2-methyl-2H-pyrazol-3 -yl)-4- methyl-3-{l-[6-(4-methyl-piperazin-l-ylamino)-pyrimidin-4-yl]-lH-imidazol-2-ylamino}- benzamide, N-(4-methyl-3-{l-[6-(4-methyl-piperazin-l-ylamino)-pyrimidin-4-yl]-lH- imidazol-2-ylamino}-phenyl)-benzamide, N-(5-tert-butyl-2-methyl-2H-pyrazol-3-yl)-4- methyl-3-{l-[6-(2-morpholin-4-yl-ethylamino)-pyrimidin-4-yl]-lH-imidazol-2-ylamino}- benzamide, N-(4-methyl-3 - { 1 -[2-(2-morpholin-4-yl-ethylamino)-pyridin-4-yl]- 1 H-imidazol- 2-ylamino}-phenyl)-3-trifluoromethyl-benzamide, N-{3-[l-(4-acetylamino-pyridin-2-yl)- lH-imidazol-2-ylamino]-4-methyl-phenyl}-3-trifluoromethyl-benzamide and 2-{2-[2- Methyl-5 -(3 -trifluoromethyl-benzoylamino)-phenylamino]-imidazol- 1 -yl} -isonicotinamide. [0023] Further preferred compounds of the invention are detailed in the Examples and Table I, infra. Pharmacology and Utility
[0024] Compounds of the invention modulate the activity of kinases and, as such, are useful for treating diseases or disorders in which kinases, contribute to the pathology and/or symptomology of the disease. Examples of kinases that are inhibited by the compounds and compositions described herein and against which the methods described herein are useful include, but are not limited to, Abl, BCR-Abl (wild-type and mutant forms), PDGF-R, trkB, c-SRC, BMX, FGFR3, b-RAF, SGK, Tie2, Lck, JNK2α2, MKK4, c- RAF, MKK6, SAPK2α and SAPK2β.
[0025] Abelson tyrosine kinase (i.e. Abl, c-Abl) is involved in the regulation of the cell cycle, in the cellular response to genotoxic stress, and in the transmission of information about the cellular environment through integrin signaling. Overall, it appears that the Abl protein serves a complex role as a cellular module that integrates signals from various extracellular and intracellular sources and that influences decisions in regard to cell cycle and apoptosis. Abelson tyrosine kinase includes sub-types derivatives such as the chimeric fusion (oncoprotein) BCR-Abl with deregulated tyrosine kinase activity or the v- Abl. BCR-Abl is critical in the pathogenesis of 95% of chronic myelogenous leukemia (CML) and 10% of acute lymphocytic leukemia. STI-571 (Gleevec) is an inhibitor of the oncogenic BCR-Abl tyrosine kinase and is used for the treatment of chronic myeloid leukemia (CML). However, some patients in the blast crisis stage of CML are resistant to STI-571 due to mutations in the BCR-Abl kinase. Over 22 mutations have been reported to date with the most common being G250E, E255V, T315I, F317L and M351T. [0026] Compounds of the present invention inhibit abl kinase, especially v-abl kinase. The compounds of the present invention also inhibit wild-type BCR-Abl kinase and mutations of BCR-Abl kinase and are thus suitable for the treatment of Bcr-abl-positive cancer and tumor diseases, such as leukemias (especially chronic myeloid leukemia and acute lymphoblastic leukemia, where especially apoptotic mechanisms of action are found), and also shows effects on the subgroup of leukemic stem cells as well as potential for the purification of these cells in vitro after removal of said cells (for example, bone marrow removal) and reimplantation of the cells once they have been cleared of cancer cells (for example, reimplantation of purified bone marrow cells). [0027] The Ras-Raf-MEK-ERK signaling pathway mediates cellular response to growth signals. Ras is mutated to an oncogenic form in ~15% of human cancer. The Raf family belongs to the serine/threonine protein kinase and it includes three members, A-Raf, B-Raf and c-Raf (or Raf-1). The focus on Raf being a drug target has centered on the relationship of Raf as a downstream effector of Ras. However, recent data suggests that B- Raf may have a prominent role in the formation of certain tumors with no requirement for an activated Ras allele (Nature 417, 949 - 954 (01 Jul 2002). In particular, B-Raf mutations have been detected in a large percentage of malignant melanomas. [0028] Existing medical treatments for melanoma are limited in their effectiveness, especially for late stage melanomas. The compounds of the present invention also inhibit cellular processes involving b-Raf kinase, providing a new therapeutic opportunity for treatment of human cancers, especially for melanoma. [0029] The compounds of the present invention also inhibit cellular processes involving c-Raf kinase. c-Raf is activated by the ras oncogene, which is mutated in a wide number of human cancers. Therefore inhibition of the kinase activity of c-Raf may provide a way to prevent ras mediated tumor growth [Campbell, S. L., Oncogene, 17, 1395 (1998)]. [0030] PDGF (Platelet-derived Growth Factor) is a very commonly occurring growth factor, which plays an important role both in normal growth and also in pathological cell proliferation, such as is seen in carcinogenesis and in diseases of the smooth-muscle cells of blood vessels, for example in atherosclerosis and thrombosis. Compounds of the invention can inhibit PDGF receptor (PDGFR) activity and are, therefore, suitable for the treatment of tumor diseases, such as gliomas, sarcomas, prostate tumors, and tumors of the colon, breast, and ovary.
[0031] Compounds of the present invention, can be used not only as a tumor- inhibiting substance, for example in small cell lung cancer, but also as an agent to treat non- malignant proliferative disorders, such as atherosclerosis, thrombosis, psoriasis, scleroderma and fibrosis, as well as for the protection of stem cells, for example to combat the hemotoxic effect of chemotherapeutic agents, such as 5-fluoruracil, and in asthma. Compounds of the invention can especially be used for the treatment of diseases, which respond to an inhibition of the PDGF receptor kinase. [0032] Compounds of the present invention show useful effects in the treatment of disorders arising as a result of transplantation, for example, allogenic transplantation, especially tissue rejection, such as especially obliterative bronchiolitis (OB), i.e. a chronic rejection of allogenic lung transplants. In contrast to patients without OB, those with OB often show an elevated PDGF concentration in bronchoalveolar lavage fluids. [0033] Compounds of the present invention are also effective in diseases associated with vascular smooth-muscle cell migration and proliferation (where PDGF and PDGF-R often also play a role), such as restenosis and atherosclerosis. These effects and the consequences thereof for the proliferation or migration of vascular smooth-muscle cells in vitro and in vivo can be demonstrated by administration of the compounds of the present invention, and also by investigating its effect on the thickening of the vascular intima following mechanical injury in vivo.
[0034] The trk family of neurotrophin receptors (trkA, trkB, trkC) promotes the survival, growth and differentiation of the neuronal and non-neuronal tissues. The TrkB protein is expressed in neuroendocrine-type cells in the small intestine and colon, in the alpha cells of the pancreas, in the monocytes and macrophages of the lymph nodes and of the spleen, and in the granular layers of the epidermis (Shibayama and Koizumi, 1996). Expression of the TrkB protein has been associated with an unfavorable progression of Wilms tumors and of neuroblastomas. TkrB is, moreover, expressed in cancerous prostate cells but not in normal cells. The signaling pathway downstream of the trk receptors involves the cascade of MAPK activation through the She, activated Ras, ERK-1 and ERK-2 genes, and the PLC-gammal transduction pathway (Sugimoto et al., 2001). [0035] The kinase, c-Src transmits oncogenic signals of many receptors. For example, over-expression of EGFR or HER2/neu in tumors leads to the constitutive activation of c-src, which is characteristic for the malignant cell but absent from the normal cell. On the other hand, mice deficient in the expression of c-src exhibit an osteopetrotic phenotype, indicating a key participation of c-src in osteoclast function and a possible involvement in related disorders.
[0036] The Tec family kinase, Bmx, a non-receptor protein-tyrosine kinase, controls the proliferation of mammary epithelial cancer cells. [0037] Fibroblast growth factor receptor 3 was shown to exert a negative regulatory effect on bone growth and an inhibition of chondrocyte proliferation. Thanatophoric dysplasia is caused by different mutations in fibroblast growth factor receptor 3, and one mutation, TDII FGFR3, has a constitutive tyrosine kinase activity which activates the transcription factor Statl, leading to expression of a cell-cycle inhibitor, growth arrest and abnormal bone development (Su et al., Nature, 1997, 386, 288-292). FGFR3 is also often expressed in multiple myeloma-type cancers. Inhibitors of FGFR3 activity are useful in the treatment of T-cell mediated inflammatory or autoimmune diseases including but not limited to rheumatoid arthritis (RA), collagen II arthritis, multiple sclerosis (MS), systemic lupus erythematosus (SLE), psoriasis, juvenile onset diabetes, Sjogren's disease, thyroid disease, sarcoidosis, autoimmune uveitis, inflammatory bowel disease (Crohn's and ulcerative colitis), celiac disease and myasthenia gravis.
[0038] The activity of serum and glucocorticoid-regulated kinase (SGK), is correlated to perturbed ion-channel activities, in particular, those of sodium and/or potassium channels and compounds of the invention can be useful for treating hypertension. [0039] Lin et al (1997) J. Clin. Invest. 100, 8: 2072-2078 and P. Lin (1998) PNAS
95, 8829-8834, have shown an inhibition of tumor growth and vascularization and also a decrease in lung metastases during adenoviral infections or during injections of the extracellular domain of Tie-2 (Tek) in breast tumor and melanoma xenograft models. Tie2 inhibitors can be used in situations where neovascularization takes place inappropriately (i.e. in diabetic retinopathy, chronic inflammation, psoriasis, Kaposi's sarcoma, chronic neovascularization due to macular degeneration, rheumatoid arthritis, infantile haemangioma and cancers).
[0040] Lck plays a role in T-cell signaling. Mice that lack the Lck gene have a poor ability to develop thymocytes. The function of Lck as a positive activator of T-cell signaling suggests that Lck inhibitors may be useful for treating autoimmune disease such as rheumatoid arthritis.
[0041] JNKs, along with other MAPKs, have been implicated in having a role in mediating cellular response to Cancer, thrombin-induced platelet aggregation, immunodeficiency disorders, autoimmune diseases, cell death, allergies, osteoporosis and heart disease. The therapeutic targets related to activation of the JNK pathway include chronic myelogenous leukemia (CML), rheumatoid arthritis, asthma, osteoarthritis, ischemia, cancer and neurodegenerative diseases. As a result of the importance of INK activation associated with liver disease or episodes of hepatic ischemia, compounds of the invention may also be useful to treat various hepatic disorders. A role for JNK in cardiovascular disease such as myocardial infarction or congestive heart failure has also been reported as it has been shown JNK mediates hypertrophic responses to various forms of cardiac stress. It has been demonstrated that the JNK cascade also plays a role in T-cell activation, including activation of the IL-2 promoter. Thus, inhibitors of JNK may have therapeutic value in altering pathologic immune responses. A role for JNK activation in various cancers has also been established, suggesting the potential use of JNK inhibitors in cancer. For example, constitutively activated JNK is associated with HTLV-1 mediated tumorigenesis [Oncogene 13:135-42 (1996)] . JNK may play a role in Kaposi's sarcoma (KS). Other proliferative effects of other cytokines implicated in KS proliferation, such as vascular endothelial growth factor (VEGF), IL-6 and TNF , may also be mediated by JNK. In addition, regulation of the c-jun gene in p210 BCR-ABL transformed cells corresponds with activity of JNK, suggesting a role for JNK inhibitors in the treatment for chronic myelogenous leukemia (CML) [Blood 92:2450-60 (1998)].
[0042] Certain abnormal proliferative conditions are believed to be associated with raf expression and are, therefore, believed to be responsive to inhibition of raf expression. Abnormally high levels of expression of the raf protein are also implicated in transformation and abnormal cell proliferation. These abnormal proliferative conditions are also believed to be responsive to inhibition of raf expression. For example, expression of the c-raf protein is believed to play a role in abnormal cell proliferation since it has been reported that 60% of all lung carcinoma cell lines express unusually high levels of c-raf mRNA and protein. Further examples of abnormal proliferative conditions are hyper- proliferative disorders such as cancers, tumors, hyperplasia, pulmonary fibrosis, angiogenesis, psoriasis, atherosclerosis and smooth muscle cell proliferation in the blood vessels, such as stenosis or restenosis following angioplasty. The cellular signaling pathway of which raf is a part has also been implicated in inflammatory disorders characterized by T- cell proliferation (T-cell activation and growth), such as tissue graft rejection, endotoxin shock, and glomerular nephritis, for example. [0043] - The stress activated protein kinases (SAPKs) are a family of protein kinases that represent the penultimate step in signal transduction pathways that result in activation of the c-jun transcription factor and expression of genes regulated by c-jun. In particular, c-jun is involved in the transcription of genes that encode proteins involved in the repair of DNA that is damaged due to genotoxic insults. Therefore, agents that inhibit SAPK activity in a cell prevent DNA repair and sensitize the cell to agents that induce DNA damage or inhibit DNA synthesis and induce apoptosis of a cell or that inhibit cell proliferation.
[0044] Mitogen-activated protein kinases (MAPKs) are members of conserved signal transduction pathways that activate transcription factors, translation factors and other target molecules in response to a variety of extracellular signals. MAPKs are activated by phosphorylation at a dual phosphorylation motif having the sequence Thr-X-Tyr by mitogen- activated protein kinase kinases (MKKs). In higher eukaryotes, the physiological role of MAPK signaling has been correlated with cellular events such as proliferation, oncogenesis, development and differentiation. Accordingly, the ability to regulate signal transduction via these pathways (particularly via MKK4 and MKK6) could lead to the development of treatments and preventive therapies for human diseases associated with MAPK signaling, such as inflammatory diseases, autoimmune diseases and cancer. [0045] The family of human ribosomal S6 protein kinases consists of at least 8 members (RSK1, RSK2, RSK3, RSK4, MSK1, MSK2, p70S6K and p70S6 Kb). Ribosomal protein S6 protein kinases play important pleotropic functions, among them is a key role in the regulation of mRNA translation during protein biosynthesis (Eur. J. Biochem 2000 November; 267(21): 6321-30, Exp Cell Res. Nov. 25, 1999; 253 (l):100-9, Mol Cell Endocrinol. May 25, 1999;151(l-2):65-77). The phosphorylation of the S6 ribosomal protein by p70S6 has also been implicated in the regulation of cell motility (Immunol. Cell Biol. 2000 August;78(4):447-51) and cell growth (Prog. Nucleic Acid Res. Mol. Biol., 2000;65: 101-27), and hence, may be important in tumor metastasis, the immune response and tissue repair as well as other disease conditions.
[0046] The SAPK's (also called "jun N-terminal kinases" or "JNK's") are a family of protein kinases that represent the penultimate step in signal transduction pathways that result in activation of the c-jun transcription factor and expression of genes regulated by c- jun. In particular, c-jun is involved in the transcription of genes that encode proteins involved in the repair of DNA that is damaged due to genotoxic insults. Agents that inhibit
SAPK activity in a cell prevent DNA repair and sensitize the cell to those cancer therapeutic modalities that act by inducing DNA damage.
[0047] BTK plays a role in autoimmune and/or inflammatory disease such as systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple vasculitides, idiopathic thrombocytopenic purpura (ITP), myasthenia gravis, and asthma.. Because of BTK's role in
B-cell activation, inhibitors of BTK are useful as inhibitors of B-cell mediated pathogenic activity, such as autoantibody production, and are useful for the treatment of B-cell lymphoma and leukemia.
[0048] CHK2 is a member of the checkpoint kinase family of serine/threonine protein kinases and is involved in a mechanism used for surveillance of DNA damage, such as damage caused by environmental mutagens and endogenous reactive oxygen species. As a result, it is implicated as a tumor suppressor and target for cancer therapy.
[0049] CSK influences the metastatic potential of cancer cells, particularly colon cancer.
[0050] Fes is a non-receptor protein tyrosine kinase that has been implicated in a variety of cytokine signal transduction pathways, as well as differentiation of myeloid cells.
Fes is also a key component of the granulocyte differentiation machinery.
[0051] Flt3 receptor tyrosine kinase activity is implicated in leukemias and myelodysplastic syndrome. In approximately 25% of AML the leukemia cells express a constitutively active form of auto-phosphorylated (p) FLT3 tyrosine kinase on the cell surface. The activity of p-FLT3 confers growth and survival advantage on the leukemic cells. Patients with acute leukemia, whose leukemia cells express p-FLT3 kinase activity, have a poor overall clinical outcome. Inhibition of p-FLT3 kinase activity induces apoptosis
(programmed cell death) of the leukemic cells.
[0052] Inhibitors of IKKα and IKKβ (1 & 2) are therapeutics for diseases which include rheumatoid arthritis, transplant rejection, inflammatory bowel disease, osteoarthritis, asthma, chronic obstructive pulmonary disease, atherosclerosis, psoriasis, multiple sclerosis, stroke, systemic lupus erythematosus, Alzheimer's disease, brain ischemia, traumatic brain injury, Parkinson's disease, amyotrophic lateral sclerosis, subarachnoid hemorrhage or other diseases or disorders associated with excessive production of inflammatory mediators in the brain and central nervous system.
[0053] Met is associated with most types of the major human cancers and expression is often correlated with poor prognosis and metastasis. Inhibitors of Met are therapeutics for diseases which include cancers such as lung cancer, NSCLC (non small cell lung cancer), bone cancer, pancreatic cancer, skin cancer, cancer of the head and neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, colon cancer, breast cancer, gynecologic tumors (e. g., uterine sarcomas, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina or carcinoma of the vulva), Hodgkin's Disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system (e. g., cancer of the thyroid, parathyroid or adrenal glands), sarcomas of soft tissues, cancer of the urethra, cancer of the penis, prostate cancer, chronic or acute leukemia, solid tumors of childhood, lymphocytic lymphomas, cancer of the bladder, cancer of the kidney or ureter (e. g., renal cell carcinoma, carcinoma of the renal pelvis), pediatric malignancy, neoplasms of the central nervous system (e. g., primary CNS lymphoma, spinal axis tumors, brain stem glioma or pituitary adenomas), cancers of the blood such as acute myeloid leukemia, chronic myeloid leukemia, etc, Barrett's esophagus (pre-malignant syndrome) neoplastic cutaneous disease, psoriasis, mycoses fungoides and benign prostatic hypertrophy, diabetes related diseases such as diabetic retinopathy, retinal ischemia and retinal neovascularization, hepatic cirrhosis, cardiovascular disease such as atherosclerosis, immunological disease such as autoimmune disease and renal disease. Preferably, the disease is cancer such as acute myeloid leukemia and colorectal cancer. [0054] The Nima-related kinase 2 (Nek2) is a cell cycle-regulated protein kinase with maximal activity at the onset of mitosis that localizes to the centrosome. Functional studies have implicated Nek2 in regulation of centrosome separation and spindle formation. Nek2 protein is elevated 2- to 5-fold in cell lines derived from a range of human tumors including those of cervical, ovarian, prostate, and particularly breast. [0055] p70S6K-mediated diseases or conditions include, but are not limited to, proliferative disorders, such as cancer and tuberous sclerosis. [0056] In accordance with the foregoing, the present invention further provides a method for preventing or treating any of the diseases or disorders described above in a subject in need of such treatment, which method comprises administering to said subject a therapeutically effective amount See, "Administration and Pharmaceutical Compositions ", infra) of a compound of Formula I or a pharmaceutically acceptable salt thereof. For any of the above uses, the required dosage will vary depending on the mode of administration, the particular condition to be treated and the effect desired.
Administration and Pharmaceutical Compositions
[0057] In general, compounds of the invention will be administered in therapeutically effective amounts via any of the usual and acceptable modes known in the art, either singly or in combination with one or more therapeutic agents. A therapeutically effective amount may vary widely depending on the severity of the disease, the age and relative health of the subject, the potency of the compound used and other factors. In general, satisfactory results are indicated to be obtained systemically at daily dosages of from about 0.03 to 2.5mg/kg per body weight. An indicated daily dosage in the larger mammal, e.g. humans, is in the range from about 0.5mg to about lOOmg, conveniently administered, e.g. in divided doses up to four times a day or in retard form. Suitable unit dosage forms for oral administration comprise from ca. 1 to 50mg active ingredient. [0058] Compounds of the invention can be administered as pharmaceutical compositions by any conventional route, in particular enterally, e.g., orally, e.g., in the form of tablets or capsules, or parenterally, e.g., in the form of injectable solutions or suspensions, topically, e.g., in the form of lotions, gels, ointments or creams, or in a nasal or suppository form. Pharmaceutical compositions comprising a compound of the present invention in free form or in a pharmaceutically acceptable salt form in association with at least one pharmaceutically acceptable carrier or diluent can be manufactured in a conventional manner by mixing, granulating or coating methods. For example, oral compositions can be tablets or gelatin capsules comprising the active ingredient together with a) diluents, e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycine; b) lubricants, e.g., silica, talcum, stearic acid, its magnesium or calcium salt and/or polyethyleneglycol; for tablets also c) binders, e.g., magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylceliulose and or polyvinylpyrrolidone; if desired d) disintegrants, e.g., starches, agar, alginic acid or its sodium salt, or effervescent mixtures; and/or e) absorbents, colorants, flavors and sweeteners. Injectable compositions can be aqueous isotonic solutions or suspensions, and suppositories can be prepared from fatty emulsions or suspensions. The compositions may be sterilized and/or contain adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers. In addition, they may also contain other therapeutically valuable substances. Suitable formulations for transdermal applications include an effective amount of a compound of the present invention with' a carrier. A carrier can include absorbable pharmacologically acceptable solvents to assist passage through the skin of the host. For example,, transdermal devices are in the form of a bandage comprising a backing member, a reservoir containing the compound optionally with carriers, optionally a rate controlling barrier to deliver the compound to the skin of the host at a controlled and predetermined rate over a prolonged period of time, and means to secure the device to the skin. Matrix transdermal formulations may also be used. Suitable formulations for topical application, e.g., to the skin and eyes, are preferably aqueous solutions, ointments, creams or gels well-known in the art. Such may contain solubilizers, stabilizers, tonicity enhancing agents, buffers and preservatives.
[0059] Compounds of the invention can be administered in therapeutically effective amounts in combination with one or more therapeutic agents (pharmaceutical combinations). For example, synergistic effects can occur with other immunomodulatory or anti-inflammatory substances, for example when used in combination with cyclosporin, rapamycin, or ascomycin, or immunosuppressant analogues thereof, for example cyclosporin A (CsA), cyclosporin G, FK-506, rapamycin, or comparable compounds, corticosteroids, cyclophosphamide, azathioprine, methotrexate, brequinar, leflunomide, mizoribine, mycophenolic acid, mycophenolate mofetil, 15-deoxyspergualin, immunosuppressant antibodies, especially monoclonal antibodies for leukocyte receptors, for example MHC, CD2, CD3, CD4, CD7, CD25, CD28, B7, CD45, CD58 or their ligands, or other immunomodulatory compounds, such as CTLA41g. Where the compounds of the invention are administered in conjunction with other therapies, dosages of the co-administered compounds will of course vary depending on the type of co-drug employed, on the specific drug employed, on the condition being treated and so forth.
[0060] The invention also provides for a pharmaceutical combinations, e.g. a kit, comprising a) a first agent which is a compound of the invention as disclosed herein, in free form or in pharmaceutically acceptable salt form, and b) at least one co-agent. The kit can comprise instructions for its administration.
[0061] The terms "co-administration" or "combined administration" or the like as utilized herein are meant to encompass administration of the selected therapeutic agents to a single patient, and are intended to include treatment regimens in which the agents are not necessarily administered by the same route of administration or at the same time. [0062] The term "pharmaceutical combination" as used herein means a product that results from the mixing or combining of more than one active ingredient and includes both fixed and non-fixed combinations of the active ingredients. The term "fixed combination" means that the active ingredients, e.g. a compound of Formula I and a co- agent, are both administered to a patient simultaneously in the form of a single entity or dosage. The term "non-fixed combination" means that the active ingredients, e.g. a compound of Formula I and a co-agent, are both administered to a patient as separate entities either simultaneously, concurrently or sequentially with no specific time limits, wherein such administration provides therapeutically effective levels of the 2 compounds in the body of the patient. The latter also applies to cocktail therapy, e.g. the administration of 3 or more active ingredients.
Processes for Making Compounds of the Invention
[0063] The present invention also includes processes for the preparation of compounds of the invention. In the reactions described, it can be necessary to protect reactive functional groups, for example hydroxy, amino, imino, thio or carboxy groups, where these are desired in the final product, to avoid their unwanted participation in the reactions. Conventional protecting groups can be used in accordance with standard practice, for example, see T.W. Greene and P. G. M. Wuts in "Protective Groups in Organic Chemistry", John Wiley and Sons, 1991. [0064] Compounds of Formula I can be prepared by proceeding as in the following Reaction Scheme I:
Reactions Scheme I
Figure imgf000029_0001
(2) I in which Rls R2, R3, 4, n and m are as defined for Formula I in the Summary of the Invention. A compound of Formula I can be prepared by reacting a compound of formula 2 with a compound of formula 3 in the presence of a suitable base (e.g., DIPEA, or the like) and a suitable solvent (e.g., butanol, THF, DMF, or the like). The reaction proceeds in a temperature range of about 80 to about 120°C and can take up to about 20 hours to complete.
[0065] A detailed example of the synthesis of a compound of formula I can be found in the Examples, infra.
Additional Processes for Making Compounds of the Invention
[0066] A compound of the invention can be prepared as a pharmaceutically acceptable acid addition salt by reacting the free base form of the compound with a pharmaceutically acceptable inorganic or organic acid. Alternatively, a pharmaceutically acceptable base addition salt of a compound of the invention can be prepared by reacting the free acid form of the compound with a pharmaceutically acceptable inorganic or organic base. Alternatively, the salt forms of the compounds of the invention can be prepared using salts of the starting materials or intermediates.
[0067] The free acid or free base forms of the compounds of the invention can be prepared from the corresponding base addition salt or acid addition salt from, respectively. For example a compound of the invention in an acid addition salt form can be converted to the corresponding free base by treating with a suitable base (e.g., ammonium hydroxide solution, sodium hydroxide, and the like). A compound of the invention in a base addition salt form can be converted to the corresponding free acid by treating with a suitable acid
(e.g., hydrochloric acid, etc.).
[0068] Compounds of the invention in unoxidized form can be prepared from N- oxides of compounds of the invention by treating with a reducing agent (e.g., sulfur, sulfur dioxide, triphenyl phosphine, lithium borohydride, sodium borohydride, phosphorus trichloride, tribromide, or the like) in a suitable inert organic solvent (e.g. acetonitrile, ethanol, aqueous dioxane, or the like) at 0 to 80°C.
[0069] Prodrug derivatives of the compounds of the invention can be prepared by methods known to those of ordinary skill in the art (e.g., for further details see Saulnier et al., (1994), Bioorganic and Medicinal Chemistry Letters, Vol. 4, p. 1985). For example, appropriate prodrugs can be prepared by reacting a non-derivatized compound of the invention with a suitable carbamylating agent (e.g., 1,1-acyloxyalkylcarbanochloridate, para- nitrophenyl carbonate, or the like).
[0070] Protected derivatives of the compounds of the invention can be made by means known to those of ordinary skill in the art. A detailed description of techniques applicable to the creation of protecting groups and their removal can be found in T. W.
Greene, "Protecting Groups in Organic Chemistry", 3rd edition, John Wiley and Sons, Inc.,
1999.
[0071] Compounds of the present invention can be conveniently prepared, or formed during the process of the invention, as solvates (e.g., hydrates). Hydrates of compounds of the present invention can be conveniently prepared by recrystallization from an aqueous/organic solvent mixture, using organic solvents such as dioxin, tetrahydrofuran or methanol.
[0072] Compounds of the invention can be prepared as their individual stereoisomers by reacting a racemic mixture of the compound with an optically active resolving agent to form a pair of diastereoisomeric compounds, separating the diastereomers and recovering the optically pure enantiomers. While resolution of enantiomers can be carried out using covalent diastereomeric derivatives of the compounds of the invention, dissociable complexes are preferred (e.g., crystalline diastereomeric salts). Diastereomers have distinct physical properties (e.g., melting points, boiling points, solubilities, reactivity, etc.) and can be readily separated by taking advantage of these dissimilarities. The diastereomers can be separated by chromatography, or preferably, by separation/resolution techniques based upon differences in solubility. The optically pure enantiomer is then recovered, along with the resolving agent, by any practical means that would not result in racemization. A more detailed description of the techniques applicable to the resolution of stereoisomers of compounds from their racemic mixture can be found in Jean Jacques, Andre Collet, Samuel H. Wilen, "Enantiomers, Racemates and Resolutions", John Wiley And Sons, Inc., 1981.
[0073] In summary, the compounds of Formula I can be made by a process, which involves: (a) those of reaction schemes I and II, for example coupling compounds of formula 8 with R6YOH according to reaction scheme I; and (b) optionally converting a compound of the invention into a pharmaceutically acceptable salt; (c) optionally converting a salt form of a compound of the invention to a non-salt form; (d) optionally converting an unoxidized form of a compound of the invention into a pharmaceutically acceptable N-oxide; (e) optionally converting an N-oxide form of a compound of the invention to its unoxidized form; (f) optionally resolving an individual isomer of a compound of the invention from a mixture of isomers; (g) optionally converting a non-derivatized compound of the invention into a pharmaceutically acceptable prodrug derivative; and (h) optionally converting a prodrug derivative of a compound of the invention to its non-derivatized form.
[0074] Insofar as the production of the starting materials is not particularly described, the compounds are known or can be prepared analogously to methods known in the art or as disclosed in the Examples hereinafter. [0075] One of skill in the art will appreciate that the above transformations are only representative of methods for preparation of the compounds of the present invention, and that other well known methods can similarly be used.
Examples
[0076] The present invention is further exemplified, but not limited, by the following examples that illustrate the preparation of compounds of Formula I according to the invention.
Example 1 N-[4-methyl-3-fl-{6-[4-(2-morpholin-4-yl-ethyl)-phenylamino]-pyrimidin-4-yl}-lH- imidazol-2-ylamino)-phenyl]-3-trifluoromethyl-benzamide
Figure imgf000032_0001
N-(2,2-Diethoxyethyl)carbodiimide
Figure imgf000032_0002
[0077] A solution of the aminoacetaldehyde diethyl acetal (13.16g, 99 mmol) in ether (35 mL) was added to a suspension of CNBr (10.47g, 99 mmol) in hexane (35 mL) at room temperature. The reaction mixture was stirred at room temperature overnight. The solid was removed by filtration and washed with ether. The combined filtrate was concentrated. Purification by column chromatography (silica gel, eluting with dichloromethane to 4% methanol in dichloromethane, gradient) afforded the title compound (7.0 g, 44.7%, one half of the starting amine served as a sacrificial base in the reaction) (Rf: 2.70, 4% methanol in dichloromethane, stain with 10% ethanolic molybdatophosphoric acid). !H NMR 400 MHz (CDCI3) δ 4.58 (t, J= 5.2 Hz, IH), 3.77 - 3.69 (m, 2H), 3.65 (br, s, IH), 3.60 - 3.52 (m, 2H), 3.16 (t, J= 5.6 Hz, IH), 1.23 (t, 6H, J= 6.8 Hz).
N-[3-(lH-Imidazol-2-ylaminoV4-methyl-phenyl]-3-trifluoromethyl-benzamide
Figure imgf000033_0001
[0078] A mixture of N-(2,2-diethoxyethyl)carbodiimide (398 mg, 2.51 mmol), 3- amino-4-methyl-phenyl] -3 -trifluoromethyl-benzamide (649 mg, 2.20 mmol), methanesulfonic acid (143 μL, 2.20 mmol) in ethanol (25 mL) is heated at reflux for 16 hours. An additional portion of N-(2,2-diethoxyethyl)carbodiirnide (525 mg, 3.32 mmol) and methanesulfonic acid (143 μL, 2.20 mmol) are added. After an additional 3 hours refluxing, the reaction mixture is concentrated. The residue is dissolved in HCl (6N, 5 mL) and ethanol (5 mL). After stirring overnight, the reaction mixture is concentrated and basified with 25% NaOH solution to a pH of 14. The mixture is stirred for 30 minutes, extracted with CH2C12, dried, concentrated and purified by column chromatography (silica gel, eluting with 7N NH3 in methanol: dichloromethane from 2% to 4%) to give the title compound.
N - { 3 -f 1 -(6-chloro-pyrimidin-4-yl - 1 H-imidazol-2-y lamino] -4-methyl-phenyl } -3 - trifluoromethyl-benzamide
Figure imgf000033_0002
[0079] A mixture of N-[3-(lH-Imidazol-2-ylamino)-4-methyl-phenyl]-3- trifluoromethyl-benzamide (330 mg, 0.92 mmol), 4,6-dichloropyrimidine (409 mg, 2.75 mmol), N,N-diisoproρylethyl amine (500 μL, 2.87 mmol) in 2-butanol (20 mL) is heated at 110 °C. After 16 hours, the reaction mixture is concentrated. The solid is washed with saturated sodium carbonate, water, ethyl acetate, and dried to give the title compound. !H NMR 600 MHz (DMSO-d6) δ 10.71 (s, IH), 10.50 (s, IH), 9.09 (s, IH), 8.80 (s, IH), 8.33 (s, IH), 8.29 (d, J = 7.8 Hz, IH), 8.17 (s, IH), 7.96 (d, J = 8.4 Hz, IH), 7.84 (s, IH), 7.77 (t, J = 8.4 Hz, IH), 7.42 (d, J = 7.2 Hz, IH), 7.21 (d, J = 8.4 Hz, IH), 6.95 (s, IH), 2.38 (s, 3H); MS m/z 473.3 (M + l).
N-[4-methyl-3-(l-{6-[4-(2-morpholin-4-yl-ethyl)-phenylamino]-pyrimidin-4-yl)-lH- imidazol-2 -ylamino Vphenyl]-3-trifluoromethyl-benzamide
Figure imgf000034_0001
[0080] A Smith vial (2-5 mL) is charged with N -{3-[l-(6-chloro-pyrimidin-4-yl)-
1H imidazol-2-ylamino]-4-methyl-phenyl}-3-trifluoromethyl-benzamide (16.8 mg, 0.035 mmol), 4~(2-morpholin-4-yl-ethyl)-phenylamine (22 mg, 0.11 mmol), p-toluenesulfonic acid monohydrate (4.4mg, 0.023 mmol) and DMSO (0.5 mL). After purging with Argon, the vial is sealed and irradiated at 100°C for 1.5 hours in a Smith Synthesizer. The resulting solution is subjected to purification by reverse-phase LC-MS to yield the title compound. 'H NMR 600 MHz (DMSO-d6) δ 11.00 (s, IH), 10.54 (s, IH), 10.09 (s, IH), 8.69 (s, IH), 8.50 (s, IH), 8.30 (s, IH), 8.28 (d, J = 8.4 Hz, IH), 7.97 (d, J = 6.6 Hz, IH), 7.79 (t, J = 8.4 Hz IH), 7.64 (d, J = 8.4 Hz, 2H), 7.55 (s, IH), 7.50 (d, J = 8.4 Hz, IH), 7.28 (m, 3H), 7.06 (s, IH), 6.95 (s, IH), 4.03 (d, J = 12.6 Hz, 2H), 4.03 (d, J = 12.6 Hz, 2H), 3.69 (t, J = 12.6 Hz, 2H), 3.52 (d, J = 12.0 Hz, 2H), 3.36 (t, J = 7.8 Hz, 2H), 3.13 (br, 2H), 2.98 (t, J = 7.8 Hz, 2H), 2.33 (s, 3H); MS m/z 643.4 (M + 1). Example 2
N- ( 3 - [ 1 -f 6-Cyclopropylamino-pyrimidin-4-yl> 1 H-imidazol-2-ylamino] -4-methyl-phenyl} - 3-(4-methyl-imidazol-l-yl)-5-trifluoromethyl-benzamide
Figure imgf000035_0001
N-(3-Amino-4-methyl-phenyl)-benzamide
Figure imgf000035_0002
[0081] To a solution of 4-methyl-3-nitro-aniIine (15.86 g, 104 mmol), pyridine
(17.0 mL, 208 mmol) in CH2C12 (150 mL) at 0°C was added benzoyl chloride (13.30 mL, 114 mmol) dropwise. After stirring for 2h at room temperature, the reaction mixture was concentrated. The residue was washed with saturated sodium carbonate solution, water then ethyl ether to afford the desired nitro compound, which was used in the next step without any further purification. . 1H NMR 600 MHz (Acetone-d6) δ 9.85 (s, IH), 8.61 (s, IH), 8.05 - 8.02 (m, 3H), 7.60 (t, IH, J= 7.2 Hz), 7.53 (t, 2H, J= 7.2 Hz), 7.46 (d, IH, J= 7.8 Hz), 2.54. (s, 3H); MS m/z 257.3 (M + 1).
[0082] The nitro compound was dissolved in ethanol (250 mL). After hydrogenation on palladium (10 wt% on activated carbon, wet, Degussa type, 5 g) using Parr Shaker, 20 -30 psi H , 16 h, the reaction mixture was filtered through a pad of celite and washed with ethanol. The combined filtrate and washings were concentrated to afford the title compound N-(3-Amino-4-methyl-phenyl)-benzamide (22.43 g, 95 % over two steps), which was used for next reaction without any further purification.
[0083] 1H NMR 600 MHz (Acetone-d6) δ 9.40 (s, 0.4H), 9.23 (s, 0.6H), 7.96 (t, 2
H, J= 7.8 Hz), 7.55 - 7.52 (m, 1 H), 7.49 {d,l H, J= 7.2 Hz), 7.47 (d,l H, J= 7.2 Hz), 7.37 (d, 0.4 H, J= 8.4 Hz), 7.31 (s, 0.6 H), 7.17 (s, 0.4 H), 7.11 (d, 0.4 H, J= 8.4 Hz), 7.95 (d, 0.6 H, J= 8.4 Hz), 7.91 (d, 0.6 H, J= 8.4 Hz), 4.44 (br, s, 1.2 H), 2.90 (br, s, 0.8 H), 2.11 (s, 1.8 H), 1.98 (s, 1.2 H); MS m/z 227.3(M + 1). N-[3-(lH-Imidazol-2-ylamino)-4-methyl-phenyl]-benzamide
Figure imgf000036_0001
[0084] A mixture of N-(2,2-diethoxyethyl)carbodiimide (10.38 g, 65.6 mmol), 3- amino-4-methyl-phenyl]-benzamide (7.42 g, 32.8 mmol), methanesulfonic acid (3.20 mL,
49.3 mmol) in ethanol (200 mL) was heated at reflux for 19 h. The reaction mixture was concentrated (No purification was pursued in this step). The residue was dissolved in HCl solution (6N, 30 mL). After stirring for overnight, the reaction mixture was neutralized with
25% NaOH solution at 0°C to pH = 6, then basified with saturated sodium carbonate solution to pH = 11. The mixture was stirred for 30 minutes, and extracted with ethanol in CH2C12
(100 mL), then 10% ethanol in CH2C12 (2 x 100 mL). The combined organic layers were dried over Na2SO , filtered, concentrated and dried under vacuum. The residue was triturated in CH2C12 (50 mL). The solid was collected by filtration and washed with CH2C12, dried to afford the title compound N-[3-(lH-imidazol-2-ylamino)-4-methyl-phenyl]-benzamide as a white solid (4.80 g, 50%). 1H ΝMR 600 MHz (DMSO-ck) δ 10.79 (s, IH), 10.11 (s, IH),
8.00 (d, 1 H, J= 2.4 Hz), 7.94 (d, 2 H, J= 7.2 Hz ), 7.60 (s, IH), 7.56 (t, IH, J= 7.2 Hz),
7.49 (t, 2H, J= 7.2 Hz), 7.25 (dd, IH, J= 2.4, 8.4 Hz), 7.04 (d, IH, J= 7.8 Hz), 6.80 (br, s,
IH), 6.65 (br, s, IH), 2.20 (s, 3H), MS m/z 293.4(M + 1).
N-{3-[l-(6-chloiO-pyrimidin-4-yl)-lH-imidazol-2-ylamino]-4-methyl-phenyl}- benzamide
Figure imgf000036_0002
[0085] A mixture of N-[3-(lH-imidazol-2-ylamino)-4-methyl-phenyl]-3- benzamide (3.41g, 11.7 mmol), 4, 6-dichloropyrimidine (5.20 g, 34.9 mmol), Ν,Ν- diisopropylethyl amine (6.10 mL, 35.0 mmol) in 2-butanol (150 mL) was heated at 100 °C. After 16h, the reaction mixture was concentrated. The residue was washed with saturated sodium carbonate, water, ethyl acetate, dried to afford the title compound (2.65 g, 56%),t he ethyl acetate filtrate was condensed, flash chromatography (silica gel, eluting with methanol in dichloromethane from 1% to 5%, gradient) to afford an additional portion of the title compound (500 mg, 10%). !Η NMR 600 MHz DMSO-d6) δ 10.66 (s, IH), 10.26 (s, IH), 9.08 (s, 1 H), 8.80 (s, 1 H), 8.16 (s,l H), 7.98 (ά, 2H, J= 7.2 Hz), 7.82 (in, IH), 7.58 (t, IH, J= 7.8 Hz), 7.52 (t, 2H, J= 7.8 Hz), 7.39 (d, IH, J= 8.4 Hz), 7.18 (d, IH, J= 8.4 Hz),6.93 (m, IH), 2.36 (s, 3H); MS m/z 405.1 (M + 1).
N-{3-[l-(6-Cyclopropylamino-pyrimidin-4-yl)-lH-imidazol-2-ylamino]-4-methyl-phenyl}- benzamide
Figure imgf000037_0001
[0086] A mixture of N-{3-[l-(6-chloro-pyrimidin-4-yl)-lH-imidazol-2-yIamino]-
4-methyl-phenyl} -benzamide (2.65 g, 6.55 mmol), cyclopropylamine (8.8 mL, 124.43 mmol) in 2-propanol (30 mL) was heated at 65 °C for 16 h. The reaction mixture was then cooled down to room temperature and concentrated. The residue yellow solid was washed with water, dried under vacuum to afford the title compound. The obtained crude title compound was directly used for the next step reaction without any further purification. *Η ΝMR 600 MHz (OMSO-d6) δ 11.13 (bs, IH), 10.24 (s, IH), 8.77 ( , 1 H), 8.48 (bs, 1 H), 8.10 (bs, 1 H), 7.98 (d, 2H, J= 6.0 Hz), 7.71 (bs, 1 H), 7.57 (s, 1 H), 7.52 (s, 2 H), 7.34 (d, IH, J= 6.6 Hz), 7.15 (d, IH, J= 6.6 Hz), 6.88 (s, 1 H), 6.74 (bs, 1 H), 2.61 (bs, IH), 2.33 (s, 3H)5 0.82 (s, 2H), 0.53 (s, 2H); MS m/z 426.5 (M + 1). N-3-[l-(6-Cyclopropylamino-pyrimidin-4-yl)-lH-imidazol-2~yl]-4-methyl-benzene-l,3- diamine
Figure imgf000038_0001
[0087] The crude product of N- { 3 - [ 1 -(6-cyclopropylamino-pyrimidin-4-y 1)- 1 H- imidazol-2-ylamino]-4-methyl-phenyl} -benzamide was dissolved in aqueous HCl solution (6 N, 50 mL) and heated at 105 °C for 6 hours. The reaction mixture was then cooled down to room temperature. The white precipitate was filtered off and washed with water. The combined filtrate solution was concentrated to viscous oil. Addition of saturated sodium carbonate aqueous solution to the oil crushed out the title compound1 as a yellow solid, which was collected by filtration, washed with water and air dried (1.6 g, 74% over two steps). H NMR 600 MHz (DMSO-^) δ 10.91 (bs, IH), 8.44 (bs, IH), 8.06 (bs, 1 H), 7.84 (s, 1 H), 7.64 (bs, 1 H), 6.84 (s, 1 H), 6.80 (d, IH, J= 7.8 Hz), 6.70 (bs, 1 H), 6.08 (d, IH, J = 8.4 Hz), 4.82 (bs, 2H), 2.61 (bs, IH), 2.18 (s, 3H), 0.81 (s, 2H) 0.52 (s, 2H); MS m/z 322.4 (M + 1).
N-{3-[l-(6-Cyclopropylamino-pyrimidin-4-yl)-lH-imidazol-2-ylamino]-4-methyl-phenyl}- 3 -(4-methyl-imidazol- 1 -yl)-5-trifluoromethyl-benzamide
Figure imgf000038_0002
[0088] To a solution of N-3-[l-(6-cyclopropylamino-pyrimidin-4-yl)-lH- imidazoI-2-yl]-4-methyl-benzene-l,3-diamine (1.38 g, 4.28 mmol), 3-(4-methyl-imidazol-l- yl)-5-trifluoromethyl-benzoic acid (1.18 g, 4.37 mmol) and DIPEA (3 mL, 17.2 mmol) in DMF (20 mL), was added HATU (1.68 g, 4.42 mmol) as solid. The reaction mixture was stirred at room temperature for 1 hour. The solvent was evaporated and the residue oil was treated with saturated sodium bicarbonate aqueous solution. The precipitated off white solid was collected by filtration and washed with water. The solid was then slurried in methanol at 50 °C for 30 min. The solid was collected by filtration, washed with MeOH, dried under vacuum to afford the title compound (2.14 g, 87%). 1H NMR 400 MHz (OMSO-d6) δ 10.21 (bs, IH), 10.52 (s, IH), 8.78 (s, 1 H), 8.54-8.44 (m, 2 H), 8.42 (s,l H), 8.23 (s, IH), 8.19 (s, IH), 8.11 (bs, IH), 7.72 (s, 2H), 7.40 (dd, IH, J= 8.0 Hz, 1.2 Hz), 7.20 (d, IH, J= 8.4 Hz), 6.89 (d, IH, J= 1.2 Hz), 6.74 (bs, IH), 2.66 (bs, IH), 2.35 (s, 3H), 2.19 (s, 3H), 0.82 (bs, 2H), 0.53 (bs, 2H); MS m/z 574.2 (M + 1). Example 3 Synthesis of 3-[l -(6-Cyclopropylamino-pyrimidin-4-yl)- lH-imidazol-2-ylamino]- N-[4-(4-ethyl-piperazin- 1 -ylmethyl)-3 -trifluoromethyl-phenyl]-4-methyl-benzamide
Figure imgf000039_0001
4-Chloro-6-(2-chloro-imidazol-l-yl)-pyrimidine
Figure imgf000039_0002
[0089] 2-Chloro-lH-imidazole (2.0 g, 20 mmol), 4, 6-dichloropyrimidine (6 g, 40 mmol) and DIEA (10.4 ml, 60 mmol) were mixed in 40 mL butanol and refluxed at 120°C for 24 hours. The solvent was removed by rotary evaporation. The crude product was purified by flash chromatography on silica gel (0% EtOAc / hexanes to 20% EtOAc/ hexanes gradient), afforded the title compound (2.6 g, 62 % yield) as yellow solid. Rf = 0.25 (20% EtOAc/ hexanes); !H NMR 400 MHz (OMSO-d6) δ 9.13 (s, IH), 8.17 (s, IH), 7.94 (d, IH), 7.17 (d, IH); MS m/z 215.4 (M + l).
[6-(2-Chloro-imidazol- 1 -yl)-pyrimidin-4-yl]-cyclopropyl-amine
Figure imgf000040_0001
[0090] 4-Chloro-6-(2-chloro-imidazol-l-yl)-pyrimidine (0.85 g, 4 mmol) and cyclopropylamine (1.4 mL, 20 mmol) were mixed in 10 mL methanol and stirred at 50°C for 12 hours. After reaction was complete, the solvent was removed by rotary evaporation. The crude product was washed with water and taken to dryness to give the title compound (0.84 g, 90%); *H NMR 400 MHz (DMSO- ) δ 8.45 (s, IH), 8.17(d, IH), 7.75(s, IH), 7.08(s, IH), 6.80(d, IH), 3.34(s, IH), 0.78(br, 2H), 0.52(br, 2H); MS m/z 236.4 (M+l).
Figure imgf000040_0002
[0091] Into a solution of 4-(4-Ethyl-piperazin-l-ylmethyl)-3-trifluoromethyl- phenylamine (3.0 g, 1.04 mmol, 1.0 eq.) in dichloromethane (5.2 ml) was added diisopropylethyl amine (2.00 ml, 1.14 mmol, 1.1 eq.). The solution was cooled to 0 °C, after which 4-Methyl-3-nitrobenzoylchloride (2.13 g, 1.07 mmol, 1.03 eq.) was added in portions into the reaction mixture which was further equilibrated for 30 minutes. The reaction mixture was then partitioned between dichloromethane and saturated sodium carbonate solution. The organic layer was separated and the aqueous layer was extracted with dichloromethane. The combined organic extracts were washed with water, brine, dried over Na2SO4, filtered and concentrated to afford the desired product (4.58 g, 98%). The desired compound was used in the next step without further purification.
Figure imgf000041_0001
[0092] Into a solution N-[4-(4-Ethyl-piperazin-l-ylmethyl)-3-trifluoromethyl- ' phenyl]-4-methyl-3-nitro-benzamide (4.5 g, 1.00 mmol, 1.0 eq.) in MeOH (50 ml) was added Raney Nickel (0.45 g, 10wt%). The suspension was stirred under hydrogen atmosphere (1 atm) for 24 hours. At the end of reaction as indicated by HPLC, the reaction mass was filtered over celite and the filtrate was concentrated under reduced pressure to yield the desired product (4.1 g, 97%) !H NMR 400 MHz (DMSO-tfc) δ 10.24 (s, IH), 8.18 (s, IH), 8.02 (d, J= 8.0 Hz, IH), 7.66 (d, J= 8.8 Hz, IH, 7.16 (s, IH), 7.13 (m, 2H), 5.1 (s, 2H), 3.55 (s, 2H), 2.37 (m, 10H) 2.11 (s, 3H), 1.05 (t, 3H).
3-[l-(6-Cyclopropylamino-pyrimidin-4-yl)-lH-imidazol-2-ylamino]-N-[4-(4-ethyI- piperazin-l-ylmethyl)-3-trifluoromethyl-phenyl]-4-methyl-benzamide
Figure imgf000041_0002
[0093] A mixture of [6-(2-chloro-imidazol-l-yl)-pyrimidin-4-yl]-cyclopropyl- amine (2.24 g, 9.53 mmol), xxxx (2.00 g, 4.76 mmol) and MeSO3H (930 uL, 14.3 mol) in l,3-dimethyl-imidazoIidin-2-one (4 mL) was heated at 90 °C in a sealed tube. After overnight, the reaction mixture was cooled to room temperature and diluted with CHC13 and washed with saturated aqueous NaHCO3 solution. The organic layer was dried over Na2SO and concentrated. The residue was dissolved in CHC13 and purified by column chromatography (EtOAc/Hex/MeOH = 9/3/1) to give the product as a white powder which was recrystallized from CHCl3 MeOHto afford the title compound (1.15 g, 39 % yield). !H NMR 400 MHz (OMSO-d6) δ 11.29 (bs, IH), 10.42 (s, IH), 9.10 (s, 1 H), 8.50(fo, 1 H), 8.23 (bs,l H), 8.08 (bs, IH), 8.04 (d, IH, J= 9.6 Hz), 7.69 (d, IH, J= 8.0 Hz), 7.71 - 7.69 (bs, IH), 7.46 (d, IH, J= 7.6 Hz), 7.36 (d, IH, J- 7.2 Hz), 6.91 (s, IH), 6.75 (bs, IH), 3.56 (s, 2H), 2.65 (br, IH), 2.43 (s, IH), 2.43 - 2.33 (m, 10H), 0.98 (t, 3H, J= 6.8 Hz), 0.82 (bs, 2H), 0.53 (fa, 2H); MS m/z 620.3(M + 1).
[0094] By repeating the procedures described in the above examples, using appropriate starting materials, the following compounds of Formula I, as identified in Table 1, are obtained. Table 1
Figure imgf000042_0001
Figure imgf000043_0001
Figure imgf000044_0001
Figure imgf000045_0001
Figure imgf000046_0001
Figure imgf000047_0001
Figure imgf000048_0001
Figure imgf000049_0001
Figure imgf000050_0001
Figure imgf000051_0001
Figure imgf000052_0001
Figure imgf000053_0001
Figure imgf000054_0001
Figure imgf000055_0001
Figure imgf000056_0001
Figure imgf000057_0001
Figure imgf000058_0001
Figure imgf000059_0001
Figure imgf000060_0001
Figure imgf000061_0001
Figure imgf000062_0001
Figure imgf000063_0001
Figure imgf000064_0001
Figure imgf000065_0001
Figure imgf000066_0001
Figure imgf000067_0001
Figure imgf000068_0001
Figure imgf000069_0001
Figure imgf000070_0001
Figure imgf000071_0001
Figure imgf000072_0001
Figure imgf000073_0001
Figure imgf000074_0001
Figure imgf000075_0001
Figure imgf000076_0001
Figure imgf000077_0001
Figure imgf000078_0001
Figure imgf000079_0001
Figure imgf000080_0001
Figure imgf000081_0001
Assays [0095] Compounds of the present invention are assayed to measure their capacity to selectively inhibit cell proliferation of 32D cells expressing BCR-Abl (32D-p210) compared with parental 32D cells. Compounds selectively inhibiting the proliferation of these BCR-Abl transformed cells are tested for anti-proliferative activity on Ba/F3 cells expressing either wild type or the mutant forms of Bcr-abl. In addition, compounds are assayed to measure their capacity to inhibit FGFR3, b-RAF, Abl, BMX, BTK, CHK2, c- RAF, CSK, c-SRC, Fes, Flt3, IKKα, IKKβ, JNK2α2, Lck, Met, MKK4, MKK6, MST2, NEK2, p70S6K, PDGFRα, PKA, PKBα, PKD2, Rskl, SAPK2α, SAPK2β, SAPK3, SGK, Tie2 and TrkB kinases.
Inhibition of cellular BCR-Abl dependent proliferation (High Throughput method)
[0096] The murine cell line used is the 32D hemopoietic progenitor cell line transformed with BCR-Abl cDNA (32D-p210). These cells are maintained in RPMI/10% fetal calf serum (RPMI FCS) supplemented with penicillin 50 μg/mL, streptomycin 50 μg/mL and L-glutamine 200 mM. Untransformed 32D cells are similarly maintained with the addition of 15% of WEHI conditioned medium as a source of IL3. [0097] 50 μl of a 32D or 32D-p210 cells suspension are plated in Greiner 384 well microplates (black) at a density of 5000 cells per well. 50nl of test compound (1 mM in DMSO stock solution) is added to each well (STI571 is included as a positive control). The cells are incubated for 72 hours at 37 'C, 5% CO2. 10 μl of a 60% Alamar Blue solution (Tek diagnostics) is added to each well and the cells are incubated for an additional 24 hours. The fluorescence intensity (Excitation at 530 run, Emission at 580 nm) is quantified using the Acquest™ system (Molecular Devices).
Inhibition of cellular BCR-Abl dependent proliferation
[0098] 32D-p210 cells are plated into 96 well TC plates at a density of 15,000 cells per well. 50 μL of two fold serial dilutions of the test compound (Cmax is 40 μM) are added to each well (STI571 is included as a positive control). After incubating the cells for 48 hours at 37 °C, 5% CO2, 15 μL of MTT (Promega) is added to each well and the cells are incubated for an additional 5 hours. The optical density at 570nm is quantified spectrophotometrically and IC$o values, the concentration of compound required for 50% inhibition, determined from a dose response curve. Effect on cell cycle distribution
[0099] 32D and 32D-p210 cells are plated into 6 well TC plates at 2.5x106 cells per well in 5 ml of medium and test compound at 1 or 10 μM is added (STI571 is included as a control). The cells are then incubated for 24 or 48 hours at 37 "C, 5% CO . 2 ml of cell suspension is washed with PBS, fixed in 70% EtOH for 1 hour and treated with PBS/EDTA RNase A for 30 minutes. Propidium iodide (Cf= 10 μg/ml) is added and the fluorescence intensity is quantified by flow cytometry on the FACScalibur™ system (BD Biosciences). Test compounds of the present invention demonstrate an apoptotic effect on the 32D-p210 cells but do not induce apoptosis in the 32D parental cells.
Effect on Cellular BCR-Abl Autophosphorylation
[00100] BCR-Abl autophosphorylation is quantified with capture Elisa using a c-abl specific capture antibody and an antiphosphotyrosine antibody. 32D-p210 cells are plated in 96 well TC plates at 2xl05 cells per well in 50 μL of medium. 50 μL of two fold serial dilutions of test compounds (Cmaxis 10 μM) are added to each well (STI571 is included as a positive control). The cells are incubated for 90 minutes at 37 °C, 5% CO2. The cells are then treated for 1 hour on ice with 150 μL of lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 5 mM EDTA, 1 mM EGTA and l% NP-40) containing protease and phosphatase inhibitors. 50 μL of cell lysate is added to 96 well optiplates previously coated with anti-abl specific antibody and blocked. The plates are incubated for 4 hours at 4 °C After washing with TBS-Tween 20 buffer, 50 μL of alkaline-phosphatase conjugated anti-phosphotyrosine antibody is added and the plate is further incubated overnight at 4 °C. After washing with TBS-Tween 20 buffer, 90 μL of a luminescent substrate are added and the luminescence is quantified using the Acquest™ system (Molecular Devices). Test compounds of the invention that inhibit the proliferation of the BCR-Abl expressing cells, inhibit the cellular BCR-Abl autophosphorylation in a dose-dependent manner.
Effect on proliferation of cells expressing mutant forms of Bcr-abl [00101] Compounds of the invention are tested for their antiproliferative effect on
Ba/F3 cells expressing either wild type or the mutant forms of BCR-Abl (G250E, E255V, T315I, F317L, M351T) that confers resistance or diminished sensitivity to STI571. The antiproliferative effect of these compounds on the mutant-BCR-Abl expressing cells and on the non transformed cells were tested at 10, 3.3, 1.1 and 0.37 μM as described above (in media lacking IL3). The IC50 values of the compounds lacking toxicity on the untransformed cells were determined from the dose response curves obtained as describe above.
FGFR3 (Enzymatic Assay)
[00102] Kinase activity assay with purified FGFR3 (Upstate) is carried out in a final volume of 10 μL containing 0.25 μg/mL of enzyme in kinase buffer (30 mM Tris-HCl ρH7.5, 15 mM MgCI2, 4.5 mM MnCl2, 15 μM Na3VO and 50 μg/mL BSA), and substrates (5 μg/mL biotin-poly-EY(Glu, Tyr) (CIS-US, Inc.) and 3 μM ATP). Two solutions are made: the first solution of 5 μl contains the FGFR3 enzyme in kinase buffer was first dispensed into 384- format ProxiPlate® (Perkin-Elmer) followed by adding 50 nL of compounds dissolved in DMSO, then 5 μl of second solution contains the substrate (poly- EY) and ATP in kinase buffer was added to each wells. The reactions are incubated at room temperature for one hour, stopped by adding 10 μL of HTRF detection mixture, which contains 30 mM Tris-HCl pH7.5, 0.5 M KF, 50 mM ETDA, 0.2 mg/mL BSA, 15 μg/mL streptavidin-XL665 (CIS-US, Inc.) and 150 ng/mL cryptate conjugated anti-phosphotyrosine antibody (CIS-US, Inc.). After one hour of room temperature incubation to allow for streptavidin-biotin interaction, time resolved florescent signals are read on Analyst GT (Molecular Devices Corp.). IC50 values are calculated by linear regression analysis of the percentage inhibition of each compound at 12 concentrations (1:3 dilution from 50 μM to 0.28 nM). In this assay, compounds of the invention have an IC5o in the range of 10 nM to 2 μM.
FGFR3 (Cellular Assay)
[00103] Compounds of the invention are tested for their ability to inhibit transformed Ba F3-TEL-FGFR3 cells proliferation, which is depended on FGFR3 cellular kinase activity. Ba F3-TEL-FGFR3 are cultured up to 800,000 cells/mL in suspension, with RPMI 1640 supplemented with 10% fetal bovine serum as the culture medium. Cells are dispensed into 384-well format plate at 5000 cell/well in 50 μL culture medium. Compounds of the invention are dissolved and diluted in dimethylsufoxide (DMSO). Twelve points 1 :3 serial dilutions are made into DMSO to create concentrations gradient ranging typically from 10 mM to 0.05 μM. Cells are added with 50 nL of diluted compounds and incubated for 48 hours in cell culture incubator. AlamarBlue® (TREK Diagnostic Systems), which can be used to monitor the reducing environment created by proliferating cells, are added to cells at final concentration of 10%. After additional four hours of incubation in a 37 °C cell culture incubator, fluorescence signals from reduced AlamarBlue® (Excitation at 530 nm, Emission at 580 nm) are quantified on Analyst GT (Molecular Devices Corp.). IC50 values are calculated by linear regression analysis of the percentage inhibition of each compound at 12 concentrations.
FLT3 and PDGFRβ (Cellular Assay)
[00104] The effects of compounds of the invention on the cellular activity of FLT3 and PDGFRβ are conducted using identical methods as described above for FGFR3 cellular activity, except that instead of using Ba F3-TEL-FGFR3, Ba F3-FLT3-ITD and Ba F3-Tel- PDGFRβ are used, respectively.
b-Raf- enzymatic assay
[00105] Compounds of the invention are tested for their ability to inhibit the activity of b-Raf. The assay is carried out in 384-well MaxiSorp plates (NUNC) with black walls and clear bottom. The substrate, IκBα is diluted in DPBS (1 :750) and 15μl is added to each well. The plates are incubated at 4°C overnight and washed 3 times with TBST (25 mM Tris, pH 8.0, 150 mM NaCl and 0.05% Tween-20) using the EMBLA plate washer. Plates are blocked by Superblock (15μl/well) for 3 hours at room temperature, washed 3 times with TBST and pat-dried. Assay buffer containing 20μM ATP (lOμl) is added to each well followed by lOOnl or 500nl of compound. B-Raf is diluted in the assay buffer (lμl into 25μl) and lOμl of diluted b-Raf is added to each well (0.4μg/well). The plates are incubated at room temperature for 2.5 hours. The kinase reaction is stopped by washing the plates 6 times with TBST. Phosph-IκBα (Ser32/36) antibody is diluted in Superblock (1:10,000) and 15μl is added to each well. The plates are incubated at 4°C overnight and washed 6 times with TBST. AP-conjugated goat-anti-mouse IgG is diluted in Superblock (1:1,500) and 15μl is added to each well. Plates are incubated at room temperature for 1 hour and washed 6 times with TBST. 15μl of fluorescent Attophos AP substrate (Promega) is added to each well and plates are incubated at room temperature for 15 minutes. Plates are read on Acquest or Analyst GT using a Fluorescence Intensity Program (Excitation 455 nm, Emission 580 nm).
b-Raf- cellular assay
[00106] Compounds of the invention are tested in A375 cells for their ability to inhibit phosphorylation of MEK. A375 cell line (ATCC) is derived from a human melanoma patient and it has a V599E mutation on the B-Raf gene. The levels of phosphorylated MEK are elevated due to the mutation of B-Raf. Sub-confluent to confluent A375 cells are incubated with compounds for 2 hours at 37 °C in serum free medium. Cells are then washed once with cold PBS and lysed with the lysis buffer containing 1% Triton X100. After centrifugation, the supernatants are subjected to SDS-PAGE, and then transferred to nitrocellulose membranes. The membranes are then subjected to western blotting with anti-phospho-MEK antibody (ser217/221) (Cell Signaling). The amount of phosphorylated MEK is monitored by the density of phospho-MEK bands on the nitrocellulose membranes.
Upstate KinaseProfiler™ - Radio-enzymatic filter binding assay
[00107] Compounds of the invention are assessed for their ability to inhibit individual members of the kinase panel. The compounds are tested in duplicates at a final concentration of 10 μM following this generic protocol. Note that the kinase buffer composition and the substrates vary for the different kinases included in the "Upstate KinaseProfiler™" panel. Kinase buffer (2.5μL, lOx - containing MnCl2 when required), active kinase (0.001-0.01 Units; 2.5μL), specific or Poly(Glu4-Tyr) peptide (5-500μM or .Olmg/ml) in kinase buffer and kinase buffer (50μM; 5μL) are mixed in an eppendorf on ice, A Mg/ATP mix (lOμL; 67.5 (or 33.75) mM MgCl2, 450 (or 225) μM ATP and 1 μCi/μl [γ- 32P]-ATP (3000Ci/mmol)) is added and the reaction is incubated at about 30°C for about 10 minutes. The reaction mixture is spotted (20μL) onto a 2cm x 2cm P81 (phosphocellulose, for positively charged peptide substrates) or Whatman No. 1 (for Poly (Glu4-Tyr) peptide substrate) paper square. The assay squares are washed 4 times, for 5 minutes each, with 0.75% phosphoric acid and washed once with acetone for 5 minutes. The assay squares are transferred to a scintillation vial, 5 ml scintillation cocktail are added and 3 P incorporation (cpm) to the peptide substrate is quantified with a Beckman scintillation counter. Percentage inhibition is calculated for each reaction.
[00108] Compounds of Formula I, in free form or in pharmaceutically acceptable salt form, exhibit valuable pharmacological properties, for example, as indicated by the in vitro tests described in this application. For example, compounds of Formula I preferably show an IC50 in the range of 1 x 10"10 to 1 x 10"5 M, preferably less than 50nM for wild type BCR-Abl and G250E, E255V, T315I, F317L and M351T BCR-Abl mutants. Compounds of Formula I preferably, at a concentration of lOmM, preferably show a percentage inhibition of greater than 50%>, preferably greater than about 70%, against Abl, Bcr-abl, c-RAF, c-SRC, JNK2α2, lck, MKK6, PDGFRα, SAPK2α, SAPK2β, Tie2 and TrkB kinases. For example: a). N- { - 1 -(6-cycloprop lamino-pyrimidin-4-yl)- 1 H-imidazol-2-ylamino]-4-methyl- phenyl}-3-(4-methyl-imidazol-l-yl)-5-trifluoromethyl-benzamide (Compound 27) has an IC50 of <0.5 nM, 20 nM, 36 nM, 59 nM <0.5 nM and <0.5 nM for wild type, G250E, E255V, T315I, F317L and M351T Bcr-abl, respectively; b). N-{3-[l-(6-Cvclopropylamino-pyrimidin-4-yl)-lH-imidazol-2-ylaminol-4-methyl- phenyl -4-(4-ethyl-piρerazin- 1 -yrmethyl)-3 -trifluoromethyl-benzamide (Compound 25) has an IC50 of 130nM and 34nM for the FGFR3 enzyme and cellular assays, respectively, and 149nM and 2nM for FLT3 and PDGFRβ, respectively; c). N-{3-[l-(6-Cvcloρropylamino-pyrimidin-4-yl)-lH-imidazol-2-ylamino]-4-methyl- ρhenyl)-4-(4-methyl-ρiperazin-l-ylmethyl)-3-trifluoromethyl-benzamide (Compound 26) has an IC50 of 65nM and 37nM for the FGFR3 enzyme and cellular assays, respectively, and 89nM and 2nM for FLT3 and PDGFRβ, respectively, d). N-(4-Methyl-3-{l- 6~(2-morpholin-4-yl-ethylamino)-ρyrimidin-4-yl]-lH-imidazol-2- ylamino}-phenyl)-3-trifluoromethyl-benzamide (Compound 3), at a concentration of lOμM, inhibits the following kinases by the percentage shown in brackets (for example, 100% means complete inhibition, 0% means no inhibition): wild-type Abl (97%), c-RAF (100%), c-SRC (99%), JNK2α2 (97%), lck (100%), MKK6 (100%), PDGFRα (97%), SAPK2α (100%), SAPK2β (100%), Tie2 (99%) and TrkB (97%). [00109] It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference for all purposes.

Claims

WE CLAIM:
1. A compound of Formula I:
Figure imgf000089_0001
I in which: m and n are independently selected from 0, 1 and 2; Ri is selected from -XNR5R5, -XOR5, -XC(O)R5, -XR5 and -XS(O)0-2R5; wherein X is a bond or Cι- alkylene optionally substituted by 1 to 2 Chalky 1 radicals; R5 is selected from hydrogen, C1-6alkyl, C6-ιoaryl-Co- alkyl, C5-ι0heteroaryl-Co-4alkyl, C3- ιocycloalkyl-Co-4alkyl and C3-ιoheterocycloalkyl-C0-4alkyl; and R6 is selected from hydrogen and Cι-6alkyl; or R5 and R6 together with the nitrogen to which R5 and Re are both attached form heteroaryl or heterocycloalkyl; wherein any aryl, heteroaryl, cycloalkyl and heterocycloalkyl of R5 or the combination of R5 and 5 can be optionally substituted with 1 to 3 radicals independently selected from halo, nitro, cyano, hydroxy, C^an yl, Cι-6alkoxy, halo-substituted-alkyl, halo- substituted-alkoxy, -XNR7R8, -XOR7, -XNR7S(O)2R8, -XNR7S(O)R8, -XNR7SR8, - XC(O)NR7R8, -XC(O)NR7XNR7R8, -XNR7C(O)NR7R8, -XNR7XNR7R8, -XNR7XOR7, - XNR7C(=NR7)NR7R8, -XS(O)2R9, -XNR7C(O)R8, -XNR7C(O)R9, -XR9, -XC(O)OR8, - XS(O)2NR7R8, -XS(O)NR7R8 and -XSNR7R8; wherein X is a bond or C1-4alkylene; R7 and R8 are independently selected from the group consisting of hydrogen and Cι- alkyl; and R9 is selected from C3-ιoheterocycloalkyl and C5-ιoheteroaryl; wherein said heterocycloalkyl or heteroaiyl of R9 is optionally substituted with a radical selected from the group consisting of C] alkyl, -XNR7XNR7R7, XNR7XOR7 and -XOR7; R2 and R4 are independently selected from halo, hydroxy, Cι-4alkyl, Cj.
4alkoxy,
Figure imgf000089_0002
and halo-substituted-Cι-4alkoxy; R3 is selected from -NRioRn, -NRι0C(O)Rπ, -NRι0S(O)0-2Rn and -
NRιoC(O)NRιoRπ; wherein Rio is selected from hydrogen and Cι-6alkyl; Rπ is selected from Cό-ioaryl, C5-ιoheteroaryl, C3-ι0cycloalkyl and C3-ι0heterocycloalkyl; wherein any aryl, heteroaryl, cycloalkyl or heterocycloalkyl of Rπ is optionally substituted by 1 to 3 radicals selected from halo, nitro, cyano, hydroxy, Cι-6alkyl,
Figure imgf000090_0001
halo-substituted-alkyl, halo- substituted-alkoxy, -NRι2C(O)Rι3, -NRι2C(O)NRι2Rι3, -C(O)NRι2Rι3, -NR12S(O)0-2Rι3 and -S(O)o-2NRι2Rι3; wherein Rι2 is selected from hydrogen and Cι-6alkyl; Rϊ3 is selected from Cβ-ioaryl, Cs-ioheteroaryl, C3-ιocycloalkyl and C3-ι0heterocycloalkyl; wherein any aryl, heteroaiyl, cycloalkyl or heterocycloalkyl of Rι3 is optionally substituted with 1 to 3 radicals independently selected from halo, C^an yl, halo-substituted-Cι.6alkyl, Cι-6alkoxy, halo- substituted-Cι.6alkoxy, -XNR7R8, C6-ιoaryl-C0.4alkyl, C5-ιoheteroaryl-Co- alkyl, C3- iocycloalkyl-C0. alkyl, C3-ιoheterocycloalkyl-Co-4alkoxy and C3-ι0heterocycloalkyl-Co-4alkyl; wherein X, R7 and R8 are as described above and wherein any aryl, heteroaryl, cycloalkyl or heterocycloalkyl substituent of Rι3 is further optionally substituted by 1 to 3 radicals independently selected from halo, Cι-6alkyl, halo-substituted-Cι-6alkyl, hydroxy-substituted- Cι.6alkyl, Cι-6alkoxy, C3-ιoheterocycloalkyl and halo-substituted-C]-6alkoxy; and the pharmaceutically acceptable salts, hydrates, solvates and isomers thereof.
2. The compound of claim 1 of Formula la:
Figure imgf000090_0002
in which: p is selected from 0 and 1; n is selected from 0, 1, 2 and 3; q is selected from 0 and 1; R5 is selected from hydrogen, Cι-6alkyl, C6-ιoaryl-Co-4alkyl, C5-ιoheteroaryl-C0- alkyl, C3-ιocycloalkyl-Co- alkyl and C3-10heterocycloalkyl-Co-4alkyl; and Rs is selected from hydrogen and Cι-6alkyl; or R5 and R6 together with the nitrogen to which R5 and R6 are both attached form heteroaryl or heterocycloalkyl; wherein any aryl, heteroaryl, cycloalkyl and heterocycloalkyl of R5 or the combination of R5 and 5 can be optionally substituted with 1 to 3 radicals independently selected from halo, nitro, cyano, hydroxy, Ci^alkyl, Ci-βalkoxy, halo-substituted-alkyl, halo- substituted-alkoxy, -XNR7R8, -XOR7, -XNR7S(O)2R8, -XNR7S(O)R8, -XNR7SR8, - XC(O)NR7R8, -XC(O)NR7XNR7R8, -XNR7C(O)NR7R8, -XNR7XNR7R8, -XNR7XOR7, - XNR7C(=NR7)NR7R85 -XS(O)2R9, -XNR7C(O)R8, -XNR7C(O)R9, -XR9, -XC(O)OR8, - XS(O)2NR7R8, -XS(O)NR7R8 and -XSNR7R8; wherein X is a bond or C alkylene; R7 and R8 are independently selected from the group consisting of hydrogen and Cι-4alkyl; and R9 is selected from C3-ιoheterocycloalkyl and C5-ιoheteroaryl; wherein said heterocycloalkyl or heteroaryl of R9 is optionally substituted with a radical selected from the group consisting of CMalkyl, -XNR7XNR7R7, XNR7XOR7 and -XOR7; wherein X and R7 are as described above; Rio is selected from hydrogen and Cι-6alkyl; R15 is selected from halo, nitro, cyano, hydroxy, C].6alkyl, Cι-6alkoxy, halo- substituted-alkyl and halo-substituted-alkoxy; and R]6 is selected from -NR]2C(O)Rι3, -NR]2C(O)NRι2R13, -C(O)NRι2R13, - NRι2S(O)o-2Rι3 and -S(O)0-2NRι2Rι3; wherein Rι2 is selected from hydrogen and CMalkyl; Rι3 is selected from C6-ιoaryl, C5-ιoheteroaryl, C3-ιocycloalkyl and C3-ιoheterocycloalkyl; wherein any aryl, heteroaryl, cycloalkyl or heterocycloalkyl of R]3 is optionally substituted with 1 to 3 radicals independently selected from halo, Cι-6alkyl, halo-substituted-Cι-6alkyI, halo-substituted-Cι-6alkoxy, -XNR7R8,
Figure imgf000091_0001
Cs-ioheteroaiyl-Co- 4alkyl, C3-ιocycloalkyl-Co-4alkyl, C3-ιoheterocycloalkyl-C0-4alkoxy and C3-ιoheterocycloalkyl- Co-4alkyl; wherein X, R7 and R8 are as described above and wherein any aryl, heteroaryl, cycloalkyl or heterocycloalkyl substituent of Rι3 is further optionally substituted by 1 to 3 radicals independently selected from halo, Cι-6alkyl, halo-substituted-Ci-δalkyl, hydroxy- substituted-Cι-6alkyl, Ci-βalkoxy, C3-ιoheterocycloalkyl and halo-substituted-Cι.6alkoxy.
3. The compound of claim 2 in which R5 is selected from hydrogen, morpholino- ethyl, cyclopropyl, methyl, 3-(2-oxo-pyrrolidin-l-yl)-propyl, benzo[l,3]dioxol-5-yl, 3-(4- methyl-piperazin- 1 -yl)-propyl, hydroxymethyl-phenyl, ( 1 -hydroxyethyl)-phenyl, morpholino, pyridinyl, methyl-carbonyl, methyl-sulfonyl, methyl-pyridinyl, amino- cyclohexyl, piperidinyl, methyl-piperazinyl-ethyl, dimethyl-pyrazolyl, methyl-pyrazolyl, dimethyl-pyridinyl, methyl-pyridinyl, ethyl-piperazinyl-pyridinyl, amino-carbonyl-pyridinyl, cyano-pyridinyl, dimethyl-amino-ethyl, methoxy-ethyl, methyl-pyrrolidinyl-ethyl, ethyl- pyrazolyl, dimethyl-amino-propyl, isopropyl, furanyl-methyl, methyl-piperazinyl-propyl, benzo[l,3]dioxol-5-ylmethyl, 2-methyl-6-morpholin-4-yl-pyridin-3-yl, methyl-pyrimidinyl, methoxy-pyridinyl, fluoro-phenyl, dimethyl-amino-ethyl-aminocarbonyl, pyridinyl-methyl, thiazolyl-methyl, methyl-pyrazinyl-methyl, imidazolyl-propyl, amino-carbonyl-phenyl, ; or R5 and Re together with the nitrogen atom to which they are both attached form a group selected from morpholino, piperidinyl and piperazinyl optionally substituted with a group selected from ethyl, pyridinyl and morpholino.
4. The compound of claim 3 in which Rι6 is selected from -NHC(O)Rj3, - NHC(O)NHRι3, -C(O)NHRι3, -NHS(O)2R and -S(O)2NHRι3; wherein R1 is selected from phenyl, pyridazinyl, pyridinyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, quinoxalinyl, thienyl and thiazolyl; wherein Rι3 is optionally substituted with 1 to 3 radicals independently selected from methyl, t-butyl, halo, trifluoromethyl, diethyl-amino, dimethyl-amino, benzyl, piperidinyl-amino, pyrrolidinyl-methoxy, ethyl-piperazinyl-methyl, morpholino, methyl- piperazinyl, methyl-piperazinyl-methyl, ethyl-piperazinyl, methyl-imidazolyl, morpholino- methyl, pyrrolidinyl-piperidinyl, piperazinyl-methyl, hydroxy-piperidinyl, 1-methyl- piperidin-4-yloxy, piperidinyl-oxy, methyl-pyrazinyl, pyrazinyl and hydroxyethyl- piperazinyl.
5. The compound of claim 1 selected from N-[4-methyl-3-(l-{6-[4-(2-morpholin- 4-yl-ethyl)-phenylamino]-pyrimidin-4-yl}rlH-imidazol-2-ylamino)-phenyl]-3- trifluoromethyl-benzamide, N- { 3 -[ 1 -(6-cyclopropylamino-pyrimidin-4-yl)- lH-imidazol-2- ylamino]-4-methyl-phenyl} -3-(4-ethyl-piperazin- 1 -yl)-5-trifluoromethyl-benzamide, N-(4- methyl-3-{l-[6-(2-morpholin-4-yl-ethylamino)-pyrimidin-4-yl]-lH-imidazol-2-ylamino}- phenyl)-3-trifluoromethyl-benzamide, N-{3-[l-(6-cyclopropylamino-pyrimidin-4-yl)-lH- imidazol-2-ylamino]-4-methyl-phenyl}-3-trifluoromethyl-benzamide, N-{4-methyl-3-[l-(6- methylamino-pyrimidin-4-yl)-lH-imidazol-2-ylamino]-phenyl}-3-trifluoromethyl- benzamide, N-[4-methyl-3-(l-{6-[3-(2-oxo-pyrrolidin-l-yl)-propylamino]-pyrimidin-4-yl}- lH-imidazol-2-ylamino)-phenyl]-3-trifluoromethyl-benzamide, N-(3-{ 1 -[6- (benzo[l,3]dioxol-5-ylamino)-pyrimidin-4-yl]-lH-imidazol-2-ylamino}-4-methyl-phenyl)- 3 -trifluoromethyl-benzamide, N- [4-methyl-3 -( 1 -{ 6-[3 -(4-methyl-piperazin- 1 -yl)- propylamino]-pyrimidin-4-yl}-lH-imidazol-2-ylamino)-phenyl]-3-trifluoromethyl- benzamide, {6-[2-(2-chloro-phenylamino)-imidazol-l-yl]-pyrimidin-4-yl}-cyclopropyl- amine, (3-{6-[2-(2-chloro-phenylamino)-imidazol-l-yl]-pyrimidin-4-ylamino}-phenyl)- methanol, l-(3-{6-[2-(2-chloro-phenylamino)-imidazol-l-yl]-pyrimidin-4-ylamino}- phenyl)-ethanol, {6-[2-(2-chloro-phenylamino)-imidazol-l-yl]-pyrimidin-4-yl}-[4-(2- morpholin-4-yl-ethyl)-phenyl]-amine, {6-[2-(2-chloro-phenylamino)-imidazol-l-yl]- pyrimidin-4-yl}-(4-morpholin-4-yl-phenyl)-amine, N-(3-{6-[2-(2-chloro-phenylamino)- imidazol-l-yl]-pyrimidin-4-ylamino}-phenyl)-acetamide, l-(3-{6-[2-(2-chloro- phenylamino)-imidazol- 1 -yl]-pyrimidin-4-ylamino } -propyl)-pyrrolidin-2-one, benzo[l,3]dioxol-5-yl-{6-[2-(2-chloro-phenylamino)-imidazol-l-yl]-pyrimidin-4-yl}-amine, { 6-[2-(2-chloro-phenylamino)-imidazol- 1 -yl]-pyrimidin-4-yl} -pyridin-3 -yl-amine, N-(4- methyl-3-{l-[6-(pyridin-3-ylamino)-pyrimidin-4-yl]-lH-imidazol-2-ylamino}-phenyl)-3- trifluoromethyl-benzamide, {6-[2-(2-chloro-phenylamino)-imidazol- 1 -yl]-pyrimidin-4-yl} - (6-methyl-pyridin-3 -yl)-amine, N-(4-methyl-3 - { 1 -[6-(6-methyl-pyridin-3 -ylamino)- pyrimidin-4-yl]-lH-imidazol-2-ylamino}-phenyl)-3-trifluoromethyl-benzamide, N-{3-[l-(6- cyclopropylamino-pyrimidin-4-yl)-lH-imidazol-2-ylamino]-4-methyl-phenyl}-3-morpholin- 4-yl-5 -trifluoromethyl-benzamide, N- {3 -[ 1 -(6-cyclopropylamino-pyrimidin-4-yl)- 1 H- imidazol-2-ylamino]-4-methyl-ρhenyl}-3-(4-methyl-piperazin-l-yl)-5-trifluoromethyl- benzamide, N-{3-[l-(6-cyclopropylamino-pyrimidin-4-yl)-lH-imidazol-2-ylamino]-4- methy 1-phenyl} -3 -(4-ethyl-piperazin- 1 -y l)-5 -trifluoromethyl-benzamide, N- { 3 - [ 1 -(6- cyclopropylamino-pyrimidin-4-yl)-lH-imidazol-2-ylamino]-4-methyl-phenyl}-4-morpholin- 4-yl-3-trifluoromethyl-benzamide, N-{3-[l-(6-cyclopropylamino-pyrimidin-4-yl)-lH- imidazol-2-ylamino]-4-methyl-phenyl}-4-(4-ethyl-piperazin-l-ylmethyl)-3-trifluoromethyl- benzamide, N- {3-[ 1 -(6-cyclopropylamino-pyrimidin-4-yl)- 1 H-imidazol-2-y lamino] -4- methyl-phenyl} -4-(4-methyl-piperazin- 1 -ylmethyl)-3 -trifluoromethyl-benzamide, N- {3 -[ 1 - (6-cyclopropylamino-pyrimidin-4-yl)-lH-imidazol-2-ylamino]-4-methyl-phenyl}-3-(4- methyl-imidazol-l-yl)-5-trifluoromethyl-benzamide, 3-(4-methyl-imidazol-l-yl)-N-{4- methyl-3-[l-(6-methylamino-pyrimidin-4-yl)-lH-imidazol-2-ylamino]-phenyl}-5- trifluoromethyl-benzamide, N- {4-methyl-3-[ 1 -(6-methylamino-pyrimidin-4-yl)- 1 H- imidazol-2-y lamino] -phenyl} -4-morpholin-4-yl-3 -trifluoromethyl-benzamide, 3-(4-ethyl- piperazin-l-yl)-N-{4-methyl-3-[l-(6-methylamino-pyrimidin-4-yl)-lH-imidazol-2-ylamino]- phenyl}-5-trifluoromethyl-benzamide, N-{4-methyl-3-[l-(6-methylamino-pyrimidin-4-yl)- 1 H-imidazol-2-ylamino]-phenyl} -3 -(4-methyl-piperazin- 1 -yl)-5-trifluoromethyl-benzamide, N- { 3 - [ 1 -(6-methy lamino-pyrimidin-4-y 1)- 1 H-imidazol-2-y lamino] -phenyl } -4-(4-methyl- piperazin-l-ylmethyl)-3-trifluoromethyl-benzamide, 3-(4-ethyl-piperazin-l-ylmethyl)-N-{4- methyl-3-[l -(6-methylamino-pyrimidin-4-yl)- 1 H-imidazol-2-ylamino]-phenyl} -5- trifluoromethy 1-benzamide, N- { 3 - [ 1 -(6-cyclopropylamino-pyrimidin-4-y 1)- 1 H-imidazol-2- ylamino]-4-methyl-phenyl}-4-morpholin-4-ylmethyl-3-trifluoromethyl-benzamide, N-{4- methyl-3-[l-(6-methylamino-pyrimidin-4-yl)-lH-imidazol-2-ylamino]-phenyl}-4- morpholin-4-ylmethyl-3-trifluoromethyl-benzamide, N-{3-[l-(6-amino-pyrimidin-4-yl)-lH- imidazol-2-ylamino]-4-methyl-phenyl}-4-(4-ethyl-piperazin-l-ylmethyl)-3-trifluoromethyl- benzamide, N-{3-[l-(6-amino-pyrimidin-4-yl)-lH-imidazol-2-ylamino]-4-methyl-phenyl}- 4-(4-methy 1-piperazin- 1 -y lmethyl)-3 -trifluoromethyl-benzamide, N- { 3 - [ 1 -(6-amino- pyrimidin-4-yl)-lH-imidazol-2-ylamino]-phenyl}-3-(4-methyl-imidazol-l-yl)-5- trifluoromethyl-benzamide, N-{3-[l-(6-amino-pyrimidin-4-yl)-lH-imidazol-2-ylamino]-4- methyl-phenyl } -4-morpholin-4-yl-3 -trifluoromethyl-benzamide, N- { 3 - [ 1 -(6-amino- pyrimidin-4-y 1)- 1 H-imidazol-2 -ylamino] -4-methyl-phenyl } -3 -(4-ethyl-piperazin- 1 -y l)-5 - trifluoromethyl-benzamide, N-{3-[l-(6-amino-pyrimidin-4-yl)-lH-imidazol-2-ylamino]-4- methyl-phenyl}-3-(4-methyl-piperazin-l-yl)-5-trifluoromethyl-benzamide, N-{3-[l-(6- amino-pyrimidin-4-yl)-lH-imidazol-2-ylamino]-4-methyl-phenyl}-3-morpholin-4-ylmethyl- 5 -trifluoromethyl-benzamide, 3-[l-(6-cyclopropylamino-pyrimidin-4-yl)-lH-imidazol-2- ylamino]-5-methoxy-N-[4-(2-methyl-imidazol-l-yl)-3-trifluoromethyl-phenyl]-benzamide, N-{3-[l-(6-acetylamino-pyrimidin-4-yl)-lH-imidazol-2-ylamino]-4-methyl-phenyl}-3- trifluoromethyl-benzamide, N-{3-[l-(6-methanesulfonylamino-pyrimidin-4-yl)-lH- imidazol-2-y lamino] -4-methyl-phenyl} -3 -trifluoromethyl-benzamide, N- { 3 -[ 1 -(2- cyclopropylamino-pyrimidin-4-yl)-lH-imidazol-2-ylamino]-4-methyl-phenyl}-3- trifluoromethyl-benzamide, 3-[l-(2-cyclopropylamino-pyrimidin-4-yl)-lH-imidazol-2- ylamino]-4-methyl-N-[4-(2-methyl-imidazol-l-yl)-3-trifluoromethyl-phenyl]-benzamide, N- {3-[l-(6-cyclopropylamino-pyrimidin-4-yl)-lH-imidazol-2-ylamino]-4-methyl-phenyl}-3- piperazin-l-ylmethyl-5 -trifluoromethyl-benzamide, N-{3-[l-(6-amino-pyrimidin-4-yι)-lH- imidazol-2-y lamino] -4-methyl-phenyl} -3 -piperazin- 1 -y lmethyl-5 -trifluoromethylbenzamide, N- { 3 - [ 1 -(6-cyclopropylamino-pyrimidin-4-y 1)- 1 H-imidazol-2-y lamino] -5 - methoxy-phenyl} -4-(4-methyl-piperazin- 1 -ylmethyl)-3 -trifluoromethyl-benzamide, N- { 3-[ 1 - (6-cyclopropylamino-pyrimidin-4-yl)-lH-imidazol-2-ylamino]-5-methoxy-phenyl}-3-(4- ethyl-piperazin-l-ylmethyl)-5-trifluoromethyl-benzamide, N-{3-[l-(6-cyclopropylamino- pyrimidin-4-yl)-lH-imidazol-2-ylamino]-4-methyl-phenyl}-3-(piperidin-4-yloxy)-5- trifluoromethyl-benzamide, N-{3-[l-(6-amino-pyrimidin-4-yl)-lH-imidazol-2-ylamino]-4- methyl-phenyl } -3 -(piperidin-4-yloxy)-5 -trifluoromethyl-benzamide, N- { 3 -[ 1 -(6- cyclopropylamino-pyrimidin-4-yl)-lH-imidazol-2-ylamino]-5-methoxy-phenyl}-3-(4- pyrrolidin- 1 -yl-piperidin- 1 -yl)-5-trifluoromethyl-benzamide, 1 - {3 -[ 1 -(6-cyclopropylamino- pyrimidin-4-yl)-lH-imidazol-2-ylamino]-4-methyl-phenyl}-3-[4-(2-methyl-imidazol-l-yl)- 3-trifluoromethyl-phenyl]-urea, l-{3-[l-(6-cyclopropylamino-pyrimidin-4-yl)-lH-imidazol- 2-ylamino]-4-methyl-phenyl}-3-[4-(4-ethyl-piperazin-l-ylmethyl)-3-trifluoromethyl- phenyl]-urea, pyridazine-4-carboxylic acid {3-[l-(6-cyclopropylamino-pyrimidin-4-yl)-lH- imidazol-2-ylamino]-4-methyl-phenyl}-amide, 2-chloro-N-{3-[l-(6-cyclopropylamino- pyrimidin-4-yl)-lH-imidazol-2-ylamino]-4-methyl-phenyl}-isonicotinamide, furan-2- carboxylic acid {3-[l-(6-cyclopropylamino-pyrimidin-4-yl)-lH-imidazol-2-ylamino]-4- methyl-phenyl} -amide, 1 -methyl- lH-pyrrole-2-carboxy lie acid {3-[l-(6-cycIopropyIamino- pyrimidin-4-yl)-lH-imidazol-2-ylamino]-4-methyl-phenyl} -amide, lH-imidazole-2- carboxylic acid {3-[l-(6-cyclopropylamino-pyrimidin-4-yl)-lH-imidazol-2-ylamino]-4- methyl-phenyl} -amide, N-{3-[l-(6-cyclopropylamino-pyrimidin-4-yl)-lH-imidazol-2- ylamino]-4-methyl-phenyl}-4-trifluoromethyl-benzamide, N-{3-[l-(6-cyclopropylamino- pyrimidin-4-yl)-lH-imidazol-2-ylamino]-4-methyl-phenyl}-6-methyl-nicotinamide, 1-tert- butyl-5 -methyl- 1 H-pyrazole-3 -carboxylic acid { 3 -[ 1 -(6-cyclopropylamino-pyrimidin-4-yl)- lH-imidazol-2-ylamino]-4-methyl-phenyl}-amide, N-[4-(4-ethyl-piperazin-l-ylmethyl)-3- trifluoromethyl-phenyl]-4-methyl-3-{l-[6-(2-morpholin-4-yl-ethylamino)-pyrimidin-4-yl]- 1 H-imidazol-2 -ylamino} -benzamide, 3-(4-methyl-imidazol-l-yl)-N-(4-methyl-3-{l-[6-(2- morpholin-4-yl-ethylamino)-pyrimidin-4-yl]-lH-imidazol-2-ylamino}-phenyl)-5- trifluoromethyl-benzamide, 4-methyl-N-[4-(2-methyl-imidazol-l-yl)-3-trifluoromethyl- phenyl]-3-{l-[6-(2-morpholin-4-yl-ethylamino)-pyrimidin-4-yl]-lH-imidazol-2-ylamino}- benzamide, N-(4-methyl-3-{l-[6-(2-morpholin-4-yl-ethylamino)-pyrimidin-4-yl]-lH- imidazol-2-ylamino}-phenyl)-3-(l-methyl-piperidin-4-yloxy)-5-trifluoromethyl-benzamide, pyrazine-2-carboxylic acid { 3 - [ 1 -(6-cyclopropylamino-pyrimidin-4-yl)- 1 H-imidazol-2- ylamino]-4-methyl-phenyl}-amide, 5-methyl-pyrazine-2-carboxylic acid {3-[l-(6- cyclopropylamino-pyrimidin-4-yl)-lH-imidazol-2-ylamino]-4-methyl-phenyl}-amide, quinoxaline-6-carboxylic acid {3-[l-(6-cyclopropylamino-pyrimidin-4-yl)-lH-imidazol-2- ylamino]-4-methyl-phenyl}-amide, 5-tert-butyl-2-methyl-4-morpholin-4-ylmethyl-furan-3- carboxylic acid { 3 -[ 1 -(6-cyclopropylamino-pyrimidin-4-yl)- 1 H-imidazol-2-ylamino] -4- methyl-phenyl} -amide, 5 -tert-butyl-2-methyl-2H-pyrazole-3 -carboxylic acid {3-[l-(6- cyclopropylamino-pyrimidin-4-yl)-lH-imidazol-2-ylamino]-4-methyl-phenyl}-amide, 2- benzyl-5-tert-butyl-2H-pyrazole-3-carboxylic acid {3-[l -(6-cyclopropylamino-pyrimidin-4- yl)-lH-imidazol-2-ylamino]-4-methyl-phenyl}-amide, N-{3-[l-(6-cyclopropylamino- pyrimidin-4-y 1)- 1 H-imidazol-2-ylamino] -4-methyl-phenyl} -3 -(piperidin-4-ylamino)~5 - trifluoromethyl-benzamide, N-{3-[l-(6-cyclopropylamino-pyrimidin-4-yl)-lH-imidazol-2- ylamino]-4-methyl-phenyl}-3-(pyrrolidin-2-ylmethoxy)-5-trifluoromethyl-benzamide, 5-tert- butyl-2-methyl-furan-3 -carboxylic acid {3-[l-(6-cyclopropylamino-pyrimidin-4-yl)-lH- imidazol-2-ylamino]-4-methyl-phenyl}-amide, 5-tert-butyl-3-methyl-furan-2-carboxylic acid { 3 - [ 1 -(6-cyclopropy lamino-pyrimidin-4-yl) - 1 H-imidazol-2-y lamino] -4-methyl-phenyl } - amide, 5 -tert-butyl-2-diethylamino-furan-3 -carboxylic acid {3-[l-(6-cyclopropylamino- pyrimidin-4-yl)-lH-imidazol-2-ylamino]-4-methyl-phenyl}-amide, 5-tert-butyl-4- diethylamino-2-methyl-furan-3-carboxylic acid {3-[l -(6-cyclopropylamino-pyrimidin-4-yl)- lH-imidazol-2-ylamino]-4-methyl-phenyl}-amide, 5-tert-butyl-thiophene-2-carboxylic acid {3-[l-(6-cycloproρylamino-pyrimidin-4-yl)-lH-imidazol-2-ylamino]-4-methyl-phenyl}- amide, 5-tert-butyl-3-methyl-furan-2-carboxylic acid (4-methyl-3-{l-[6-(2-morpholin-4-yl- ethylamino)-pyrimidin-4-yl]-lH-imidazol-2-ylamino}-phenyl)-amide, 5-tert-butyl- thiophene-2-carboxylic acid (4-methyl-3- { 1 -[6-(2-morpholin-4-yl-ethylamino)-pyrimidin-4- yl]-lH-imidazol-2 -ylamino} -phenyl)-amide, 5 -tert-butyl-2-methyl-furan-3 -carboxylic acid (4-methyl-3-{l-[6-(2-morpholin-4-yl-ethylamino)-pyrimidin-4-yl]-lH-imidazol-2-ylamino}- phenyl)-amide, N-(3 - { 1 -[6-(4-amino-cyclohexylamino)-pyrimidin-4-yl]- 1 H-imidazol-2- y lamino} -4-methyl-phenyl)-3 -trifluoromethyl-benzamide, N-(4-methyl-3 - { 1 -[6-(piperidin-4- ylamino)-pyrimidin-4-yl]-lH-imidazol-2-ylamino}-ρhenyl)-3-trifluoromethyl-benzamide, N-[4-methyl-3 -( 1 - { 6-[2-(4-methyl-piperazin- 1 -yl)-ethylamino]-pyrimidin-4-yl} - 1 H- imidazol-2-ylamino)-phenyl]-3-trifluoromethyl-benzamide, N-(3-{l-[6-(2,5-dimethyl-2H- pyrazol-3-ylamino)-pyrimidin-4-yl]-lH-imidazol-2-ylamino}-4-methyl-phenyl)-3- trifluoromethyl-benzamide, N-(4-methyl-3-{l-[6-(4-methyl-piperazin-l-ylamino)-pyrimidin- 4-yl]-lH-imidazol-2-ylamino}-phenyl)-3-trifluoromethyl-benzamide, N-(4-methyl-3-{l-[6- (2-methyl-2H-pyrazol-3 -ylamino)-pyrimidin-4-yl]- 1 H-imidazol-2 -ylamino} -phenyl)-3 - trifluoromethyl-benzamide, N-(3-{l-[6-(2,6-dimethyl-pyridin-3-ylamino)-pyrimidin-4-yl]- 1 H-imidazol-2 -ylamino} -4-methyl-phenyl)-3 -trifluoromethyl-benzamide, N-(4-methyl-3 - { 1 - [6-(2-methyl-pyridin-3-ylamino)-pyrimidin-4-yl]-lH-imidazol-2-ylamino}-phenyl)-3- trifluoromethyl-benzamide, N-{3-[l-(6-cyclopropylamino-pyrimidin-4-yl)-lH-imidazol-2- ylamino]-4-methyl-phenyl}-3-(4-methyl-piperazin-l-yl)-5-trifluoromethyl-benzamide, N- { 3 - [ 1 -(6-cyclopropy lamino-pyrimidin-4-y 1)- 1 H-imidazol-2-y lamino] -4-methyl-phenyl } -3 - [4-(2-hydroxy-ethyl)-piperazin-l-yl]-5-trifluoromethyl-benzamide, N-{3-[l-(6- cyclopropylamino-pyrimidin-4-yl)-lH-imidazol-2-ylamino]-4-methyl-phenyl}-3-piperazin- l-yl-5 -trifluoromethyl-benzamide, N-{4-chloro-3-[l-(6-cyclopropylamino-pyrimidin-4-yl)- lH-imidazol-2-ylamino]-phenyl}-benzamide, N-{3-[l-(6-cyclopropylamino-pyrimidin-4- y 1)- 1 H-imidazol-2-y lamino] -4-fluor o-phenyl} -benzamide, N- { 3 - [ 1 -(6-cyclopropy lamino- pyrimidin-4-yl)- 1 H-imidazol-2-ylamino] -2-methyl-phenyl} -benzamide, N- { 5 -[ 1 -(6- cyclopropylamino-pyrimidin-4-yl)-lH-imidazol-2-ylamino]-2-fluoro-phenyl}-benzamide, N- { 5 - [ 1 -(6-cyclopropylamino-pyrimidin-4-y 1)- 1 H-imidazol-2-y lamino] -2-methyl-phenyl } - benzamide, N-{4-chloro-3-[l-(6-cyclopropylamino-pyrimidin-4-yl)-lH-imidazol-2- ylamino]-phenyl}-4-morpholin-4-ylmethyl-3-trifluoromethyl-benzamide, N-{3-[l-(6- cyclopropylamino-pyrimidin-4-yl)-lH-imidazol-2-ylamino]-4-fluoro-phenyl}-4-morpholin- 4-ylmethyl-3 -trifluoromethyl-benzamide, N- {3-[ 1 -(6-cyclopropylamino-pyrimidin-4-yl)- 1 H- imidazol-2-ylamino]-2-methyl-phenyl}-4-morpholin-4-ylmethyl-3-trifluoromethyl- benzamide, N- {4-chloro-3 -[ 1 -(6-cyclopropylamino-pyrimidin-4-yl)- 1 H-imidazol-2- ylamino]-phenyl}-3-(4-methyl-imidazol-l-yl)-5-trifluoromethyl-benzamide, N-{3-[l-(6- cyclopropylamino-pyrimidin-4-yl)-lH-imidazol-2-ylamino]-4-fluoro-phenyl}-3-(4-methyl- imidazol-l-yl)-5 -trifluoromethyl-benzamide, N-{3-[l-(6-cyclopropylamino-pyrimidin-4-yl)- lH-imidazol-2-ylamino]-2-methyl-phenyl}-3-(4-methyl-imidazol-l-yl)-5-trifluoromethyl- benzamide, N-{5-[l-(6-cyclopropylamino-pyrimidin-4-yl)-lH-imidazol-2-ylamino]-2- fluoro-phenyl}-3-(4-methyl-imidazol-l-yl)-5-trifluoromethyl-benzamide, N-{5-[l-(6- cyclopropylamino-pyrimidin-4-yl)-lH-imidazol-2-ylamino]-2-methyl-phenyl}-3-(4-methyl- imidazol-l-yl)-5-trifluoromethyl-benzamide, N-{3-[l-(6-cyclopropylamino-pyrimidin-4-yl)- lH-imidazol-2-ylamino]-4-methoxy-phenyl}-benzamide, N-{3-[l-(6-cyclopropylamino- pyrimidin-4-yl)-lH-imidazol-2-ylamino]-4-methyl-phenyl}-3-trifluoromethyl- benzenesulfonamide, 3 - [ 1 -(6-cyclopropy lamino-pyrimidin-4-y 1)- 1 H-imidazol-2-y lamino] -4- methyl-N-(3-trifluoromethyl-phenyl)-benzenesulfonamide, N-{3-[l-(6-cyclopropylamino- pyrimidin-4-yl)-lH-imidazol-2-ylamino]-4-fluoro-phenyl}-3-dimethylamino-5- trifluoromethyl-benzamide, N- { 5-[ 1 -(6-cyclopropylamino-pyrimidin-4-yl)- 1 H-imidazol-2- ylamino]-2-methyl-phenyl}-3-dimethylamino-5-trifluoromethyl-benzamide, N-{4-chloro-3- [ 1 -(6-cyclopropy lamino-pyrimidin-4-yl)- 1 H-imidazol-2-ylamino] -phenyl } -3 - dimethylamino-5-trifluoromethyl-benzamide, 3 -(4-methyl-imidazol- 1 -yl)-N-(4-methyl-3 - { 1 - [6-(pyridin-2-ylamino)-pyrimidin-4-yl]-lH-imidazol-2-ylamino}-phenyl)-5-trifluoromethyl- benzamide, 4-(4-ethyl-piperazin-l-ylmethyl)-N-(4-methyl-3-{l-[6-(pyridin-2-ylamino)- pyrimidin-4-yl]-lH-imidazol-2-ylamino}-phenyl)-3-trifluoromethyl-benzamide, 3-(4-ethyl- piperazin-l-yl)-N-(4-methyl-3-{l-[6-(pyridin-2-ylamino)-pyrimidin-4-yl]-lH-imidazol-2- ylamino}-phenyl)-5-trifluoromethyl-benzamide, 4-chloro-N-(4-methyl-3-{l-[6-(pyridin-2- ylamino)-pyrimidin-4-y 1] - 1 H-imidazol-2-ylamino } -phenyl)-3 -trifluoromethyl-benzamide, N-[3-(l-{6-[5-(4-ethyl-piperazin-l-yl)-pyridin-2-ylamino]-pyrimidin-4-yl}-lH-imidazol-2- ylamino)-4-methyl-phenyl] -3 -trifluoromethyl-benzamide, N-(4-methyl-3 - { 1 - [6-(4-methyl- pyridin-2-ylamino)-pyrimidin-4-yl]-lH-imidazol-2-ylamino}-phenyl)-3-trifluoromethyl- benzamide, N-(3-{l-[6-(4,6-dimethyl-pyridin-2-ylamino)-pyrimidin-4-yl]-lH-imidazol-2- ylamino}-4-methyl-phenyl)-3 -trifluoromethyl-benzamide, 6-(6-{2-[2-methyl-5-(3- trifluoromethyl-benzoylamino)-phenylamino]-imidazol- 1 -yl} -pyrimidin-4-ylamino)- nicotinamide, N-(4-methy 1-3 - { 1 - [6-(5 -methy l-pyridin-2-y lamino)-pyrimidin-4-y 1] - 1 H- imidazol-2-ylamino}-phenyl)-3-trifluoromethyl-benzamide, N-(3-{l-[6-(5-cyano-pyridin-2- ylamino)-pyrimidin-4-yl]-lH-imidazol-2-ylamino}-4-methyl-phenyl)-3-trifluoromethyl- benzamide, 4-chloro-N- { 3 -[ 1 -(6-cyclopropylamino-pyrimidin-4-yl)- lH-imidazol-2- ylamino]-4-methyl-phenyl}-3-trifluoromethyl-benzamide5 4-chloro-N-(4-methyl-3-{l-[6-(2- morpholin-4-yl-ethylamino)-pyrimidin-4-yl]- lH-imidazol-2-ylamino} -phenyl)-3 - trifluoromethyl-benzamide, 5-tert-butyl-2-methyl-2H-pyrazole-3-carboxylic acid (4-methyl- 3 - { 1 -[6-(2-morpholin-4-yl-ethylamino)-pyrimidin-4-yl]- 1 H-imidazol-2-ylamino } -phenyl)- amide, N-(3 - { 1 - [6-(2-dimethylamino-ethylamino)-pyrimidin-4-yl]- 1 H-imidazol-2-y lamino } - 4-methyl-phenyl)-3-trifluoromethyl-benzamide, N-(4-methyl-3-{ 1 -[6-(3-morpholin-4-yl- propylamino)-pyrimidin-4-yl]-lH-imidazol-2-ylamino}-phenyl)-3-trifluoromethyl- benzamide, N-(3-{l-[6-(2-methoxy-ethylamino)-pyrimidin-4-yl]-lH-imidazol-2-ylamino}- 4-methyl-phenyl)-3-trifluoromethyl-benzamide, N-[4-methyI-3-(l-{6-[2-(l-methyl- pyrrolidin-2-yl)-ethylamino]-pyrimidin-4-yl}-lH-imidazol-2-ylamino)-phenyl]-3- trifluoromethyl-benzamide, N-(4-methyl-3 - { 1 -[6-(pyridin-2-ylamino)-pyrimidin-4-yl]- 1 H- imidazol-2-ylamino}-phenyl)-3 -trifluoromethyl-benzamide, N-[4-methyl-3-(l-pyrimidin-4- yl-lH-imidazol-2-ylamino)-phenyl]-3-trifluoromethyl-benzamide, N-[4-methyl-3-(l- pyrimidin-2-yl- lH-imidazol-2-ylamino)-phenyl]-3 -trifluoromethyl-benzamide, N- { 4- methyl-3-[l-(4-methylamino-pyrimidin-2-yl)-lH-imidazol-2-ylamino]-phenyl}-3- trifluoromethyl-benzamide, N- {4-methyl-3 -[1 -(2-methylamino-pyrimidin-4-yl)- 1 H- imidazol-2-ylamino]-phenyl}-3-trifluoromethyl-benzamide, N-(4-methyl-3-{l-[4-(2- moi holin-4-yl-ethylamino)-pyrimidin-2-yl]-lH-imidazol-2-ylamino}-phenyl)-3- trifluoromethyl-benzamide, N-(4-methyl-3-{l-[2-(2-morpholin-4-yl-ethylamino)-pyrimidin- 4-yl]- 1 H-imidazol-2 -ylamino} -phenyl)-3 -trifluoromethyl-benzamide, N-(3 - { 1 -[6-(2-ethyl- 2H-pyrazol-3-ylamino)-pyrimidin-4-yl]-lH-imidazol-2-ylamino}-4-methyl-phenyl)-3- trifluoromethyl-benzamide, N-(3-{l-[6-(3-dimethylamino-propylamino)-pyrimidin-4-yl]- lH-imidazol-2-ylamino}-4-methyl-phenyl)-3-trifluoromethyl-benzamide, N-{3-[l-(6- isopropylamino-pyrimidin-4-yl)-lH-imidazol-2-ylamino]-4-methyl-phenyl}-3- trifluoromethyl-benzamide, N-[3-(l-{6-[(furan-3-ylmethyl)-amino]-pyrimidin-4-yl}-lH- imidazol-2-ylamino)-4-methyl-phenyl]-3 -trifluoromethyl-benzamide, N-[4-methyl-3 -( 1 - {6- [3 -(4-methyl-piperazin- 1 -yl)-propylamino]-pyrimidin-4-yl} - 1 H-imidazol-2 -ylamino)- phenyl] -3 -trifluoromethyl-benzamide, N-[3-(l-{6-[(benzo[l,3]dioxol-5-ylmethyl)-amino]- pyrimidin-4-yl}-lH-imidazol-2-ylamino)-4-methyl-phenyl]-3-trifluoromethyl-benzamide, N-(4-methyl-3-{l-[6-(2-methyl-6-morpholin-4-yl-pyridin-3-ylamino)-ρyrimidin-4-yl]-lH- imidazol-2-ylamino}-phenyl)-3 -trifluoromethyl-benzamide, N-(4-methyl-3-{l-[6-(4-methyl- pyrimidin-2-ylamino)-pyrimidin-4-yl]-lH-imidazol-2-ylamino}-phenyl)-3-trifluoromethyl- benzamide, N-(3 - { 1 -[6-(6-methoxy-pyridin-3 -ylamino)-pyrimidin-4-yl]- 1 H-imidazol-2- ylamino}-4-methyl-phenyl)-3 -trifluoromethyl-benzamide, N-{4-methyl-3-[l-(6-morpholin- 4-yl-ρyrimidin-4-yl)- lH-imidazol-2-ylamino]-phenyl} -3 -trifluoromethyl-benzamide, N-(3- {l-[6-(4-ethyl-piperazin-l-yl)-pyrimidin-4-yl]-lH-imidazol-2-ylamino}-4-methyl-phenyl)- 3 -trifluoromethyl-benzamide, N-(3 - { 1 -[6-(3 -fluoro-phenylamino)-pyrimidin-4-yl] - 1H- imidazol-2-y lamino } -4-methy l-phenyl)-3 -trifluoromethyl-benzamide, N-(3 - { 1 - [6-(3 - dimethylamino-ethyl-formamide-phenylamino)-pyrimidin-4-yl]-lH-imidazol-2-ylamino}-4- methyl-phenyl)-3-trifluoromethyl-benzamide, N-[4-methyl-3-(l-{6-[(pyridin-3-ylmethyl)- amino]-pyrimidin-4-yl}-lH-imidazol-2-ylamino)-phenyl]-3-trifluoromethyl-benzamide, N- [4-methyl-3-(l-{6-[(pyridin-4-ylmethyl)-amino]-pyrimidin-4-yl}-lH-imidazol-2-ylamino)- pheny 1] -3 -trifluoromethyl-benzamide, N-(4-methyl-3 - { 1 - [6-(4-morpholin-4-yl-piperidin- 1 - yl)-pyrimidin-4-yl]-lH-imidazol-2-ylamino}-phenyl)-3-trifluoromethyl-benzamide, N-[4- methyl-3-(l-{6-[(thiazol-2-ylmethyl)-amino]-pyrimidin-4-yl}-lH-imidazol-2-ylamino)- pheny 1] -3 -trifluoromethyl-benzamide, N-[4-methyl-3 -( 1 - { 6- [(pyridin-2-ylmethyl)-amino] - pyrimidin-4-yl}-lH-imidazol-2-ylamino)-phenyl]-3-trifluoromethyl-benzamide, N-[4- methyl-3-( 1 - { 6-[(6-methyl-pyrazin-2-ylmethyl)-amino] -pyrimidin-4-yl} - lH-imidazol-2- ylamino)-phenyl]-3-trifluoromethyl-benzamide, N-(4-methyl-3-{ 1 -[6-(4-pyridin-2-yl- piperazin-l-yl)-pyrimidin-4-yl]-lH-imidazol-2-ylamino}-phenyl)-3-trifluoromethyl- benzamide, N-(3-{l-[6-(3-imidazol-l-yl-propylamino)-pyrimidin-4-yl]-lH-imidazol-2- ylamino}-4-methyl-phenyl)-3-trifluoromethyl-benzamide, N-(4-methyl-3-{l-[6-(pyrazin-2- ylamino)-pyrimidin-4-yl]-lH-imidazol-2-ylamino}-phenyl)-3-trifluoromethyl-benzamide, N-(3-{l-[6-(3-formamide-phenylamino)-pyrimidin-4-yl]-lH-imidazol-2-ylamino}-4-methyl- phenyl)-3-trifluoromethyl-benzamide, 4-methyl-3-{ 1 -[6-(2-morpholin-4-yl-ethylamino)- pyrimidin-4-y 1] - 1 H-imidazol-2-ylamino } -N-(3 -trifluoromethyl-pheny l)-benzamide, 4- methyl-3 - { 1 -[6-(4-methyl-piperazin- 1 -ylamino)-pyrimidin-4-yl]- 1 H-imidazol-2-y lamino} - N-(3 -trifluoromethyl-pheny l)-benzamide, N-(4-chloro-3 -trifluoromethy l-phenyl)-4-methyl- 3-{l-[6-(2-morpholin-4-yl-ethylamino)-pyrimidin-4-yl]-lH-imidazol-2-ylamino}- benzamide, N-(4-chloro-3 -trifluoromethy l-phenyl)-4-methy 1-3 - { 1 -[6-(4-methyl-piperazin- 1 - ylamino)-pyrimidin-4-yl]-lH-imidazol-2-ylamino} -benzamide, l-tert-butyl-5 -(4-methy 1- piperazin- 1 -ylmethy 1)- 1 H-pyrazole-3 -carboxylic acid { 3 - [ 1 -(6-cyclopropylamino-pyrimidin- 4-yl)-lH-imidazol-2-ylamino]-4-methyl-phenyl} -amide, l-tert-butyl-5-morpholin-4- ylmethyl-lH-pyrazole-3-carboxylic acid {3-[l-(6-cyclopropylamino-pyrimidin-4-yl)-lH- imidazol-2-ylamino]-4-methyl-phenyl}-amide, N-(4-tert-butyl-thiazol-2-yl)-4-methyl-3-{l- [6-(2-morpholin-4-yl-ethylamino)-pyrimidin-4-yl]-lH-imidazol-2-ylamino}-benzamide, N- (4-tert-butyl-thiazol-2-yl)-4-methyl-3-{l-[6-(4-methyl-piperazin-l-ylamino)-pyrimidin-4- yl]- 1 H-imidazol-2 -ylamino} -benzamide, N-(5-tert-butyl-2-methyl-2H-pyrazol-3 -yl)-4- methyl-3-{l-[6-(4-methyl-piperazin-l-ylamino)-pyrimidin-4-yl]-lH-imidazol-2-ylamino}- benzamide, N-(4-methyl-3-{ 1 -[6-(4-methyl-piperazin- 1 -ylamino)-pyrimidin-4-yl]- 1H- imidazol-2-ylamino}-phenyl)-benzamide, N-(5-tert-butyl-2-methyl-2H-pyrazol-3-yl)-4- methyl-3-{l-[6-(2-morpholin-4-yl-ethylamino)-pyrimidin-4-yl]-lH-imidazol-2-ylamino}- benzamide, N-(4-methyl-3-{ l-[2-(2-morpholin-4-yl-ethylamino)-pyridin-4-yl]-lH-imidazol- 2-y lamino } -phenyl)-3 -trifluoromethyl-benzamide, N- { 3 - [ 1 -(4-acetylamino-pyridin-2-y 1)- • lH-imidazol-2-ylamino]-4-methyl-phenyl}-3-trifluoromethyl-benzamide and 2-{2-[2- Methyl-5-(3-trifluoromethyl-benzoylamino)-phenylamino]-imidazol-l-yl}-isonicotinamide.
6. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1 in combination with a pharmaceutically acceptable excipient.
7. A method for treating a disease in an animal in which inhibition of kinase activity can inhibit or ameliorate the pathology and/or symptomology of the kinase mediated disease, which method comprises administering to the animal a therapeutically effective amount of a compound of Claim 1.
8. The method of claim 5 in which the kinase is selected from the group consisting of Abl, BCR-Abl, PDGF-R, trkB, c-SRC, BMX, FGFR3, b-RAF, SGK, Tie2, Lck, JNK2α2, MKK4, c-RAF, MKK6, SAPK2α and SAPK2β.
9. The use of a compound of claim 1 in the manufacture of a medicament for treating a disease in an animal in which the kinase activity of Abl, BCR-Abl, PDGF-R, trkB, c-SRC, BMX, FGFR3, b-RAF, SGK, Tie2, Lck, JNK2α2, MKK4, c-RAF, MKK6, SAPK2α and/or SAPK2β contributes to the pathology and/or symptomology of the disease.
PCT/US2005/020371 2004-06-10 2005-06-09 Compounds and compositions as protein kinase inhibitors WO2005123719A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
CN2005800175344A CN1960988B (en) 2004-06-10 2005-06-09 Compounds and compositions as protein kinase inhibitors
US11/628,881 US7745437B2 (en) 2004-06-10 2005-06-09 Compounds and compositions as protein kinase inhibitors
EP05759571A EP1758892B1 (en) 2004-06-10 2005-06-09 Compounds and compositions as protein kinase inhibitors
ES05759571T ES2396135T3 (en) 2004-06-10 2005-06-09 Compounds and compositions as protein kinase inhibitors
JP2007527742A JP4688876B2 (en) 2004-06-10 2005-06-09 Compounds and compositions as protein kinase inhibitors
MXPA06014247A MXPA06014247A (en) 2004-06-10 2005-06-09 Compounds and compositions as protein kinase inhibitors.
BRPI0511978-2A BRPI0511978A (en) 2004-06-10 2005-06-09 compounds and compositions as protein kinase inhibitors
CA2567662A CA2567662C (en) 2004-06-10 2005-06-09 Compounds and compositions as protein kinase inhibitors
AU2005254982A AU2005254982B2 (en) 2004-06-10 2005-06-09 Compounds and compositions as protein kinase inhibitors
IL179613A IL179613A0 (en) 2004-06-10 2006-11-27 Compounds and compositions as protein kinase inhibitors
TNP2006000406A TNSN06406A1 (en) 2004-06-10 2006-12-07 Compounds and compositions as protein kinase inhibitors
NO20070160A NO20070160L (en) 2004-06-10 2007-01-09 Compounds and Compositions as Protein Kinase Inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57849104P 2004-06-10 2004-06-10
US60/578,491 2004-06-10

Publications (1)

Publication Number Publication Date
WO2005123719A1 true WO2005123719A1 (en) 2005-12-29

Family

ID=35509612

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/020371 WO2005123719A1 (en) 2004-06-10 2005-06-09 Compounds and compositions as protein kinase inhibitors

Country Status (21)

Country Link
US (1) US7745437B2 (en)
EP (1) EP1758892B1 (en)
JP (1) JP4688876B2 (en)
CN (1) CN1960988B (en)
AR (1) AR049511A1 (en)
AU (1) AU2005254982B2 (en)
BR (1) BRPI0511978A (en)
CA (1) CA2567662C (en)
EC (1) ECSP067070A (en)
ES (1) ES2396135T3 (en)
IL (1) IL179613A0 (en)
MA (1) MA28679B1 (en)
MX (1) MXPA06014247A (en)
MY (1) MY144044A (en)
NO (1) NO20070160L (en)
PE (1) PE20060398A1 (en)
RU (1) RU2401265C2 (en)
TN (1) TNSN06406A1 (en)
TW (1) TW200610762A (en)
WO (1) WO2005123719A1 (en)
ZA (1) ZA200609450B (en)

Cited By (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006064375A2 (en) * 2004-12-16 2006-06-22 Ab Science Aminoaryl substituted five-membered ring heterocyclic compounds for the treatment of diseases
WO2006117560A1 (en) * 2005-05-05 2006-11-09 Astrazeneca Ab Pyrazolyl-amino- substituted pyrimidines and their use in the treatment of cancer
WO2008042639A1 (en) 2006-10-02 2008-04-10 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2008073480A1 (en) * 2006-12-11 2008-06-19 Irm Llc Compounds and compositions as kinase inhibitors
JP2009532440A (en) * 2006-04-07 2009-09-10 ノバルティス アクチエンゲゼルシャフト A combination comprising a) a pyrimidylaminobenzamide compound and b) a Thr315Ile kinase inhibitor
WO2010100127A1 (en) * 2009-03-04 2010-09-10 Novartis Ag Disubstituted imidazole derivatives as modulators of raf kinase
EP2251042A2 (en) 2006-09-22 2010-11-17 Novartis AG Method of optimizing the treatment of philadelphia-positive leukemia with abl tyrosine kinase inhibitors
WO2011103423A1 (en) 2010-02-18 2011-08-25 Incyte Corporation Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors
US8501758B2 (en) 2009-08-28 2013-08-06 Irm Llc Compounds and compositions as protein kinase inhibitors
EP2671891A2 (en) 2008-06-27 2013-12-11 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
US8691807B2 (en) 2011-06-20 2014-04-08 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
US8722693B2 (en) 2007-06-13 2014-05-13 Incyte Corporation Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US8933085B2 (en) 2010-11-19 2015-01-13 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
US8933086B2 (en) 2005-12-13 2015-01-13 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-B]pyridines and pyrrolo[2,3-B]pyrimidines as Janus kinase inhibitors
US8962622B2 (en) 2006-09-08 2015-02-24 Roche Palo Alto Llc Benzotriazole kinase modulators
US8987443B2 (en) 2013-03-06 2015-03-24 Incyte Corporation Processes and intermediates for making a JAK inhibitor
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
US9181271B2 (en) 2012-11-01 2015-11-10 Incyte Holdings Corporation Tricyclic fused thiophene derivatives as JAK inhibitors
US9193733B2 (en) 2012-05-18 2015-11-24 Incyte Holdings Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
US9216984B2 (en) 2009-05-22 2015-12-22 Incyte Corporation 3-[4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl]octane—or heptane-nitrile as JAK inhibitors
WO2016014542A1 (en) 2014-07-21 2016-01-28 Dana-Farber Cancer Institute, Inc. Imidazolyl kinase inhibitors and uses thereof
US9249145B2 (en) 2009-09-01 2016-02-02 Incyte Holdings Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
US9334274B2 (en) 2009-05-22 2016-05-10 Incyte Holdings Corporation N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
US9359358B2 (en) 2011-08-18 2016-06-07 Incyte Holdings Corporation Cyclohexyl azetidine derivatives as JAK inhibitors
US9387208B2 (en) 2011-11-23 2016-07-12 Novartis Ag Pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate
US9464088B2 (en) 2010-03-10 2016-10-11 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
US9487521B2 (en) 2011-09-07 2016-11-08 Incyte Holdings Corporation Processes and intermediates for making a JAK inhibitor
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
US9522910B2 (en) 2011-06-16 2016-12-20 Obshchestvo s ogranichennoy otvetstvennostyou “Fusion Pharma” Protein kinase inhibitors (variants), use thereof in treating oncological diseases and a pharmaceutical composition based thereon
US9655854B2 (en) 2013-08-07 2017-05-23 Incyte Corporation Sustained release dosage forms for a JAK1 inhibitor
KR20170091516A (en) * 2016-01-29 2017-08-09 한양대학교 에리카산학협력단 Novel imidazole derivates having JNK-inhibitory activity and use thereof
US9802957B2 (en) 2014-04-30 2017-10-31 Incyte Corporation Processes of preparing a JAK1 inhibitor and new forms thereto
US10166191B2 (en) 2012-11-15 2019-01-01 Incyte Corporation Sustained-release dosage forms of ruxolitinib
US10233157B2 (en) 2012-03-13 2019-03-19 Dana-Farber Cancer Institute, Inc. SIK inhibitor for use in a method of treating an inflammatory and/or immune disorder
US10265321B2 (en) 2014-08-08 2019-04-23 Dana-Farber Cancer Institute, Inc. Uses of salt-inducible kinase (SIK) inhibitors
US10457691B2 (en) 2014-07-21 2019-10-29 Dana-Farber Cancer Institute, Inc. Macrocyclic kinase inhibitors and uses thereof
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
US10758543B2 (en) 2010-05-21 2020-09-01 Incyte Corporation Topical formulation for a JAK inhibitor
US10899736B2 (en) 2018-01-30 2021-01-26 Incyte Corporation Processes and intermediates for making a JAK inhibitor
US10954242B2 (en) 2016-07-05 2021-03-23 The Broad Institute, Inc. Bicyclic urea kinase inhibitors and uses thereof
US11007194B2 (en) 2011-11-11 2021-05-18 Array Biopharma Inc. Method of treating a proliferative disease
US11241435B2 (en) 2016-09-16 2022-02-08 The General Hospital Corporation Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis
US11285158B2 (en) 2017-02-28 2022-03-29 The General Hospital Corporation Uses of pyrimidopyrimidinones as SIK inhibitors
US11304949B2 (en) 2018-03-30 2022-04-19 Incyte Corporation Treatment of hidradenitis suppurativa using JAK inhibitors
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
US12121521B2 (en) 2022-01-21 2024-10-22 The General Hospital Corporation Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045047A1 (en) * 2003-07-11 2005-10-12 Arena Pharm Inc ARILO AND HETEROARILO DERIVATIVES TRISUSTITUIDOS AS MODULATORS OF METABOLISM AND PROFILAXIS AND TREATMENT OF DISORDERS RELATED TO THEMSELVES
TW200533357A (en) 2004-01-08 2005-10-16 Millennium Pharm Inc 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases
ME02461B (en) 2005-05-10 2017-02-20 Incyte Holdings Corp Modulators of indoleamine 2,3-dioxygenase and methods of using the same
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
HUE035029T2 (en) 2008-05-21 2018-03-28 Ariad Pharma Inc Phosphorous derivatives as kinase inhibitors
MY171866A (en) 2008-07-08 2019-11-05 Incyte Holdings Corp 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
US8765747B2 (en) 2009-06-12 2014-07-01 Dana-Farber Cancer Institute, Inc. Fused 2-aminothiazole compounds
US9180127B2 (en) 2009-12-29 2015-11-10 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
JP2012102090A (en) * 2010-10-15 2012-05-31 Sumitomo Chemical Co Ltd Pyrimidine compound and use thereof for harmful organism control
JP5999177B2 (en) 2011-05-04 2016-09-28 アリアド・ファーマシューティカルズ・インコーポレイテッド Compound for inhibiting cell proliferation of EGFR-activated cancer
JP6106685B2 (en) 2011-11-17 2017-04-05 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド Inhibitors of C-JUN-N-terminal kinase (JNK)
AU2013204563B2 (en) 2012-05-05 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
CN107652289B (en) 2012-06-13 2020-07-21 因塞特控股公司 Substituted tricyclic compounds as FGFR inhibitors
MX369550B (en) * 2012-09-27 2019-11-12 Chugai Pharmaceutical Co Ltd Fgfr3 fusion gene and pharmaceutical drug targeting same.
EP2909194A1 (en) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
USRE48175E1 (en) 2012-10-19 2020-08-25 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
TW202214254A (en) 2013-03-01 2022-04-16 美商英塞特控股公司 USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3Kδ RELATED DISORDERS
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
JP6449244B2 (en) 2013-04-19 2019-01-09 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Bicyclic heterocycles as FGFR inhibitors
WO2015058140A1 (en) 2013-10-18 2015-04-23 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
EP3057955B1 (en) 2013-10-18 2018-04-11 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
US9862688B2 (en) 2014-04-23 2018-01-09 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
US10017477B2 (en) 2014-04-23 2018-07-10 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
US10870651B2 (en) 2014-12-23 2020-12-22 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
WO2016134320A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
MA41551A (en) 2015-02-20 2017-12-26 Incyte Corp BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS
JP6861166B2 (en) 2015-03-27 2021-04-21 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド Inhibitor of cyclin-dependent kinase
WO2016201370A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
WO2017044858A2 (en) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
EA038109B1 (en) 2016-03-01 2021-07-07 Пропеллон Терапьютикс Инк. Inhibitors of wdr5 protein-protein binding
WO2017147701A1 (en) 2016-03-01 2017-09-08 Ontario Institute For Cancer Research (Oicr) Inhibitors of wdr5 protein-protein binding
AR111960A1 (en) 2017-05-26 2019-09-04 Incyte Corp CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION
WO2019079469A1 (en) 2017-10-18 2019-04-25 Incyte Corporation Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors
US11306079B2 (en) 2017-12-21 2022-04-19 Incyte Corporation 3-(5-amino-pyrazin-2-yl)-benzenesulfonamide derivatives and related compounds as PI3K-gamma kinase inhibitors
SI3762368T1 (en) 2018-03-08 2022-06-30 Incyte Corporation Aminopyrazine diol compounds as pi3k-y inhibitors
US11220510B2 (en) 2018-04-09 2022-01-11 Incyte Corporation Pyrrole tricyclic compounds as A2A / A2B inhibitors
DK3788047T3 (en) 2018-05-04 2024-09-16 Incyte Corp Solid forms of an FGFR inhibitor and methods of making the same
SG11202010882XA (en) 2018-05-04 2020-11-27 Incyte Corp Salts of an fgfr inhibitor
US11168089B2 (en) 2018-05-18 2021-11-09 Incyte Corporation Fused pyrimidine derivatives as A2A / A2B inhibitors
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
CN113166153A (en) 2018-07-05 2021-07-23 因赛特公司 Fused pyrazine derivatives as A2A/A2B inhibitors
JP2021535182A (en) 2018-09-05 2021-12-16 インサイト・コーポレイションIncyte Corporation Crystal form of phosphoinositide 3-kinase (PI3K) inhibitor
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11078204B2 (en) 2018-11-13 2021-08-03 Incyte Corporation Heterocyclic derivatives as PI3K inhibitors
WO2020102216A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Substituted heterocyclic derivatives as pi3k inhibitors
WO2020102150A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Heterocyclic derivatives as pi3k inhibitors
US11596692B1 (en) 2018-11-21 2023-03-07 Incyte Corporation PD-L1/STING conjugates and methods of use
TWI829857B (en) 2019-01-29 2024-01-21 美商英塞特公司 Pyrazolopyridines and triazolopyridines as a2a / a2b inhibitors
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
US11472791B2 (en) 2019-03-05 2022-10-18 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021030537A1 (en) 2019-08-14 2021-02-18 Incyte Corporation Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
PE20221905A1 (en) 2019-10-11 2022-12-23 Incyte Corp BICYCLIC AMINES AS INHIBITORS OF CDK2
MX2022004513A (en) 2019-10-14 2022-07-19 Incyte Corp Bicyclic heterocycles as fgfr inhibitors.
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
BR112022010664A2 (en) 2019-12-04 2022-08-16 Incyte Corp DERIVATIVES OF A FGFR INHIBITOR
JP2023505258A (en) 2019-12-04 2023-02-08 インサイト・コーポレイション Tricyclic heterocycles as FGFR inhibitors
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4323405A1 (en) 2021-04-12 2024-02-21 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
CA3220274A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
US20230399331A1 (en) 2022-06-14 2023-12-14 Incyte Corporation Solid forms of jak inhibitor and process of preparing the same
US20240101557A1 (en) 2022-07-11 2024-03-28 Incyte Corporation Fused tricyclic compounds as inhibitors of kras g12v mutants

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6747031B2 (en) * 1997-02-19 2004-06-08 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002302445A (en) * 2001-02-02 2002-10-18 Takeda Chem Ind Ltd Jnk inhibitor
JP2005500261A (en) * 2001-04-10 2005-01-06 バーテックス　ファーマシューティカルズ　インコーポレイテッド Isoxazole derivatives as inhibitors of Src and other protein kinases
EP1389206B1 (en) * 2001-04-13 2006-09-13 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
CA2446864C (en) * 2001-05-16 2011-02-15 Vertex Pharmaceuticals Incorporated Inhibitors of src and other protein kinases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6747031B2 (en) * 1997-02-19 2004-06-08 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of EP1758892A4
T. W. GREENE; P. G. M. WUTS: "Protective Groups in Organic Chemistry", 1991, JOHN WILEY AND SONS

Cited By (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006064375A2 (en) * 2004-12-16 2006-06-22 Ab Science Aminoaryl substituted five-membered ring heterocyclic compounds for the treatment of diseases
WO2006117560A1 (en) * 2005-05-05 2006-11-09 Astrazeneca Ab Pyrazolyl-amino- substituted pyrimidines and their use in the treatment of cancer
US8946245B2 (en) 2005-12-13 2015-02-03 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
US9079912B2 (en) 2005-12-13 2015-07-14 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors
US8933086B2 (en) 2005-12-13 2015-01-13 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-B]pyridines and pyrrolo[2,3-B]pyrimidines as Janus kinase inhibitors
US10398699B2 (en) 2005-12-13 2019-09-03 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
US10639310B2 (en) 2005-12-13 2020-05-05 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
US9206187B2 (en) 2005-12-13 2015-12-08 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase
US9662335B2 (en) 2005-12-13 2017-05-30 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors
US9974790B2 (en) 2005-12-13 2018-05-22 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors
US11331320B2 (en) 2005-12-13 2022-05-17 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
US9814722B2 (en) 2005-12-13 2017-11-14 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors
US11744832B2 (en) 2005-12-13 2023-09-05 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
EP2574340A2 (en) 2006-04-07 2013-04-03 Novartis AG Combination comprising a pyrimidylaminobenzamide compound and a THR315LLEe kinase inhibitor
RU2481840C2 (en) * 2006-04-07 2013-05-20 Новартис Аг COMBINATION, INCLUDING A) PYRIMIDYLAMINOBENZAMIDE AND B) KINASE Thr315lle INHIBITOR
JP2009532440A (en) * 2006-04-07 2009-09-10 ノバルティス アクチエンゲゼルシャフト A combination comprising a) a pyrimidylaminobenzamide compound and b) a Thr315Ile kinase inhibitor
JP2013224304A (en) * 2006-04-07 2013-10-31 Novartis Ag COMBINATION COMPRISING PYRIMIDYLAMINOBENZAMIDE COMPOUND AND Thr315Ile KINASE INHIBITOR
US8962622B2 (en) 2006-09-08 2015-02-24 Roche Palo Alto Llc Benzotriazole kinase modulators
EP2251042A2 (en) 2006-09-22 2010-11-17 Novartis AG Method of optimizing the treatment of philadelphia-positive leukemia with abl tyrosine kinase inhibitors
KR101101675B1 (en) * 2006-10-02 2011-12-30 노파르티스 아게 Compounds and compositions as protein kinase inhibitors
EA015751B1 (en) * 2006-10-02 2011-12-30 АйАрЭм ЭлЭлСи Compounds and compositions as protein kinase inhibitors
WO2008042639A1 (en) 2006-10-02 2008-04-10 Irm Llc Compounds and compositions as protein kinase inhibitors
AU2007305016B2 (en) * 2006-10-02 2011-11-03 Novartis Ag Compounds and compositions as protein kinase inhibitors
US8202876B2 (en) 2006-10-02 2012-06-19 Irm Llc Compounds and compositions as protein kinase inhibitors
JP2010505862A (en) * 2006-10-02 2010-02-25 アイアールエム・リミテッド・ライアビリティ・カンパニー Compounds and compositions as protein kinases
WO2008073480A1 (en) * 2006-12-11 2008-06-19 Irm Llc Compounds and compositions as kinase inhibitors
US11213528B2 (en) 2007-06-13 2022-01-04 Incyte Holdings Corporation Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US10610530B2 (en) 2007-06-13 2020-04-07 Incyte Corporation Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US10016429B2 (en) 2007-06-13 2018-07-10 Incyte Corporation Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US8722693B2 (en) 2007-06-13 2014-05-13 Incyte Corporation Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US8829013B1 (en) 2007-06-13 2014-09-09 Incyte Corporation Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US8822481B1 (en) 2007-06-13 2014-09-02 Incyte Corporation Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US9376439B2 (en) 2007-06-13 2016-06-28 Incyte Corporation Salts of the janus kinase inhibitor (R)-3(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
EP2671891A2 (en) 2008-06-27 2013-12-11 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
WO2010100127A1 (en) * 2009-03-04 2010-09-10 Novartis Ag Disubstituted imidazole derivatives as modulators of raf kinase
US9623029B2 (en) 2009-05-22 2017-04-18 Incyte Holdings Corporation 3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]octane- or heptane-nitrile as JAK inhibitors
US9334274B2 (en) 2009-05-22 2016-05-10 Incyte Holdings Corporation N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
US9216984B2 (en) 2009-05-22 2015-12-22 Incyte Corporation 3-[4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl]octane—or heptane-nitrile as JAK inhibitors
US8501758B2 (en) 2009-08-28 2013-08-06 Irm Llc Compounds and compositions as protein kinase inhibitors
US10576080B2 (en) 2009-08-28 2020-03-03 Array Biopharma Inc. Compounds and compositions as protein kinase inhibitors
US9314464B2 (en) 2009-08-28 2016-04-19 Novartis Ag Compounds and compositions as protein kinase inhibitors
US10568884B2 (en) 2009-08-28 2020-02-25 Array Biopharma Inc. Compounds and compositions as protein kinase inhibitors
US9850229B2 (en) 2009-08-28 2017-12-26 Array Biopharma, Inc. Compounds and compositions as protein kinase inhibitors
US9850230B2 (en) 2009-08-28 2017-12-26 Array Biopharma, Inc. Compounds and compositions as protein kinase inhibitors
USRE49556E1 (en) 2009-08-28 2023-06-20 Array Biopharma Inc. Compounds and compositions as protein kinase inhibitors
US10005761B2 (en) 2009-08-28 2018-06-26 Array Biopharma Inc. Compounds and compositions as protein kinase inhibitors
US9593100B2 (en) 2009-08-28 2017-03-14 Array Biopharma, Inc. Compounds and compositions as protein kinase inhibitors
US9593099B2 (en) 2009-08-28 2017-03-14 Array Biopharma, Inc. Compounds and compositions as protein kinase inhibitors
US9249145B2 (en) 2009-09-01 2016-02-02 Incyte Holdings Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
WO2011103423A1 (en) 2010-02-18 2011-08-25 Incyte Corporation Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors
US9999619B2 (en) 2010-03-10 2018-06-19 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
US9464088B2 (en) 2010-03-10 2016-10-11 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
US10695337B2 (en) 2010-03-10 2020-06-30 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
US11285140B2 (en) 2010-03-10 2022-03-29 Incyte Corporation Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
US10758543B2 (en) 2010-05-21 2020-09-01 Incyte Corporation Topical formulation for a JAK inhibitor
US11219624B2 (en) 2010-05-21 2022-01-11 Incyte Holdings Corporation Topical formulation for a JAK inhibitor
US11590136B2 (en) 2010-05-21 2023-02-28 Incyte Corporation Topical formulation for a JAK inhibitor
US10869870B2 (en) 2010-05-21 2020-12-22 Incyte Corporation Topical formulation for a JAK inhibitor
US11571425B2 (en) 2010-05-21 2023-02-07 Incyte Corporation Topical formulation for a JAK inhibitor
US10640506B2 (en) 2010-11-19 2020-05-05 Incyte Holdings Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidines derivatives as JAK inhibitors
US8933085B2 (en) 2010-11-19 2015-01-13 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
US9522910B2 (en) 2011-06-16 2016-12-20 Obshchestvo s ogranichennoy otvetstvennostyou “Fusion Pharma” Protein kinase inhibitors (variants), use thereof in treating oncological diseases and a pharmaceutical composition based thereon
US8691807B2 (en) 2011-06-20 2014-04-08 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
US9023840B2 (en) 2011-06-20 2015-05-05 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
US10513522B2 (en) 2011-06-20 2019-12-24 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
US11214573B2 (en) 2011-06-20 2022-01-04 Incyte Holdings Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
US9611269B2 (en) 2011-06-20 2017-04-04 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
US9359358B2 (en) 2011-08-18 2016-06-07 Incyte Holdings Corporation Cyclohexyl azetidine derivatives as JAK inhibitors
US9718834B2 (en) 2011-09-07 2017-08-01 Incyte Corporation Processes and intermediates for making a JAK inhibitor
US9487521B2 (en) 2011-09-07 2016-11-08 Incyte Holdings Corporation Processes and intermediates for making a JAK inhibitor
US11007194B2 (en) 2011-11-11 2021-05-18 Array Biopharma Inc. Method of treating a proliferative disease
US9763941B2 (en) 2011-11-23 2017-09-19 Array Biopharma, Inc. Method of treating melanoma by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate
US10258622B2 (en) 2011-11-23 2019-04-16 Array Biopharma Inc. Method of treating colorectal cancer by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)pheny1)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl) carbamate
US9387208B2 (en) 2011-11-23 2016-07-12 Novartis Ag Pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate
US10561654B2 (en) 2011-11-23 2020-02-18 Array Biopharma Inc. Pharmaceutical formulations of (S)-methyl(1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate
US10233157B2 (en) 2012-03-13 2019-03-19 Dana-Farber Cancer Institute, Inc. SIK inhibitor for use in a method of treating an inflammatory and/or immune disorder
US9193733B2 (en) 2012-05-18 2015-11-24 Incyte Holdings Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
US9181271B2 (en) 2012-11-01 2015-11-10 Incyte Holdings Corporation Tricyclic fused thiophene derivatives as JAK inhibitors
US11851442B2 (en) 2012-11-01 2023-12-26 Incyte Corporation Tricyclic fused thiophene derivatives as JAK inhibitors
US9777017B2 (en) 2012-11-01 2017-10-03 Incyte Holdings Corporation Tricyclic fused thiophene derivatives as JAK inhibitors
US10370387B2 (en) 2012-11-01 2019-08-06 Incyte Holdings Corporation Tricyclic fused thiophene derivatives as JAK inhibitors
US9908895B2 (en) 2012-11-01 2018-03-06 Incyte Corporation Tricyclic fused thiophene derivatives as JAK inhibitors
US11161855B2 (en) 2012-11-01 2021-11-02 Incyte Corporation Tricyclic fused thiophene derivatives as JAK inhibitors
US10166191B2 (en) 2012-11-15 2019-01-01 Incyte Corporation Sustained-release dosage forms of ruxolitinib
US11576865B2 (en) 2012-11-15 2023-02-14 Incyte Corporation Sustained-release dosage forms of ruxolitinib
US11576864B2 (en) 2012-11-15 2023-02-14 Incyte Corporation Sustained-release dosage forms of ruxolitinib
US11337927B2 (en) 2012-11-15 2022-05-24 Incyte Holdings Corporation Sustained-release dosage forms of ruxolitinib
US11896717B2 (en) 2012-11-15 2024-02-13 Incyte Holdings Corporation Sustained-release dosage forms of ruxolitinib
US10874616B2 (en) 2012-11-15 2020-12-29 Incyte Corporation Sustained-release dosage forms of ruxolitinib
US8987443B2 (en) 2013-03-06 2015-03-24 Incyte Corporation Processes and intermediates for making a JAK inhibitor
US9221845B2 (en) 2013-03-06 2015-12-29 Incyte Holdings Corporation Processes and intermediates for making a JAK inhibitor
US9714233B2 (en) 2013-03-06 2017-07-25 Incyte Corporation Processes and intermediates for making a JAK inhibitor
US9655854B2 (en) 2013-08-07 2017-05-23 Incyte Corporation Sustained release dosage forms for a JAK1 inhibitor
US10561616B2 (en) 2013-08-07 2020-02-18 Incyte Corporation Sustained release dosage forms for a JAK1 inhibitor
US11045421B2 (en) 2013-08-07 2021-06-29 Incyte Corporation Sustained release dosage forms for a JAK1 inhibitor
US9802957B2 (en) 2014-04-30 2017-10-31 Incyte Corporation Processes of preparing a JAK1 inhibitor and new forms thereto
US10450325B2 (en) 2014-04-30 2019-10-22 Incyte Corporation Processes of preparing a JAK1 inhibitor and new forms thereto
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
US10457691B2 (en) 2014-07-21 2019-10-29 Dana-Farber Cancer Institute, Inc. Macrocyclic kinase inhibitors and uses thereof
US10287268B2 (en) 2014-07-21 2019-05-14 Dana-Farber Cancer Institute, Inc. Imidazolyl kinase inhibitors and uses thereof
EP3171874A4 (en) * 2014-07-21 2017-12-27 Dana-Farber Cancer Institute, Inc. Imidazolyl kinase inhibitors and uses thereof
WO2016014542A1 (en) 2014-07-21 2016-01-28 Dana-Farber Cancer Institute, Inc. Imidazolyl kinase inhibitors and uses thereof
US10975058B2 (en) 2014-07-21 2021-04-13 Dana-Farber Cancer Institute, Inc. Imidazolyl kinase inhibitors and uses thereof
US10265321B2 (en) 2014-08-08 2019-04-23 Dana-Farber Cancer Institute, Inc. Uses of salt-inducible kinase (SIK) inhibitors
KR101894096B1 (en) 2016-01-29 2018-09-05 삼진제약주식회사 Novel imidazole derivates having JNK-inhibitory activity and use thereof
KR20170091516A (en) * 2016-01-29 2017-08-09 한양대학교 에리카산학협력단 Novel imidazole derivates having JNK-inhibitory activity and use thereof
US11725011B2 (en) 2016-07-05 2023-08-15 The General Hospital Corporation Bicyclic urea kinase inhibitors and uses thereof
US10954242B2 (en) 2016-07-05 2021-03-23 The Broad Institute, Inc. Bicyclic urea kinase inhibitors and uses thereof
US11241435B2 (en) 2016-09-16 2022-02-08 The General Hospital Corporation Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis
US11285158B2 (en) 2017-02-28 2022-03-29 The General Hospital Corporation Uses of pyrimidopyrimidinones as SIK inhibitors
US11878019B2 (en) 2017-02-28 2024-01-23 The General Hospital Corporation Uses of pyrimidopyrimidinones as SIK inhibitors
US11278541B2 (en) 2017-12-08 2022-03-22 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
US10899736B2 (en) 2018-01-30 2021-01-26 Incyte Corporation Processes and intermediates for making a JAK inhibitor
US11304949B2 (en) 2018-03-30 2022-04-19 Incyte Corporation Treatment of hidradenitis suppurativa using JAK inhibitors
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
US12121521B2 (en) 2022-01-21 2024-10-22 The General Hospital Corporation Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis

Also Published As

Publication number Publication date
EP1758892A1 (en) 2007-03-07
ES2396135T3 (en) 2013-02-19
EP1758892B1 (en) 2012-10-17
BRPI0511978A (en) 2008-01-22
MXPA06014247A (en) 2007-03-12
TNSN06406A1 (en) 2008-02-22
CN1960988B (en) 2012-01-25
ECSP067070A (en) 2007-01-26
US20070225286A1 (en) 2007-09-27
PE20060398A1 (en) 2006-06-05
AU2005254982B2 (en) 2008-11-27
JP2008502729A (en) 2008-01-31
IL179613A0 (en) 2007-05-15
ZA200609450B (en) 2008-05-28
CA2567662C (en) 2012-11-27
AR049511A1 (en) 2006-08-09
RU2007100136A (en) 2008-07-20
AU2005254982A1 (en) 2005-12-29
NO20070160L (en) 2007-01-09
RU2401265C2 (en) 2010-10-10
EP1758892A4 (en) 2010-07-28
US7745437B2 (en) 2010-06-29
CA2567662A1 (en) 2005-12-29
CN1960988A (en) 2007-05-09
TW200610762A (en) 2006-04-01
MY144044A (en) 2011-07-29
MA28679B1 (en) 2007-06-01
JP4688876B2 (en) 2011-05-25

Similar Documents

Publication Publication Date Title
EP1758892B1 (en) Compounds and compositions as protein kinase inhibitors
EP1899329B1 (en) Pyrimidine-substituted benzimidazole derivatives as protein kinase inhibitors
EP1891066B1 (en) Compounds and compositions as protein kinase inhibitors
US8202876B2 (en) Compounds and compositions as protein kinase inhibitors
AU2006227790B2 (en) Compounds and compositions as protein kinase inhibitors
EP1940844B1 (en) Compounds and compositions as protein kinase inhibitors
AU2006311910A1 (en) Protein kinase inhibitors
WO2008137794A1 (en) Compounds and compositions as c-kit and pdgfr kinase inhibitors
WO2007092531A2 (en) Compounds and compositions as protein kinase inhibitors
KR100935273B1 (en) Compounds and compositions as protein kinase inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2006/09450

Country of ref document: ZA

Ref document number: 200609450

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 12006502276

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 6842/DELNP/2006

Country of ref document: IN

Ref document number: 551344

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2567662

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 179613

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 200580017534.4

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 06122179

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 2005254982

Country of ref document: AU

Ref document number: PA/a/2006/014247

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020067025907

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2007527742

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2005759571

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: DZP2007000017

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 2007100136

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 2005254982

Country of ref document: AU

Date of ref document: 20050609

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005254982

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1020067025907

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2005759571

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11628881

Country of ref document: US

Ref document number: 2007225286

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 11628881

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0511978

Country of ref document: BR